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OBESITy AND RELATED DISORDERS
Obesity is one of the largest global health emergencies of the 21st century. According 
to the World Health Organisation, obesity is defined as a body mass index (BMI) of >30 
kg/m2. Since 1980, the prevalence of obesity has doubled worldwide to a number of 
603.7 million adults (12.0% of the world population) in 2015 (1). Moreover, this number 
is expected to further increase in the coming years (2). Obesity deregulates metabolic 
processes including glucose and lipid handling and results in systemic inflammation. 
Therefore, obesity is a major risk factor for the development of type 2 diabetes mellitus 
(T2D), dyslipidemia and cardiovascular diseases (CVD). In line with this, the prevalence 
of diabetes is rapidly increasing as well, from 425 million adults with diabetes in 2017 to 
an estimated number of 629 million adults in 2045 (3), of whom 91% will have T2D. CVD 
are the most common causes of death among people with diabetes, currently account-
ing for over 2.5 million deaths worldwide (3).
WhITE AND BROWN ADIPOSE TISSuE
Obesity is the consequence of excessive storage of fat in the adipose tissue organ. 
Under ‘lean’ conditions, approximately 15% of body weight in men and about 25% of 
body weight in women is contributed by adipose tissue, while in obesity these percent-
ages can increase up to >40% (4,5). The most abundant type of adipose tissue is white 
adipose tissue (WAT), which is located throughout the body and has a function in lipid 
storage and insulation. Two major WAT depots can be distinguished: subcutaneous WAT, 
located underneath the skin, and visceral adipose tissue, which surrounds the internal 
organs and is mainly located in the abdominal cavity (6). WAT stores excessive lipids 
and sugar in the form of triglycerides. Under conditions of high energy demands (e.g. 
exercise, fasting or cold exposure), WAT can release fatty acids derived from these tri-
glycerides into the blood, via a process known as intracellular lipolysis. These fatty acids 
can subsequently be taken up by other tissues to fuel metabolism, e.g. skeletal muscle 
in case of exercise. Besides WAT, a different shade of adipose tissue exists, namely brown 
adipose tissue (BAT). For a long time, BAT was considered to be only present in neonates. 
However, since 2009, it has been established that human adults still have active BAT as 
well (7-9). BAT is predominantly located in the supraclavicular and para-aortic regions 
(8) and combusts fatty acids and to a lesser extent glucose into heat (i.e. thermogen-
esis), thereby maintaining body temperature under conditions below thermoneutrality 
(10). Although the total amount of WAT largely exceeds that of BAT (with an estimated 
average of 12-35 kg of WAT versus max. 200-300 g of BAT) (11), BAT has an extremely 
large capacity to convert energy stored in fatty acids and glucose into heat. It has been 
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estimated that fully activated BAT can produce up to 300 W/kg, whereas most other 
tissues produce only 1 W/kg (12).
AETIOLOGy Of INSuLIN RESISTANCE AND RELATION WITh DySLIPIDEMIA
While storage of large amounts of fat in WAT in obesity is not harmful per se, the ac-
companying dyslipidemia and insulin resistance can pose a health risk. Blood glucose 
levels are tightly regulated within a narrow range by balancing the endogenous glucose 
production and the uptake by peripheral tissues. Insulin is the most important hormone 
involved in the glucose homeostasis. Insulin is released by β-cells of the pancreas in 
response to high blood glucose levels. The main action of insulin is to lower blood glu-
cose levels. This can be established by stimulating the uptake of glucose by peripheral 
tissues, including muscle and adipose tissue. During the development of obesity, WAT 
depots expand to increase the storage capacity. In this process adipocytes increase in 
size, a process called hypertrophy (13). Hypertrophic adipocytes release pro-inflamma-
tory adipokines, including tumor necrosis factor α and interleukin 6 (14,15), that trigger 
the immune system resulting in infiltration of immune cells including macrophages 
(16). Pro-inflammatory cytokines can inhibit insulin signalling, which induces insulin 
resistance of the tissue (17). Eventually, when adipocytes become too large and blood 
supply is insufficient, hypoxia occurs which triggers cell death, thereby further attract-
ing macrophages. Immune cell infiltration of WAT is one of the main characteristics 
of dysfunctional WAT in obesity. Moreover, dysfunctional adipocytes become insulin 
resistant leading to the release fatty acids (FA) into the circulation. High levels of circu-
lating free FA inhibit glucose uptake and combustion (18,19), thereby elevating blood 
glucose and insulin levels in a process called insulin resistance, which may lead to T2D 
(18,20,21). In addition, an increased flux of free FA to the liver, combined with hepatic 
insulin resistance, stimulates hepatic triglyceride synthesis and VLDL secretion which 
further contributes to the development of dyslipidemia (22). Also, insulin resistance 
reduces the expression of lipoprotein lipase (LPL) in skeletal muscle and adipose tissue, 
which reduces VLDL catabolism, thereby further accelerating hypertriglyceridemia and 
dyslipidemia (23). When the maximum storage capacity of WAT is reached, triglycerides 
are stored in other organs (e.g. ‘ectopic fat accumulation’), including liver, skeletal 
muscle and pancreas (24,25). In the pancreas local lipid accumulation causes pancreatic 
dysfunction, and eventually loss of insulin production, which even further exacerbates 
hyperglycemia and dyslipidemia (25,26). Of note, ectopic fat accumulation is considered 




ThE SOuTh ASIAN POPuLATION, A POPuLATION AT INCREASED RISk fOR 
METABOLIC DISEASE
Obesity rates differ between ethnicities. Particularly in South Asians, originating from the 
Indian subcontinent and constituting 20% of the world population, obesity prevalence 
is estimated to reach 50% in urban areas (29), and obesity-associated complications in-
cluding T2D are highly prevalent (30). Moreover, South Asians develop T2D at a younger 
age and lower BMI compared to white Caucasians (31,32). In addition, the South Asian 
ethnicity itself is considered an independent risk factor for CVD (33). The underlying 
mechanisms of this increased risk for metabolic disease are not completely understood, 
but cannot fully be explained by their higher prevalence of ‘classical’ risk factors includ-
ing obesity and dyslipidemia (33-36). Therefore, it is likely that a combination of many 
additional risk factors explain the elevated risk on development of metabolic disease 
in this population (35,37). However, the nature of these additional risk factors have not 
been elucidated yet.
Obesity manifests differently in South Asians as compared to white Caucasians. With 
comparable BMI, South Asians have a higher body fat percentage than white Caucasians 
(38,39). In addition, body fat distribution is different in South Asians, with higher intra-
abdominal and truncal subcutaneous adipose tissue dispositions and more ectopic fat 
disposition, possibly contributing to an increased risk on developing insulin resistance 
and eventually T2D (40-43). Not only the amount and distribution of body fat differs, it 
has also been proposed that adipocyte function is disturbed in South Asians (44,45).
Another ‘classical’ risk factor for metabolic disease, especially for CVD, is dyslipid-
emia. An unfavourable lipid profile, consisting of high levels of triglycerides and low-
density-lipoprotein (LDL)-cholesterol (46) and low levels of high-density-lipoprotein 
(HDL)-cholesterol (46,47) is frequently present in South Asians. In addition, impaired 
endothelial function (i.e. reduced endothelium-dependent vasodilation and increased 
vessel stiffness) has been described in South Asians (48-50), which further predisposes 
to atherosclerosis development and thus CVD. Interestingly, already in cord blood of 
neonates elevated levels of triglycerides, non-HDL-cholesterol and E-selectin (marker of 
endothelial dysfunction) are observed (51), which underscores that (some) metabolic 
disturbances are already present early in life.
However, the above-mentioned ‘classical’ risk factors probably do not explain the full 
picture. ‘Non-classical’ risk factors such as differences in genetic make-up, diet, or dif-
ferences in energy metabolism could therefore not be overlooked when exploring risk 
factors for the development of metabolic disease in the South Asian population. With 
respect to genetic make-up, so far no genetic polymorphisms have been identified that 
could account for the ethnic difference in predisposition for obesity or T2D (52). Neither 
do differences in dietary intake or exercise fully explain the increased risk (52). However, 
Chapter 1
12 |
there is increasing evidence that energy metabolism might be differently regulated in 
South Asians as compared to white Caucasians. We previously showed that healthy lean 
South Asians have 32% lower resting energy expenditure as compared to BMI-matched 
white Caucasians (53) and less energy-combusting BAT as assessed with [18F]fluorode-
oxyglucose positron emission tomography-computed tomography ([18F]FDG PET/CT). 
These factors likely contribute to their lower energy metabolism and could thereby, at 
least in part, contribute to the development of metabolic disease.
Taken together, all of the above-mentioned ‘classical’ and ‘non-classical’ risk factors 
(summarized figure 1) can potentially contribute to the increased susceptibility for 
metabolic disease in the South Asian population. However, the list is probably not 
complete. Additional studies are warranted to gain more insight in the factors that are 
involved in the increased risk on metabolic disease in this vulnerable population.
When additional risk factors for the development of metabolic disease will have been 
identified, specific treatment strategies can be developed to target these diseases. 
Current treatment strategies for obesity are often focussed on reducing food intake via 
dieting or on increasing energy expenditure via increased physical activity. However, 
GENETICS 
EXERCISE 
- Less physical activity 
DIET 
- High saturated fat 
- High carbohydrates 
- Low fibers  
ADIPOSE TISSUE 
- Amount:  
- Increased fat percentage 
- Distribution:  
- More intra-abdominal fat 
- More truncal fat 
- Function:  
- Hypertrophic adipocytes 
- Increased  
      pro-inflammatory cytokines 
- Lower adiponectin 
DYSLIPIDEMIA 
- High TG 
- High LDL-C 
- Low HDL-C 
ENDOTHELIUM  
- Elevated E-selectin 




- Ectopic fat disposition 
SKELETAL MUSCLE 
- Ectopic fat disposition 
- Impaired mitochondrial 
function 
CLASSICAL RISK FACTORS NON-CLASSICAL RISK FACTORS 
INSULIN RESISTANCE 
South Asian 
figure 1. known ‘classical’ and ‘non-classical’ risk factors for metabolic disease in the South Asian 





these interventions are generally not effective on the long-term. In fact, the only effec-
tive anti-obesity intervention thus far is invasive bariatric surgery (54). Therefore, novel 
treatment strategies are warranted. Since BAT is able to combust lipids and glucose, 
thereby increasing energy expenditure, modulation of this tissue is considered to be an 
interesting target to combat obesity and T2D.
PhySIOLOGICAL ACTIvATION Of BAT
In line with its function to produce heat, the main physiological activator of BAT is cold 
exposure (10). BAT is highly innervated by sympathetic neurons. Upon cold exposure, 
the sympathetic outflow from the hypothalamus towards BAT is increased. Sympathetic 
neurons release norepinephrine that binds to β3-adrenergic receptors on the brown 
adipocyte membrane, at least in mice (55-57). In humans it is still under debate what 
receptor(s) is (are) involved in BAT activation. As a result, the uncoupling protein-1 (UCP-
1) in the inner membrane of the mitochondria becomes activated. UCP-1 uncouples 
mitochondrial respiration from adenosine triphosphate production resulting in the dis-
sipation of chemical energy as heat (58,59). At the same time, BAT releases endocannabi-
noids, which are believed to act on endocannabinoid (CB) receptors at the presynaptic 
terminal of sympathetic nerve endings to inhibit noradrenalin signalling (60,61). This 
sequence of events likely serves as a feedback mechanism to prevent excessive activa-
tion of BAT by cold (depicted in figure 2). Interestingly, circulating endocannabinoid 
levels are elevated in obesity (62-64). It remains to be determined whether circulating 
endocannabinoid levels also differs between South Asians and white Caucasians and if 
endocannabinoids could contribute to increased risk on metabolic disease in the South 
Asian population.
During thermogenesis, BAT combusts FA derived from intracellular lipid stores, 
thereby lowering intracellular lipid levels. As a consequence, the intracellular lipid stores 
become depleted and need to be replenished. To this end, BAT takes up free FA and 
triglyceride (TG)-derived FA from TG-rich lipoproteins in the blood (65). The TG-derived 
FA uptake by BAT is dependent on LPL, which is present on the vessel wall (66,67). LPL 
is regulated by many factors including angiopoietin-like 4 (ANGPTL4) (68,69). ANGPTL4 
inhibits LPL thereby preventing the uptake of TG-derived FA by metabolic tissues (68) 
and at the same time stimulates intracellular lipolysis in WAT to further increase circulat-
ing free FA levels (70). ANGPTL4 is suggested to be differently regulated in BAT and WAT. 
Preclinical studies have shown that upon cooling, ANGPTL4 levels increase in WAT while 
they decrease in BAT in order to facilitate shuttling of FA from WAT to BAT (71). However, 
the effects of cold exposure on ANGPTL4 in humans is still unknown. In addition, cold 
exposure increases sympathetic outflow towards WAT which adds to enhanced lipolysis 
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and more release of FA into the bloodstream (72). These FA can be directly taken up 
by BAT or travel to the liver, where there are used for the synthesis into triglycerides. 
Triglycerides can subsequently be secreted into the blood in the form of VLDL. Notably, 
pre-clinical studies indicate the presence of a feed-forward mechanism in which FA, 
released by WAT, in the brain, further increases sympathetic outfl ow to BAT to stimulate 
the combustion of FA for thermogenesis (73).
Thus, sympathetic activation of BAT following cold exposure results in combustion 
of TG-derived FA towards heat. Evidence for the importance of active BAT in energy 
metabolism comes from pre-clinical and clinical trials. In rodent studies, cold exposure 















figure 2. Link between the sympathetic nervous system and the endocannabinoid system during 
cold exposure. Cold exposure increases output of the sympathetic nervous system to peripheral organs. 
Sympathetic simulation of white adipose tissue (WAT) stimulates lipolysis which results in release of free 
fatty acids (FFA) into the bloodstream. In addition, sympathetic stimulation of the liver increases the pro-
duction and release of very-low-density lipoproteins (VLDL) into the bloodstream. Sympathetic stimulation 
of brown adipose tissue (BAT) induces thermogenesis thereby combusting intracellular lipid stores. The 
intracellular lipid stores can be replenished through uptake of WAT and liver-derived (triglyceride-derived)-
fatty acids from the blood. BAT, brown adipose tissue; FFA, free fatty acids; SNS, sympathetic nervous sys-




activates BAT, increases energy expenditure, decreases fat mass and increases glucose 
tolerance and insulin sensitivity (10,66,74). Human trials have also shown that 10 days 
(75) or 4 weeks (76) of intermittent cold acclimatisation enhances BAT activity and 
increases energy expenditure in both lean (75,76) and obese individuals (77). Moreover, 
intermittent cold exposure increases BAT activity and alleviates peripheral insulin resis-
tance in T2D patients (78), suggesting a pivotal role for BAT in whole-body metabolism. 
These data underscore that activation of BAT by cold exposure could be a valuable tool 
to for the treatment of obesity and related diseases such as T2D and CVD.
PhARMACOLOGICAL ACTIvATION Of BAT
Albeit that the metabolic benefits of BAT activation by means of cold exposure have 
been well established, prolonged cold exposure is not a very convenient treatment op-
tion for humans. Therefore, more suitable therapeutic modalities such as pharmaceuti-
cal activation of BAT are currently being investigated. Promising therapeutic approaches 
are either direct modulation of activating receptors on the brown adipocyte itself or in-
direct modulation of BAT activity by manipulating the sympathetic outflow towards BAT 
(figure 3). An example of a drug that directly stimulates the β3-adrenergic receptor on 
brown adipocytes is mirabegron. Mirabegron is already on the market for the treatment 
of overactive bladder disease and clinical studies indicate that one dose of mirabegron 
(200 mg) activates BAT as effectively as acute cold exposure in young healthy lean men 
(79). It remains to be determined if long-term administration of this compound indeed 
improves glucose and lipid profiles and prevents/ reverses obesity and diabetes devel-
opment. In addition, it would be interesting to investigate if mirabegron is also effective 
in different risk populations, including South Asians.
A second class of drugs that has the potential to activate BAT are drugs that modu-
late incretin hormone signalling, such as dipeptidyl peptidase-4 (DPP4) inhibitors 
and glucagon-like peptide-1 (GLP-1) receptor agonists. DPP4 inhibitors enhance the 
bioavailability of incretin hormones including GLP-1, while GLP-1 receptor agonists 
directly stimulate the GLP-1 receptors. GLP-1 receptor stimulation in the hypothalamus 
increases sympathetic outflow to peripheral metabolic tissues in rodents (80) and is 
thereby able to modulate BAT activity. Pre-clinical studies indeed show increased BAT 
activity, increased energy expenditure, an improved glucose and lipid metabolism upon 
oral administration with the DPP4 inhibitor sitagliptin (81) or central administration 
of the GLP-1 receptor agonist exenatide (82,83). If this is also the case in humans, and 
whether different effects would be observed between ethnicities, e.g. between South 
Asians versus white Caucasians, still needs to be elucidated.
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OuTLINE Of ThIS ThESIS
As is evident from this chapter, obesity and related metabolic diseases including T2D 
and CVD are a growing health care concern. Especially South Asian individuals are at 
increased risk for the development of metabolic diseases, but the underlying mecha-
nisms are still not fully elucidated. Furthermore, current intervention strategies for the 
treatment of obesity are not eff ective on the long-term, apart from bariatric surgery. 
Although increasing energy expenditure by modulation of BAT seems a promising novel 
approach, modulation of BAT activation by cold exposure in humans is far from optimal. 
Therefore, the studies described in this thesis were aimed at 1) unravelling the underly-
ing mechanisms that could explain the increased predisposition for metabolic disease 
in the South Asian population and 2) identifying novel treatment strategies that activate 
BAT and increase energy expenditure in risk population, including South Asians and 
individuals with overweight and prediabetes, with the ultimate goal to combat obesity, 
T2D and CVD.
















figure 3. Novel pharmacological approaches to directly and indirectly activate brown adipose tis-
sue. Sitagliptin and exenatide indirectly activate brown adipose tissue through increasing endogenous 
glucagon-like-peptide-1 and activating central GLP-1 receptors, respectively. Mirabegron directly activates 
brown adipose tissue through modulation of adrenergic receptors on brown adipocytes. BAT, Brown adi-





In the first part of this thesis, we focused on identification of factors that could, at least 
in part, explain the enhanced susceptibility for the development of metabolic disease 
in the South Asian population. First, we focused on the endocannabinoid system. The 
endocannabinoid system is known to play an important role in energy metabolism by 
regulating appetite, intracellular lipolysis and energy expenditure and is found to be 
over-activated in subjects with obesity. In addition, endocannabinoids are thought to act 
in a negative feedback loop to prevent excessive BAT activity. Theoretically, differences 
in endocannabinoid signalling between South Asians and white Caucasians can thus 
contribute to the difference in predisposition for metabolic disease. Therefore, in Chap-
ter 2, we first investigated whether endocannabinoid tone is higher in subjects from 
South Asian descent by studying circulating endocannabinoid levels in young health 
lean white Caucasian and South Asian men. Since endocannabinoid tone is a reflection 
of local endocannabinoid regulation in metabolically active organs, we next focussed 
on differences in local endocannabinoid signalling in WAT and skeletal muscle. To this 
end, we studied, in Chapter 3, gene expression of cannabinoid receptors and enzymes 
involved in endocannabinoid synthesis and degradation in middle-aged, overweight, 
prediabetic white Caucasian and South Asian individuals. Next, we shifted our focus to 
other factors that could possibly explain the difference in predisposition for metabolic 
disease between South Asians and white Caucasians. BAT is a metabolic organ which 
takes up lipids from the circulation to fuel thermogenesis. Angiopoietin-like (ANGPTL4) 
inhibits LPL-dependent uptake of TG-derived fatty acids by metabolic tissues. Since 
differences in substrate uptake by BAT could explain a difference in BAT function, we 
investigated, in Chapter 4, the effect of BAT activation (by means of short-term cold 
exposure) on circulating ANGPTL4 levels in white Caucasians and South Asians. As 
combustion of lipids by BAT results in the generation of lipid-associated metabolites, 
we next explored the effect of short-term cooling on lipid-associated metabolites in 
blood. In Chapter 5 we investigated the changes in metabolites upon mild cooling and 
whether these responses differed between the two ethnicities.
In the second part of this thesis, we focussed on two promising pharmacological 
strategies to activate BAT. In Chapter 6, the effect of the β3-adrenergic receptor agonist 
mirabegron was investigated on BAT activity and energy expenditure. To this end, young 
healthy lean white Caucasian and South Asian men participated in a three day random-
ized cross-over study in which they were exposed to either short-term cooling, admin-
istration of mirabegron or placebo. The acute effects on lipid and glucose metabolism, 
energy expenditure and BAT activity were studied and potential differences in responses 
between the two ethnicities were assessed. In Chapter 7, we aimed at investigating the 
effect of chronic administration of the DPP4 inhibitor sitagliptin on lipid and glucose 
metabolism, energy expenditure and metabolism of BAT, WAT and skeletal muscle in 
another population at high risk for metabolic disease (e.g. overweight, prediabetic sub-
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jects). A double-blinded randomized placebo-controlled trial was performed in which 
30 overweight, prediabetic white Caucasian men received either sitagliptin or placebo 
for a duration of 12 weeks. Pre- and post-treatment blood samples were collected, in-
direct calorimetry was performed to measure energy expenditure, and an oral bolus of 
glucose was given to determine glucose tolerance. In addition, a skeletal muscle biopsy 
was taken to assess effects of sitagliptin on expression of genes involved in glucose and 
lipid metabolism and mitochondrial function. Furthermore, glucose uptake by BAT was 
assessed using [18F]FDG PET/CT.
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South Asians have a higher risk to develop obesity and related disorders compared to 
white Caucasians. This is likely in part due to their lower resting energy expenditure 
(REE) as related with less energy-combusting brown adipose tissue (BAT). Since over-
activation of the endocannabinoid system is associated with obesity and low BAT 
activity, we hypothesized that South Asians have a higher endocannabinoid tone. 
Healthy lean white Caucasian (n=10) and South Asian (n=10) men were cold-exposed 
to activate BAT. Before and after cooling, REE was assessed and plasma was collected 
for analysis of endocannabinoids and lipids. At thermoneutrality, South Asians had 
higher plasma levels of 2-arachidonoylglycerol (2-AG; 11.36 vs 8.19 pmol/mL, p<0.05), 
N-arachidonylethanolamine (AEA; 1.04 vs 0.89 pmol/mL, p=0.05) and arachidonic acid 
(AA; 23.24 vs 18.22 nmol/mL, p<0.001). After pooling of both ethnicities, plasma 2-AG 
but not AEA positively correlated with triglycerides (R2=0.32, p<0.05) and body fat 
percentage (R2=0.18, p<0.05). Interestingly, AA negative correlated with REE (R2=0.46, 
p=0.001) and positively with body fat percentage (R2=0.33, p<0.01). Cooling increased 
endocannabinoids. In conclusion, South Asian compared to white Caucasian men have 
higher endocannabinoid tone. This suggests that endocannabinoids may, at least in 
part, underlie the disadvantageous metabolic phenotype of South Asians later in life.
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INTRODuCTION
South Asians originally descend from the sub-Indian continent and comprise about 24% 
of the world population. This population is at higher risk for developing a disadvanta-
geous metabolic phenotype consisting of obesity, dyslipidemia and insulin resistance 
compared to white Caucasians, making them more prone to develop type 2 diabetes 
(T2D) at a younger age and lower body mass index (BMI) (1). The underlying mechanism 
of the increased predisposition for this unfavorable metabolic profile in South Asians is 
not well understood, but might be related to a disturbed energy metabolism (2).
The endocannabinoid system (ECS) is known to play an important role in energy 
metabolism by regulating appetite, lipolysis and energy expenditure (3). The ECS is 
composed of endogenous lipid messengers (endocannabinoids), two distinct G-
protein-coupled receptors, i.e. type 1 and type 2 cannabinoid (CB1 and CB2) receptors, 
and enzymes responsible for the synthesis and inactivation of the endocannabinoids. N-
arachidonylethanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG) are the 
best-studied endocannabinoids. They are synthesized on demand from the membrane 
lipid precursors N-acylphosphatidylethanoamines and diacylglycerides, respectively. 
Furthermore, there are endogenous bioactive lipids called N-acylethanolamines (NAEs), 
such as N-linoleoylethanolamine (LEA), N-palmitoylethanolamine (PEA), N-oleoyleth-
anolamine (OEA) and N-stearoylethanolamine (SEA), which are produced through the 
same biosynthetic pathway as AEA. NAEs are able to indirectly modulate cannabinoid 
receptor activity by interfering with endocannabinoid metabolism. In addition, OEA 
modulates satiety through its interaction with PPARα(4,5). The ECS is present in both 
central and peripheral tissues that are involved in maintaining energy balance. These 
include the hypothalamus, liver, pancreas, skeletal muscle, white adipose tissue (WAT) 
and brown adipose tissue (BAT) (6).
High ECS activity has been associated with human obesity (7,8). More specifically, 
elevated circulating AEA and 2-AG levels have been reported in obese individuals (8-10) 
and circulating 2-AG levels are positively correlated with different measures of adiposity, 
including BMI and body fat percentage (8), supporting a causal role of the ECS in energy 
metabolism. Indeed, reduction in 2-AG formation has been associated with reduced 
food intake in fasted mice (11,12) and chronic systemic blockade of the CB1 receptor 
with the inverse agonist rimonabant leads to long-term maintained weight loss and 
reduction of dyslipidemia in obese rodents (13,14) and humans (15-17).
Mouse studies have shown that the beneficial metabolic effects of CB1 receptor 
blockade are, at least in part, mediated via activation of energy-combusting BAT (18). 
Moreover, cold mediated BAT activation leads to a tissue-specific upregulation of en-
docannabinoids in BAT via CB1 receptors, thereby possibly controlling BAT activity by 
negative feed-back mechanisms (19). BAT is present and active in human adults and 
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dissipates triglyceride (TG)-derived fatty acids towards heat, thereby contributing to 
energy expenditure (20-23). Cold acclimatization, the most important physiological 
activator of BAT, has been shown to recruit and activate BAT in obese humans (24). The 
precise role of the ECS in human BAT activation remains to be determined. Interestingly, 
we have previously shown that South Asian individuals have lower BAT volume and ac-
tivity, as measured with [18F]fluorodeoxyglucose ([18F]FDG) PET-CT scanning, compared 
to white Caucasians, which might, at least in part, contribute to their high susceptibility 
to develop obesity and T2D (25). The underlying cause of the decreased BAT volume in 
South Asians is still a question that remains.
The main aim of this study was to investigate if healthy lean South Asians men who 
have not yet developed a disadvantageous metabolic phenotype have a higher en-
docannabinoid tone as compared to white Caucasians. Furthermore, we investigated 
whether cold mediated BAT activation leads to upregulation of endocannabinoid levels 
in humans. In addition, we aimed to assess whether plasma endocannabinoid levels 
correlate with BAT function, energy expenditure and serum lipid levels.
MATERIALS AND METhODS
Ethics
Venous blood samples were collected as part of a previously conducted observational 
study aimed at investigating BAT activity and volume in Dutch South Asian and white 
Caucasian individuals (25). This study was approved by the Medical Ethical Committee 
of the Leiden University Medical Center (LUMC) and undertaken in accordance with 
the principles of the revised Declaration of Helsinki. All volunteers provided written 
informed consent. Trial registration number: Netherlands Trial Register 2473.
Participants and study design
We enrolled twenty-four Dutch healthy lean men, between 18-28 years of age, with a BMI 
18-25 kg/m2. Twelve men were of Dutch South Asian descent and twelve of Dutch white 
Caucasian descent (25). This study was conducted at the Alrijne Hospital, Leiderdorp 
(the Netherlands) between March 2013 and June 2013 (25). In short, subjects underwent 
medical screening including their medical history, a physical examination, blood chem-
istry tests and an oral glucose tolerance test to exclude individuals with type 2 diabetes 
according to the American Diabetes Association 2010 criteria. Other exclusion criteria 
were rigorous exercise, smoking and recent body weight change up to 3 months prior 
to the start of the study.
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Study procedures
Subjects were studied after overnight fasting and 24 hours without heavy exercise. We 
determined body composition using a Dual Energy X-ray Absorptiometry (DEXA) scan 
(iDXA, GE healthcare, UK or Discovery A, Hologic, Bedford, MA, USA). Next, an intrave-
nous cannula was inserted in the antecubital vein for blood collection and injection of 
[18F]FDG. To assess BAT volume and activity, subjects were exposed to an individualized 
water cooling protocol to maximally activate BAT. In short, subjects were cooled for 
approximately 2 hours until just above shivering temperature, to ensure maximum non-
shivering thermogenesis, followed by an [18F]FDG PET-CT scan (Gemini TF PET-CT, Philips 
Healthcare, Best, the Netherlands). For the individual cooling protocol, subjects lay be-
tween two water perfused cooling mattresses (Blanketrol III, Cincinnati Sub-Zero Prod-
ucts, Cincinnati, OH, USA or ThermaWrap Universal 3166, MTRE Advanced Technologies, 
Yavne, Israel). After 60 minutes at 32°C (thermoneutral temperature), the temperature 
of the mattresses were gradually decreased with 5°C every 10 minutes until shivering 
occurred. At this point, the temperature was raised by 3°C and the official cooling period 
of 2 hours was started. After 1 hour of cooling, 2 MBq/kg [18F]FDG was administrated 
intravenously. Both in thermoneutral and cold-induced condition, indirect calorimetry 
was performed with a ventilated hood (Oxycon Pro™, CareFusion, Heidelberg, Germany). 
Venous blood samples were collected in a fasted state at the end of the thermoneutral 
period and at the end of the cooling period. After 2 hours of cooling, an [18F]FDG PET-CT 
scan was acquired starting with a low-dose CT scan followed by PET scanning.
Brown adipose tissue measurements and energy expenditure
BAT volume (in mL) and BAT activity (in standardized uptake value (SUV)) in the region 
of interest were determined from the [18F]FDG PET-CT scans (Gemini TF PET CT, Philips, 
Best, the Netherlands) by a blinded nuclear physician and a researcher. Resting energy 
expenditure (REE), respiratory quotient and rates of lipid and glucose oxidation were 
measured with indirect calorimetry using a ventilated hood system (Oxycon Pro, CareFu-
sion, Heidelberg, Germany).
Serum lipid measurements
Serum TG and free fatty acid concentrations were determined in the blood samples with 
the use of commercially available enzymatic kits 11488872 and 91096 (Roche Molecular 
Biochemicals, Indianapolis, USA) as described previously (25).
Endocannabinoid measurements
Plasma sample of only 20 subjects could be studied since four subjects were excluded 
due to insufficient volume of plasma sample left available for the analysis in 2 individuals 
of each ethnicity. In total, endocannabinoids and their congeners were quantified in 40 
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plasma samples using liquid chromatography coupled with tandem mass spectrometry 
(LC-MS/MS). From the pool of individual study samples, quality controls (QCs) were used 
to generate calibration curves. Additionally, all samples were randomized and each 
batch included calibration samples and an even distribution of QC samples and blanks.
Endocannabinoid sample extraction
Endocannabinoid extraction was performed on ice. Briefly, 50 µL of plasma was trans-
ferred into 1.5 mL Eppendorf tubes, spiked with 10 µL of deuterated internal standard 
mix (Supplementary Table S1) followed by addition of 50 µL of 0.1 M ammonium 
acetate buffer (pH 4). After two times extraction with 400 µL of methyl tert-butyl ether 
(MTBE) (443808, Sigma Aldrich, Zwijndrecht, the Netherlands), the tubes were thor-
oughly mixed for 4 min using a bullet blender (Next Advance, Inc., Averill park, NY, USA) 
at medium speed, followed by a centrifugation step (4°C, 5,000 g, 12 min). Then 750 μL 
(combined from two extractions) of the upper MTBE layer was transferred into clean 1.5 
mL Eppendorf tubes. Samples were dried in a speed vac followed by reconstitution with 
50 μL of acetonitrile/water (90/10, v/v). The reconstituted samples were centrifuged (4°C, 
14,000 g, 3 min) before transferring into LC-MS vials. 5 µL of each sample was injected 
into the LC-MS/MS system.
LC-MS/MS Analysis
A targeted analysis of 22 compounds, including endocannabinoids and related 
N-acylethanolamines (NAEs) along with their precursor molecule and metabolite ara-
chidonic acid (AA) (Supplementary Table S1), was measured using an Acquity UPLC I 
class Binary solvent manager pump (Waters, Milford, USA) in conjugation with AB SCIEX 
6500 quadrupole-ion trap (QTRAP) (AB Sciex, Massachusetts, USA). The separation was 
performed with an Acquity HSS T3 column (1.2x100 mm, 1.8 µm) maintained at 45°C. 
The aqueous mobile phase A consisted of 2 mM ammonium formate and 10 mM formic 
acid, and the organic mobile phase B was acetonitrile. The flow rate was set to 0.4 mL/
min; initial gradient conditions were 55% B held for 2 minutes and linearly ramped to 
100% B over 6 minutes and held for 2 minutes; after 10 seconds the system returned to 
initial conditions and held 2 minutes before next injection. Electrospray ionization-MS 
and a selective Multiple Reaction Mode (MRM) was used for endocannabinoid quantifi-
cation. Individually optimized MRM transitions using their synthetic standards for target 
compounds and internal standards are described in Supplementary Table S1. Relative 
standard deviations (RSD) of QC samples were calculated to monitor the data quality 
and RSD less than 15% was observed for 90% the target compounds. Peak area integra-
tion was performed with MultiQuant (AB Sciex, Version 3.0.2) data analysis software. 
The obtained peak areas of targets were corrected by appropriate internal standards. 
Calculated response ratios, determined as the peak area ratios of the target analyse to 
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the respective internal standard, were used to obtain absolute concentrations from their 
respective calibration curves. The response ratios were further corrected using in-house 
QC tool (26).
Statistical analysis
As previously mentioned, four participants (2 white Caucasians and 2 South Asians) 
were excluded from the analyses due to insufficient sample for the endocannabinoid 
measurements. Data were collected and analysed using IBM SPSS statistics version 23.0. 
Baseline characteristics were compared using unpaired student t-tests. Differences in 
plasma endocannabinoid levels in (between) groups were analysed using two tailed 
paired (unpaired) t-tests. Furthermore, linear regression analysis computed by Pearson’s 
correlation was used to determine correlations between plasma endocannabinoid lev-
els and different metabolic parameters. Regression analysis was performed both with 
and without correction for the effect of ethnicity, by respectively including/excluding 
ethnicity as a covariate. P values < 0.05 were considered as statistical significant. Data 
are presented as mean ± SEM.
RESuLTS
Clinical characteristics
The characteristics of the participants are partly previously described in (25). Twenty-four 
healthy lean men were included, however, sufficient plasma to analyse the endocannabi-
noids of only twenty participants (10 white Caucasians and 10 South Asians) was avail-
able. In this cohort of 20 participants, mean age was comparable between South Asians 
and white Caucasians (23.7 vs 25.2 years, respectively) as was BMI (21.4 vs 22.3 kg/m2), 
body fat percentage (23.4 vs 19.4%) and serum TG concentration (0.91 vs 0.82 mmol/L). 
South Asians had lower REE during thermoneutral conditions (1304 vs 1671 kcal/day, 
p<0.01) and cold conditions (1480 vs 2063 kcal/day, p<0.01), also after correction for 
lean body mass. Cold exposure increased REE significantly only in white Caucasians 
(+23.4%, p<0.01). Furthermore, BAT volume was lower in South Asians as compared to 
white Caucasians (185 mL vs 303 mL), which was borderline significant (p=0.052) while 
the difference was significant in the original study (25) due to larger sample size.
Circulating endocannabinoid levels are higher in South Asians and are 
increased after cooling
At thermoneutrality, South Asians had higher mean levels of plasma 2-AG compared 
to white Caucasians (11.36 vs 8.19 pmol/mL, p<0.05) (figure 1A). In addition, there 
was a trend towards higher mean levels of AEA in South Asians (1.04 vs 0.89 pmol/mL, 
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p=0.05) (figure 1B). Levels of AA were also higher in South Asians (23.24 vs 18.22 nmol/
mL, p<0.001) (figure 1C). No significant differences were observed for other NAEs and 
mono- and di-acyl glycerols measured, except LEA (N-linoleoylethanolamide), of which 
mean plasma levels were higher in South Asians compared to white Caucasians (5.88 vs 
3.99 pmol/mL, p<0.005) (Supplementary Table S1). Collectively, these results suggest 
that circulating endocannabinoid levels (2-AG and AEA) are higher in lean healthy male 
South Asians as compared to white Caucasians. We next assessed the endocannabinoid 
levels in plasma samples collected after short-term mild cold exposure. Interestingly, 
after cooling circulating levels of 2-AG were higher in South Asians (+41%, p<0.05) as 
well as white Caucasians (+32%, p<0.05) (figure 1A). Furthermore, AEA levels were 
significantly elevated after mild cold exposure in white Caucasians only (+16%, p<0.05) 
(figure 1B). Plasma AA significantly increased after cold exposure in both ethnic groups 
(South Asians (+22%, p<0.01) and white Caucasians (+23%, p<0.01) (figure 1C). The 
relative increases in endocannabinoid levels upon cooling were not significantly differ-
ent comparable between the two ethnicities.
Circulating endocannabinoid levels correlate with serum triglycerides and 
body fat
As the ECS is known to play an important role in energy metabolism, we investigated 
whether circulating endocannabinoid levels correlated with different metabolic param-
eters in our study cohort. For these analyses we used combined data of South Asians and 
white Caucasians. Thermoneutral 2-AG levels positively correlated with TG levels (R2=0.32, 
p<0.05) (figure 2A) and total body fat percentage (R2=0.27, p<0.05) (figure 2B), but not 
with visceral fat percentage (data not shown). In contrast, AEA levels did not correlate 
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figure 1. Circulating endocannabinoid levels are higher in South Asians and increased after short-
term cooling. Blood was collected from healthy young South Asian (n=10) and matched white Caucasian 
(n=10) individuals before (thermoneutral) and after short-term mild cooling (Cold). Liquid chromatography 
coupled with tandem mass spectrometry (LC-MS/MS) was used to measure plasma concentrations of 2-AG 
(A), AEA (B), and AA (C) concentrations. Values are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. P-values are 
based on paired t-tests (effect of cold) or unpaired t-tests (effect of ethnicity).
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correlated with AA under thermoneutral (R2=0.45, p=0.001) and cold conditions (R2=0.28 
p<0.05) (figure 3). AA also positively correlated with body fat percentage (R2=0.34, 
p<0.01) (figure 4A). Interestingly, a strong negative correlation was observed with AA 
and REE (R2=0.46, p<0.001) (figure 4B), with AA levels being higher in South Asians 
compared to white Caucasians (23.24 vs 18.22 nmol/mL, p<0.001). AA did not correlate 
with either fat or glucose oxidation (data not shown). We found no significant correla-
tions between circulating endocannabinoids and other metabolic parameters, including 
(systolic and diastolic) blood pressure, heart rate, fasting serum glucose or C-reactive 
protein (CRP) levels (data not shown). After cold exposure, there was no correlation 
between circulating endocannabinoids and REE (data not shown). Both thermoneutral 
and cold-induced REE positively correlated with BAT volume, but not activity (data not 
shown) (25). To further understand the inter-relationship between endocannabinoids 
and BAT metabolism, we performed several regression analyses. Notably, no correlation 
was found between circulating endocannabinoid levels and BAT volume (2-AG: R2=0.016, 
p=0.611; AEA: R2=0.024, p=0.531; and AA: R2=0.066, p=0.288) or activity (2-AG: R2=0.008, 
p=0.714; AEA: R2=0.132, p=0.126; and AA: R2=0.031, p=0.473), nor was there a correla-
tion between cold-induced or delta (cold minus thermoneutral) endocannabinoid levels 
upon cooling and BAT activity or volume (data not shown). To test whether the effects 
could be attributed to ethnicity, we also performed the regression analysis including 
ethnicity as covariate. Correcting for the effect of ethnicity, plasma 2-AG levels still cor-
related with serum TG levels (p<0.05) and tended to correlate with body fat percentage 
(p=0.08). In addition, thermoneutral 2-AG levels still correlated with thermoneutral AA 
levels (p<0.05), but not under cold conditions (p=0.12). Also, after correction for ethnicity 
the negative correlation between AA and REE was not significant anymore (p=0.41).
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figure 2. Thermoneutral plasma 2-AG levels positively correlate with serum triglyceride levels and 
total body fat percentage. Scatterplot of the correlations between 2-AG levels and serum TG (A) or total 
body fat percentage (B). Correlations are shown for the total group combined (n=20), white circles are 
white Caucasian individuals (n=10) and black circles are South Asian individuals (n=10), with 95% confi-




The contribution of the ECS in energy metabolism has been well established in humans 
and research has focused on manipulating this system for the treatment of metabolic 
disease, such as obesity and T2D. The South Asian population is very prone to develop 
metabolic disease; however, the underlying mechanism remains to be elusive. In the 
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figure 4. Thermoneutral plasma AA levels positively correlate with body fat percentage and nega-
tively correlate with resting energy expenditure. Scatterplot of the correlations between plasma AA 
levels measured at thermoneutrality and total body fat percentage (A) or thermoneutral resting energy 
expenditure (REE) (B) (n=20). Correlations are shown for the total group combined, black circles are South 
Asian individuals and white circles are white Caucasian individuals, with 95% confidence limits. Correlations 
were analysed using linear regression analysis.
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figure 3. Plasma 2-AG levels correlate with plasma AA levels. Scatterplot of the correlations between 
plasma 2-AG and AA in both Caucasian and South Asian individuals (n=40). Correlation is shown for the 
total group combined under thermoneutral (A) and cold conditions (B), black circles are South Asian in-
dividuals and white circles are white Caucasian individuals, with 95% confidence limits. Correlations were 
analysed using linear regression analysis.
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present study, we showed that healthy lean South Asian men without an apparent dis-
advantageous metabolic phenotype have higher circulating levels of endocannabinoids 
(2-AG and AEA) and their metabolite AA compared to matched white Caucasian men. In 
addition, plasma 2-AG levels positively correlate with serum TG and body fat percentage, 
and AA levels negatively correlate with REE and positively with body fat percentage.
To the best of our knowledge, this is the first study that shows higher plasma 2-AG, 
AEA and AA levels in healthy South Asians compared to white Caucasians. Jumpertz et 
al. (27) previously showed higher 2-AG levels in cerebrospinal fluid (CSF) of American 
Indians compared to white Caucasians. However, they did not observe differences in 
2-AG or AEA levels in plasma of these individuals. This might be due to differences in the 
study population or a difference in the sensitivity of the assay. For example, Jumpertz et 
al. included young (±29 year), overweight individuals, while in the current study young 
(±24 year), healthy individuals were included. Furthermore, in South Asians we found 
higher levels of AA, the breakdown product of endocannabinoids. Although AA can also 
be synthesized independent of endocannabinoids, these data support the notion that 
the endocannabinoid tone is higher in healthy young male individuals of South Asian 
compared to white Caucasian origin.
High circulating endocannabinoid levels in South Asians can result in overstimulation 
of cannabinoid receptors on tissues such as liver, WAT, skeletal muscle and pancreas. 
This in turn can lead to several disadvantageous metabolic effects. In mice, a high en-
docannabinoid tone in the liver, for example, contributes to the development of fatty 
liver disease (28-30). In addition, in WAT CB1 receptor activation promotes adipogen-
esis, lipogenesis and energy storage instead of combustion (3). Moreover, CB receptor 
stimulation in WAT and skeletal muscle has shown to disrupt insulin signaling thereby 
promoting insulin resistance, which in combination with reduced insulin secretion from 
the pancreas (also induced by CB receptor stimulation on pancreatic islet cells) might 
promote development of T2D (3,31). Taken together this indicates that overall high 
endocannabinoid tone can deteriorate/ induce metabolic disease. As South Asians have 
already been shown to have more hepatic steatosis (32), adipocyte hypertrophy (32), 
disturbed muscle insulin signaling (2) and lower REE (25) (i.e. high endocannabinoid 
tone reduces REE (18) and high plasma AA levels negatively correlate with REE (figure 
4B)) compared to white Caucasians, they are possibly at even greater risk for the nega-
tive metabolic effects of high endocannabinoid tone.
In addition, we observed positive correlations between plasma 2-AG and serum TG 
and body fat percentage, albeit the correlation with TG was enforced by a biological 
outlier. These results are in line with results from Bluher et al. (8) who showed positive 
correlations between circulating 2-AG levels and both body fat percentage and serum 
TG in lean and obese individuals. However, they also showed positive correlations be-
tween 2-AG and BMI and free fatty acids which could not be reproduced in our study 
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population (8). Jumper et al. (27) showed positive correlations between AEA, but not 
2-AG, and BMI and body fat percentage. However, they studied overweight individuals 
whereas we studied healthy lean individuals. Consistent with our data, they also found 
no correlation between plasma 2-AG or AEA levels and REE (27).
Furthermore, we found that plasma 2-AG and AA levels in both ethnicities are 
increased after short-term mild cooling, the physiological stimulator of BAT (33). This 
observation is consistent with a study in mice showing that BAT activation increases ex-
pression and protein levels of endocannabinoids in BAT (19). The authors hypothesized 
that increase in endocannabinoids in BAT represents a negative feedback mechanism, 
as they could locally act on the presynaptic nerve terminal to inhibit noradrenalin re-
lease, thereby preventing excessive activation of BAT (19). Possibly, also in humans the 
increase in 2-AG and AEA could be derived from BAT, however in our observational study 
the contribution of other tissues to the plasma endocannabinoid levels could not be 
excluded. Another explanation for the increased endocannabinoid levels upon cooling 
could be a higher availability of biosynthetic precursors such as diacylglycerols (DAGs) 
or N-acyl-phosphatidyl-ethanolamines (NAPEs), which are generated during lipolysis of 
WAT and/or BAT during cooling (19). In addition, it has been shown that cold exposure 
reduces the mRNA expression of the breakdown enzyme FAAH in BAT, which might also 
in part explain higher plasma endocannabinoid levels upon cooling (19). Alternative 
explanations can also not be excluded at present. For example, 2-AG has a circadian 
rhythm in humans with the lowest plasma concentration peak around 5:00 am and 
the highest peak concentration around 13:00 pm (34). Since the blood samples in the 
current study were withdrawn around 9:30 (thermoneutrality) and 12:30 (cold), a small 
increase, of approx. 15%, in plasma 2-AG could already be expected from its circadian 
rhythm. However, we found a larger 37% average increase in 2-AG when combining the 
South Asians and white Caucasians. In addition, cooling elicits a stress response in the 
body, and stress, via glucocorticoids, has been shown to increase the peripheral ECS 
tone (35,36).
Previous mouse studies showed that global blockade of the CB1 receptor by 
rimonabant activates BAT, markedly enhances energy expenditure and leads to a tissue-
specific upregulation of endocannabinoids (18,19). In fact, human studies showed that 
taranabant, another inverse agonist of the CB1 receptor also reduced food intake, induced 
weight loss and increased REE and fat oxidation in obese individuals (37). Therefore, we 
hypothesized that these effects may have been due to BAT activation. However, in our 
study there was no significant correlation between plasma endocannabinoids and BAT 
volume/activity, fatty acid or glucose oxidation. Possibly our sample size was too small 
to reliably assess this, as the variation in BAT between subjects was rather large.
A strength of this study is that we investigate differences in circulating endocannabi-
noid levels in lean healthy South Asians and white Caucasians individuals before they 
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develop metabolic diseases. This allowed us to investigate in more detail whether ethnic 
differences in endocannabinoid tone are already present before the onset of the disease 
rather than being a consequence of the metabolic disease. However, a limitation of our 
study is that we could only measure circulating endocannabinoid levels which do not 
necessarily reflect endocannabinoid signalling within peripheral organs and thus the 
endocannabinoid function. For future studies, it would be interesting to measure endo-
cannabinoid levels and levels of endocannabinoid synthesis and breakdown enzymes 
in specific tissues, such as WAT and skeletal muscle. In addition, we cannot exclude that 
‘thermoneutrality’ might have been experienced differently between the two ethnici-
ties, which might have biased our results. Furthermore, the small sample size might have 
limited the number of correlations we could detect. However, despite this we were able 
to reproduce some correlations shown previously by others underscoring the robust-
ness of these findings. Future studies in larger cohorts should verify the translational 
value of these results for the general population.
In conclusion, our data demonstrate that healthy lean South Asian men have a higher 
endocannabinoid tone compared to white Caucasian men. Provided that our cohort is 
representative for the general population, this might, at least in part, contribute to the 
development of a disadvantageous metabolic phenotype later in life. These results are 
in line with the hypothesis that the ECS functions as a negative feedback system on BAT. 
Future research should focus on elucidating the underlying cause of the high endocan-
nabinoid tone in this vulnerable population and verify potential causal relationships. 
This knowledge might lead to the development of novel treatment strategies to combat 
metabolic disease.
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The study aimed to investigate whether markers of endocannabinoid signaling differed 
between overweight men of South Asian and white Caucasian descent. We included 
overweight, prediabetic South Asian (n=10) and white Caucasian (n=10) men aged 
35-50 years. Plasma samples were analyzed for endocannabinoids, their congeners and 
lipids. In white adipose tissue (WAT) and skeletal muscle biopsies, mRNA expression of 
genes involved in the endocannabinoid system (ECS) was assessed using qRT-PCR. Fast-
ing lipid oxidation and glucose oxidation were determined with indirect calorimetry. 
Compared to white Caucasians, South Asians had higher levels of plasma 2-linoleoyl 
glycerol (p<0.01) and N-linoleoylethanolamine (p<0.05). Interestingly, in skeletal muscle 
of South Asians, expression of cannabinoid receptors CB1 and CB2 was 10-fold lower 
(p<0.001) and that of the endocannabinoid degradation enzyme FAAH2 was 5-fold 
lower (p<0.001) compared to white Caucasians. Expression of genes involved in the ECS 
in WAT were not different between the two ethnicities. After pooling of both ethnicities, 
plasma 2-AG positively correlated with plasma triglycerides (R=0.77, p<0.001) and lipid 
oxidation (R=0.55, p<0.05). Overweight South Asian men have higher plasma 2-linoleoyl 
glycerol and N-linoleoylethanolamine levels and lower expression of CB receptors and 
the endocannabinoid degradation enzyme FAAH2 in skeletal muscle compared to white 
Caucasians.
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INTRODuCTION
The prevalence of obesity and related diseases, such as type 2 diabetes (T2D), is rapidly 
increasing worldwide. Particularly in South Asians, constituting nearly one-fourth of 
the world’s population (1), an unfavorable metabolic profile consisting of obesity, dys-
lipidaemia and T2D, is highly prevalent (2). Moreover, South Asians have a higher risk 
of developing cardiovascular disease, resulting in high morbidity and mortality (3). It is 
generally thought that the increased susceptibility to metabolic disease of South Asians 
might be due to a disturbed energy metabolism (4).
The endocannabinoid system (ECS) is involved in maintaining energy balance by 
impacting on energy intake and expenditure as well as lipolysis (5). The ECS is present 
both centrally and in peripheral metabolic tissues, including the liver, pancreas, skeletal 
muscle, white adipose tissue (WAT) and brown adipose tissue (6). In skeletal muscle, en-
docannabinoids reduce glucose uptake and oxidative pathways (7, 8), thereby reducing 
energy expenditure. In WAT, endocannabinoids stimulate energy storage by increasing 
lipogenesis and adipogenesis (5, 9, 10). Thus endocannabinoid stimulation of skeletal 
muscle and WAT collectively results in a positive energy balance.
The ECS consists of G-protein-coupled cannabinoid receptors, i.e. type 1 and type 
2 (CB1 and CB2), the endogenous lipid ligands (endocannabinoids) and the enzymatic 
machinery for their synthesis and degradation. Anandamide (AEA) and 2-arachidonoyl-
glycerol (2-AG) are the most studied endocannabinoids and are synthesized on demand 
from their membrane lipids through the action of the biosynthetic enzymes N-acyl-
phosphatidyl-ethanolamine phospholipase D (NAPE-PLD) and diacylglycerol lipases 
(DAGL), respectively. Endocannabinoids are degraded by specific enzymes. Fatty acid 
amide hydrolase (FAAH1 and FAAH2) inactivates AEA and monoglycerol lipase (MAGL) 
hydrolyzes 2-AG. Arachidonic acid is a precursor molecule and metabolite for endocan-
nabinoids. AEA belongs to a family of bioactive N-acylethanolamines, which include 
N-linoleoylethanolamine, N-palmitoylethanolamine, N-oleoylethanolamine, N-stearo-
ylethanolamine and N-docosatetraenylethanolamide. These N-acylethanolamines arise 
from the same biosynthetic pathway as AEA and are capable to indirectly modulate can-
nabinoid receptor activity by interfering with endocannabinoid metabolism, known as 
an “entourage effect” (11). Palmitoylethanolamine and, especially, N-oleoylethanolamine 
interact with nuclear receptor peroxisome proliferator-activated receptor α, stimulate 
lipolysis in the liver and adipocytes and act as a satiety factor (9, 12).
We previously showed that young healthy lean South Asian men have lower resting 
energy expenditure (13) and higher circulating endocannabinoid levels compared to 
matched white Caucasians (14). High plasma endocannabinoid levels are associated 
with obesity (15) and T2D (6) and affect peripheral metabolic organs, including adipose 
tissue and skeletal muscle (5). In addition, obese individuals have reduced expression 
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of endocannabinoid degradation enzymes and CB1 receptor in adipose tissue (16, 17). 
Elevated circulating endocannabinoid levels might be a result of decreased enzymatic 
degradation (16). As little is known about ECS in overweight, prediabetic South Asian 
compared with white Caucasian men, we investigated circulating endocannabinoid 
levels and gene expression of CB receptors and enzymes involved in endocannabinoid 
synthesis and degradation in WAT and skeletal muscle of middle-aged men of South 
Asian and white Caucasian descent. We hypothesized that overweight, prediabetic 
South Asian men would have elevated plasma endocannabinoid levels and conse-




Blood and tissue samples were collected as part of a previously conducted cross-over 
study to investigate the effect of L-arginine on brown adipose tissue activity and resting 
energy expenditure in overweight, prediabetic South Asian and white Caucasian men 
(18). This study was approved by the Ethics Committee of Maastricht University Medi-
cal Center (MUMC) and the Leiden University Medical Center (LUMC) and undertaken 
in accordance with the principles of the revised Declaration of Helsinki. All volunteers 
provided written informed consent. Trial registration number and date: NCT02291458, 
14 November 2014.
Participants and study design
Twenty Dutch overweight (BMI 25-35 kg/m2) prediabetic men of South Asian (n=10) 
and white Caucasian (n=10) descent (aged 35-55 years) were enrolled. South Asians 
and white Caucasians were matched for BMI. This study was conducted at the LUMC 
(The Netherlands) between November 2014 and August 2015 (18). Subjects underwent 
medical screening including an oral glucose tolerance test to identify individuals with 
impaired glucose tolerance according to the American Diabetes Association 2010 (19) 
and/or WHO criteria. In line with the ADA criteria (19), prediabetes was defined as hav-
ing either fasting plasma glucose levels between 5.6 and 6.9 mmol/L or plasma glucose 
levels 2 h after an oral glucose tolerance test between 7.8 and 11.1 mmol/L. Exclusion 
criteria included the presence of chronic disease including T2D, smoking and recent 
body weight change up to 3 months prior to the start of the study.
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Study procedures
The study procedures were described previously (18). In short, subjects were treated for 
6 weeks with either L-arginine (9 g/day) (Argimax, Hankintatukku Oy, Karkkila, Finland) 
or placebo supplements (containing 70% microcrystalline cellulose, 29% maize starch 
and 1% magnesium stearate) in a randomized double-blind cross-over design, with a 
4-week washout period. Each treatment period was followed by two consecutive study 
days, which consisted of several measurements. During the first study day lipid oxida-
tion and glucose oxidation were determined for 30 minutes with indirect calorimetry 
using a face-mask (EZcal, IDEE, Maastricht, the Netherlands) and subsequently fasted 
venous blood samples were collected to quantify plasma triglycerides (using commer-
cially available enzymatic colorimetric kits and an ABX Pentra 400 autoanalyzer) and 
endocannabinoids (liquid chromatography coupled with tandem mass spectrometry 
(LC-MS/MS)) as described previously (14). The next day, a fasted WAT (abdominal sub-
cutaneous adipose tissue) and skeletal muscle (vastus lateralis) biopsy were collected 
as described previously (20). The tissues were instantly placed in ice-cold preservation 
medium (BIOPS, OROBOROS Instruments, Innsbruck, Austria) and stored at -80°C. There-
after, body composition was determined by means of dual x-ray absorptiometry (DEXA; 
Discovery A, Hologic, Bedford, MA, USA). From one white Caucasian no DEXA scan data 
was available due to technical problems. For the purpose of this study only the fasted 
blood samples and WAT and skeletal muscle biopsies taken after placebo treatment 
were analyzed. All samples were taken at the same time of the day in all volunteers. 
Blood samples were obtained during the first study day at 11 A.M. after a 4-hour fast. 
WAT and skeletal muscle biopsies were obtained during the second study day at 8:00 
A.M. after an overnight fast.
Endocannabinoid measurements
Plasma endocannabinoids and their congeners were quantified with LC-MS/MS. From 
the pool of individual study samples, quality controls were used to generate calibration 
curves. Additionally, all samples were randomized and each batch included calibration 
samples and an even distribution of quality control samples and blanks. The sample 
extraction procedure and method is as described in detail previously (14).
WAT and skeletal muscle gene expression
WAT and skeletal muscle biopsies of South Asians and white Caucasians after pla-
cebo treatment were analyzed. RNA was extracted using Tripure RNA isolation reagents 
(Roche, Molecular Biochemicals, Indianapolis, USA). Total RNA was reverse transcribed 
using Promega M1705 Reverse transcriptase for RT-PCR according to the instructions by 
the manufacturer to produce cDNA. Expression levels of enzymes involved in endocan-
nabinoid synthesis (DAGLA and DAGLB, NAPEPLD and PLA2G4E) and degradation (MGLL, 
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FAAH1 and FAAH2) and CB receptors (CNR1 and CNR2) were determined in a 96-well PCR 
plate by real-time PCR (Bio-Rad CFX96), using gene-specific primers (Table 1) and IQ 
SYBR-Green super mix (PromegaA6002). For analysis and quantification, Bio-Rad CFX 
Manager software version 3.1 was used. Gene expression was normalized by using 18S 
(for WAT) or GAPDH (for skeletal muscle) mRNA content and expressed as fold difference 
compared to white Caucasian using the ΔΔCT method.
Statistical analysis
Data were collected and analyzed using IBM SPSS statistics version 23.0. Baseline 
characteristics and differences in plasma endocannabinoid levels between ethnicities 
were compared using unpaired student t-tests. Furthermore, linear regression analysis 
computed by Pearson’s correlation was used to determine correlations between plasma 
endocannabinoid levels and different metabolic parameters. Regression analysis was 
performed both with and without correction for the effect of ethnicity, by respectively 
including/excluding ethnicity as a covariate. P values < 0.05 were considered as statisti-
cal significant. Data are presented as mean ± SEM. The datasets generated during and/




The clinical characteristics of the participants were partly described previously (18). In 
brief, twenty overweight, prediabetic men of South Asian (n=10) and white Caucasian 
Table 1. Sequences of forward and reverse primers
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(n=10) descent were included. Mean age (46.5±2.8 vs 47.5±2.0 years) and BMI (30.1±1.1 
vs 30.7±1.2 kg/m2) were comparable between South Asians and white Caucasians, 
respectively, as were body fat percentage (31.0±1.1% vs 30.1±1.0%), plasma triglyceride 
concentration (1.6±0.2 vs 1.5±0.2 mmol/L) and fasting glucose level (5.6±0.5 vs 5.7±0.7 
mmol/L). Resting energy expenditure was lower in South Asians as compared to white 
Caucasians (4.9±0.2 vs. 5.7±0.2 kJ/min; p<0.05), while lipid and glucose oxidation did 
not differ significantly.
South Asians have higher plasma levels of some endocannabinoids
First, we studied circulating endocannabinoid levels in both ethnicities. Plasma 2-AG 
and AEA levels were comparable between South Asians and white Caucasians (12.8±1.5 
vs 10.6±1.2 pmol/mL; figure 1A, and 1.0±0.1 vs 0.9±0.1 pmol/mL; figure 1B, respec-
tively). Plasma arachidonic acid tended to be higher in South Asians (18.3±1.1 vs 
14.6±1.6 nmol/mL, p=0.07; figure 1C). In addition, plasma 2-linoleoyl glycerol (208±23 
vs 114±17 pmol/mL, p<0.01; figure 1D) and N-linoleoylethanolamine (3.0±0.2 vs 
2.2±0.2 pmol/mL, p<0.05; figure 1E) were higher in South Asians compared to white 
Caucasians. Plasma 1-linoleoyl glycerol (243±28 vs 169±30 pmol/mL, p=0.09; Table S1), 
and N-docosatetraenylethanolamide (6.3±0.4 vs 5.3±0.4 pmol/mL, p=0.08; Table S1) 
both tended to be higher in South Asians. No significant differences were observed for 
other N-acylethanolamines and mono- and di-acyl glycerols measured.
Circulating endocannabinoid levels correlate with plasma triglycerides and 
lipid oxidation
We next investigated whether circulating endocannabinoid levels correlated with meta-
bolic parameters in our study by pooling endocannabinoid levels of the two ethnicities. 
Plasma 2-AG levels positively correlated with plasma triglyceride levels (R=0.77, p<0.001; 






































































A B C D E
figure 1. Circulating endocannabinoid levels in South Asian and white Caucasian men. Blood was col-
lected from overweight, prediabetic South Asian (n=10; black bars) and matched white Caucasian (n=10; 
white bars) men. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was used 
to measure plasma concentrations of 2-AG (A), AEA (B), arachidonic acid (AA) (C), 2-linoleoyl glycerol (2-LG) 
(D) and N-linoleoylethanolamine (LEA) (E) concentrations. Values are mean ± SEM. P-values are based on 
unpaired t-tests. * p<0.05, ** p<0.01.
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not correlate with any of these parameters (data not shown). To test whether the effects 
could be attributed to ethnicity, we repeated the regression analysis including ethnicity 
as covariate and found that this did not change the results.
South Asians have lower mRNA expression of CB receptors and 
endocannabinoid degradation enzymes in skeletal muscle
Since circulating endocannabinoid levels not necessarily reflect tissue-specific signaling, 
we next assessed mRNA expression of CB receptors and enzymes involved in endocan-
nabinoid synthesis and degradation in WAT and skeletal muscle biopsies of South Asian 
and white Caucasian men.
In WAT, expression levels of all measured genes were not different between the two 
ethnicities (figure 3A). However, in skeletal muscle, the relative expression of the deg-
radation enzyme FAAH2 (FAAH2) was 5-fold lower in South Asians compared to white 
Caucasians (-81%, p<0.001; figure 3B). In addition, expression of the other degradation 
enzymes, MAGL (MGLL) and FAAH1 (FAAH1) tended to be lower in South Asians (-22%, 
p=0.05 and -18%, p=0.07, respectively; figure 3B). Moreover, expression of both the 
CB1 (CNR1) and CB2 (CNR2) receptor was approx. 10-fold lower in South Asians as com-
pared to white Caucasians (-93%, p<0.001 and -90%, p<0.001; figure 3B). Expression 
of endocannabinoid synthesis enzymes was comparable (figure 3B) between the two 
ethnicities.
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figure 2. Plasma 2-AG levels positively correlate with plasma triglyceride levels and with lipid oxida-
tion in South Asian and white Caucasian men. Scatterplot of the correlations between 2-AG levels and 
plasma triglycerides (A) or lipid oxidation (B). Correlations are shown for the total group combined (n=20), 
white circles represent white Caucasian men (n=10) and black circles represent South Asian men (n=10), 
with 95% confidence limits. Correlations were analyzed using linear regression analysis.
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DISCuSSION
The incidence of obesity and T2D is particularly high in individuals of South Asian 
descent. In the present study, we investigated different markers of endocannabinoid 
signaling in overweight, prediabetic South Asian and white Caucasian men. Here we re-
port that, plasma 2-linoleoyl glycerol and N-linoleoylethanolamine were higher in South 
Asians compared to white Caucasians. In addition, gene expression of the enzymes 
involved in endocannabinoid degradation as well as CB receptors in skeletal muscle was 
markedly lower in South Asians as compared to white Caucasians. In addition, plasma 
2-AG correlated positively with plasma triglycerides and lipid oxidation.
We observed higher levels of the endocannabinoids 2-linoleoylglycerol and N-lino-
leoylethanolamine in overweight, prediabetic South Asian compared to white Caucasian 
men. In our previous study in healthy lean South Asians and white Caucasians we also 
observed higher endocannabinoid levels in South Asians, however, in that study other 
endocannabinoids (i.e. 2-AG and AEA) were higher (14). If we compare the effect sizes 
between the two different cohorts we observe that except for N-palmitoylethanolamide, 
all effects are in the same direction albeit that the effect sizes differ for most endocan-
nabinoids between the two cohorts. Furthermore, there is no clear pattern in the effect 
size with respect to whether it is larger in either the lean or the overweight cohorts. 
This is likely due to the different phenotype of the subjects in both cohorts. Of note, 
circulating endocannabinoid levels in this cohort of overweight, prediabetic men were 
not significantly higher compared to endocannabinoid levels measured in our previous 























































figure 3. Relative expression of synthesis and degradation enzymes of endocannabinoids and mRNA 
expression of cannabinoid (CB) receptors in South Asian and white Caucasian men. Abdominal white 
adipose tissue and skeletal muscle tissue biopsies from the vastus lateralis muscle were taken after an over-
night fasting period. Gene expression in white adipose tissue (A) and skeletal muscle (B) was determined 
by qPCR. Gene expression was normalized by using 18S (white adipose tissue) or GAPDH (skeletal muscle) 
mRNA content and expressed as fold change compared to white Caucasians using the ΔΔCT method. ND 




was insufficiently large (average BMI 22 kg/m2 in lean versus BMI 30 kg/m2 in overweight 
men) to observe differences in circulating endocannabinoid levels between the two 
cohorts.
We also found a strong correlation between 2-AG and plasma triglyceride levels. This 
correlation was also present in our previous cohort of healthy lean South Asian and 
white Caucasian men (14) and is in line with results of Bluher et al. (21). The biological 
explanation for this correlation is currently unknown. Possibly, it can at least partly be 
explained by the fact that both 2-AG and triglycerides are lipid molecules with common 
lipid intermediates as precursors (e.g. diacylglycerol), resulting in production and secre-
tion into blood of 2-AG concomitant with VLDL-triglyceride.
To investigate potential differences in endocannabinoid signaling in metabolically 
active tissues we examined WAT and skeletal muscle biopsies from these overweight, 
prediabetic men. We did not observe differences in expression of genes involved in 
endocannabinoid signaling in WAT between the two ethnicities. Interestingly, in skeletal 
muscle, we found that mRNA expression of the endocannabinoid degradation enzymes 
and CB receptors was lower in South Asians as compared to white Caucasians. Possibly, 
low expression of degradation enzymes in skeletal muscle of the South Asian men 
might have contributed to higher local endocannabinoid levels within skeletal muscle 
thereby possibly inducing CB receptor downregulation in this tissue (15). Alternatively, 
the dietary intake between South Asians and white Caucasians may have been different, 
as South Asian diets often contain low n-3 PUFA which has been shown to modulate the 
expression of endocannabinoid synthesis and degradation enzymes and CB receptors 
(22). Although all subjects used a standardized meal the evening before the study day, 
we cannot exclude that differences in diet might have influenced our results. Based on 
our study, we can thus only speculate about the underlying mechanisms, which is an 
interesting subject of future studies. Interestingly, the CB1 receptor regulates metabolic 
processes including insulin signaling, glucose uptake, and fatty acid oxidation in skeletal 
muscle (7,8). Moreover, overstimulation of CB receptors in skeletal muscle can disrupt 
insulin signaling thereby promoting insulin resistance which could eventually lead to 
development of (pre)diabetes (5). Since South Asians are known to have an increased 
risk for the development of metabolic disease, including T2D (2), dysregulation of ECS 
in skeletal muscle might thus contribute to diabetes development in this population.
Our study has several limitations. Firstly, we had a small sample size of ten South 
Asian and ten white Caucasian men. Secondly, all individuals were already metabolically 
deregulated as they are overweight and have prediabetes. This may have limited the 
differences we could observe between the two ethnic groups. In addition, we can only 
speculate about the mechanisms underlying the differences in ECS signaling between 
South Asians and white Caucasians. Future studies in larger cohort should investigate if 
these results also apply to women and lean, non-prediabetic individuals to determine 
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if these results could be translated to the general population. A strength of our study is 
that we measured both circulating endocannabinoids and gene expression of the ECS in 
WAT and skeletal muscle in the same individuals.
Taken together, our data show that, plasma 2-linoleoyl glycerol and N-linoleoyleth-
anolamine were higher in overweight, prediabetic South Asians compared to white 
Caucasians. In addition, South Asian individuals had lower expression of enzymes in-
volved in endocannabinoid degradation and CB receptors in skeletal muscle. Although 
it remains speculative, high endocannabinoid levels may deteriorate endocannabinoid 
signaling in metabolic organs, including skeletal muscle and thereby may contribute to 
the development and/or progression of obesity and possibly even T2D, both of which 
are highly prevalent in South Asians. Further studies are required to show if therapeutic 
interventions that target the ECS will improve the metabolic profile of these individuals.
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Short-term cooling increases serum 
angiopoietin-like-4 levels in healthy lean men












Cold exposure enhances sympathetic outflow to peripheral tissues, thereby stimulating 
intracellular lipolysis in white adipose tissue and increasing the lipoprotein lipase (LPL)-
dependent uptake and combustion of triglyceride-derived fatty acids (FA) by brown 
adipose tissue. Angiopoietin-like 4 (ANGPTL4) inhibits LPL and can be regulated by cold 
exposure, at least in mice. In the current study we examined the effect of short-term mild 
cooling on serum ANGPTL4 levels in healthy lean men of white Caucasian and South 
Asian descent. Healthy, lean white Caucasian (n=12) and South Asian (n=12) men were 
exposed to an individualized cooling protocol for 2 hours. Serum ANGPTL4 levels were 
measured before and after cooling and its relation with previously measured parameters 
(i.e. FFA levels, body fat percentage and resting energy expenditure) was determined. 
Short-term cooling increased ANGPTL4 levels (+17%, p<0.001). Thermoneutral ANGPTL4 
levels positively correlated with FFA levels (R2=0.250, p<0.05) and body fat percentage 
(R2=0.338, p<0.05). Furthermore, ANGPTL4 negatively correlated with resting energy 
expenditure (R2=0.235, p<0.05). The relative increase in ANGPTL4 levels was higher in 
white Caucasians compared to South Asians (25±4 vs 9±4%, p<0.05). Short-term cooling 
increases ANGPTL4 levels in healthy lean men. We anticipate that FFA liberated from 
white adipose tissue during cooling increases ANGPTL4 to limit uptake of triglyceride-
derived FA by this tissue.
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INTRODuCTION
Cold exposure enhances the sympathetic outflow towards peripheral metabolic organs, 
including white adipose tissue (WAT) and brown adipose tissue (BAT) (1,2). In WAT, 
sympathetic stimulation increases intracellular lipolysis and subsequent release of free 
fatty acids (FFA) into the bloodstream (3). In contrast, sympathetic stimulation of BAT 
increases the uptake and combustion of triglyceride (TG)-derived FA (4,5).
Uptake of TG-derived FA from TG-rich lipoproteins by metabolic organs is determined 
by the activity of lipoprotein lipase (LPL). LPL is tightly regulated by many factors includ-
ing angiopoietin-like 4 (ANGPTL4). ANGPTL4 is expressed by metabolic tissues (i.e. liver, 
WAT and BAT (6,7)) and inhibits LPL resulting in limited uptake of TG-derived FA uptake 
by tissues (8,9). ANGPTL4 expression is stimulated by elevated intracellular FFA levels 
(10), through activation of peroxisome proliferator-activated receptors (PPARs) (9). In 
mice we recently showed that cold exposure decreases ANGPTL4 protein content in BAT 
while increasing ANGPTL4 protein content in WAT (6,11). This opposite regulation of 
ANGPTL4, and thus LPL activity, in BAT and WAT makes physiological sense to secure the 
shuttling of FA towards BAT in order to meet the increased energy demand of activated 
BAT for heat production (11).
Although the regulation of ANGPTL4 upon cooling is well described in mice, the effect 
of short-term cooling on circulating ANGPTL4 levels in humans remained to be eluci-
dated. Moreover, ANGPTL4 levels may be differentially regulated in subjects of South 
Asian descent, in which we previously showed lower resting energy expenditure (REE) 
and BAT volume upon cold exposure as compared to white Caucasians (12). The aim of 
the current study was, therefore, to determine the effect of short-term mild cooling on 
serum ANGPTL4 levels in healthy lean men of white Caucasian and South Asian descent.
MATERIALS AND METhODS
For the current study, blood samples were used from a previous clinical study (12) that 
was approved by the Medical Ethical Committee of the Leiden University Medical Center 
and undertaken in accordance with the principles of the Declaration of Helsinki. All 
volunteers provided written informed consent. Netherlands Trial Register 2473.
An extensive description of the materials and methods has been described previously 
(12). In short, twenty-four healthy, young (18-28 years), lean (BMI < 25 kg/m2) white 
Caucasian (n=12) and South Asian (n=12) men, participated in a prospective case-
controlled study. Body composition was assessed by bioelectrical impedance analysis 
(BIA). An individualized water cooling protocol (2 hours mild cooling) followed by [18F]
FDG-PET-CT imaging was performed to quantify BAT volume and activity. Before and 
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after cooling, REE was measured (Oxycon) and fasted blood samples were collected. 
Pre- and post-cooling blood samples were analysed for ANGPTL4 by ELISA (10) and 
related to previously measured FFA levels, lipoprotein constituent levels (triglycerides 
(TG), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol 
(HDL-C)), body fat percentage and REE. The effects of cooling on ANGPTL4 and FFA, TG, 
LDL-C and HDL-C were assessed using paired (effect of cold) and unpaired (effect of 
ethnicity) student t-tests with the SPSS 20 software. Correlations were analysed using 
linear regression analysis, both with and without correction for the effect of ethnicity, by 
respectively including/excluding ethnicity as a covariate. For lipid and lipoprotein mea-
surements one South Asian and one white Caucasian individual were excluded because 
of familial hypercholesterolemia and hyperventilation, respectively. Data on body fat 
is missing for four South Asians and two white Caucasians because BIA measurements 
could not be not performed. Values of P<0.05 were considered statistically significant. 
Data are presented as mean ± SEM.
RESuLTS
Clinical characteristics
Clinical characteristics of the participants and REE, BAT volume and lipid and lipoprotein 
levels were described previously (12,13). In short, we observed lower thermoneutral 
REE in South Asians as compared to white Caucasians (1297±36 vs 1689±56 kcal/day, 
p<0.001). Short-term cooling significantly increased REE in white Caucasians (2027±136 
kcal/day, +20%, p<0.01) but not in South Asians (1462±37 kcal/day, +13%, ns). In addi-
tion, body fat percentage was significantly higher in South Asians compared to white 
Caucasians (16±1 vs 12±1 %, p<0.05) and BAT volume was lower in South Asians as 
compared to white Caucasians (188±23 vs 287±49 mL, p<0.05). Thermoneutral serum 
FFA levels were not different between white Caucasians and South Asians (0.66±0.09 vs 
0.88±0.12 mmol/L, n.s.). However, cooling strongly increased FFA levels in white Cauca-
sians (0.99±0.09 mmol/L, +49%, p<0.001), but not in South Asians (0.97±0.11 mmol/L, 
+10%, n.s.). In addition, South Asians had comparable thermoneutral serum TG levels 
(1.33±0.77 vs 1.27±0.12 mmol/L) as well as HDL-C levels (0.86±0.04 vs 0.92±0.07 mmol/L), 
while South Asians tended to have higher thermoneutral LDL-C levels (2.39±0.14 vs 
2.01±0.13 mmol/L, p=0.06), as compared to white Caucasians. Cooling significantly 
increased serum TG in both ethnicities (+18%, p<0.05 in white Caucasians and +24%, 
p<0.05 in South Asians), while HDL-C (+9%, p<0.05) and LDL-C (+8%, p<0.01) were only 
increased in white Caucasians upon cooling.
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Short-term cooling increases serum ANGPTL4 levels and ANGPTL4 correlates 
with ffA, body fat percentage and REE
We first evaluated the effect of short-term cooling on ANGPTL4 levels in the entire study 
population and assessed how ANGPTL4 levels correlated with previously measured meta-
bolic parameters, including serum lipid and lipoprotein levels, fat mass and REE (12,13). 
Short-term cooling increased ANGPTL4 levels (+17%, p<0.001; figure 1A). Moreover, 
thermoneutral ANGPTL4 levels correlated positively with FFA levels (R2=0.250, p<0.05; fig-
ure 1B) as well as total body fat percentage (R2=0.338, p<0.05; figure 1C), and correlated 
negatively with REE (R2=0.235, p<0.05; figure 1D). To assess whether ethnicity may have 
influenced these correlations, we re-performed the analysis with correction for ethnicity. 
After correction for ethnicity, serum ANGPTL4 levels still correlated with FFA levels (p<0.05) 
and tended to correlate with REE (p=0.06). The correlation between ANGPTL4 and body 
fat percentage was not significant anymore (p=0.25). No correlation was present between 



















































































figure 1. Short-term mild cooling increases serum ANGPTL4 levels in healthy lean men and correlate 
with metabolic parameters. Blood was collected from healthy, young lean white Caucasian (n=12) and 
matched South Asian (n=12) individuals before (Thermoneutral; TN) and after short-term cooling (COLD). 
Serum ANGPTL4 levels were measured using ELISA. (A) Grouped data of thermoneutral (TN) and cold 
(COLD) measurement (n=24). Scatterplot of the correlations between serum ANGPTL4 levels measured 
at thermoneutrality and serum free fatty acid levels at thermoneutrality (white Caucasians, n=11; South 
Asians, n=11) (B), and body fat percentage (white Caucasians, n=10; South Asians, n=8) (C) and thermo-
neutral resting energy expenditure (REE) (white Caucasians, n=12; South Asians, n=12) (D). Correlations 
are shown for the total group combined, white circles are white Caucasian individuals and black circles are 
South Asian individuals, with 95% confidence limits. Values are mean ± SEM. ***P<0.001. P-values are based 
on paired t-tests (effect of cold). Correlations were analysed using linear regression analysis.
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ANGPTL4 response upon cooling is more pronounced in white Caucasian 
compared to South Asian men
We previously showed lower REE and BAT volume upon cold exposure in South Asians 
compared to white Caucasians (12). Therefore, we hypothesized that ANGPTL4 levels 
may be differentially regulated in subjects of South Asian descent and thus explored 
the effect of short-term cooling on ANGPTL4 levels in the two ethnicities separately. 
At thermoneutrality, ANGPTL4 levels were not different between white Caucasians and 
South Asians (3.63±0.37 vs 4.52±0.41 ng/mL, p=0.122, figure 2A, B). In contrast, cooling 
markedly increased ANGPTL4 levels in white Caucasians (+25%, p<0.001; figure 2A), 
while ANGPTL4 levels only showed a tendency towards an increase in South Asians (+9%, 
p=0.09; figure 2B). After excluding two ‘biological outliers’, i.e. the white Caucasian and 
South Asian individual with the highest ANGPTL4 levels at thermoneutrality, short-term 
cooling significantly increased ANGPTL4 levels in South Asians as well (+10%, p<0.05; 
data not shown). Nevertheless, the relative increase in ANGPTL4 levels was higher in 
white Caucasian men compared to South Asian men (+25±4 vs +9±4%, p<0.05; figure 
2C). Also after excluding the two ‘biological outliers’ the relative increase was still larger 
in white Caucasians as compared to South Asians (+24±5 vs +10±4%, p<0.05; data not 
shown).
DISCuSSION
ANGPTL4 is an important regulator of LPL activity and thereby controls lipid availability. 
In the current study we examined the effect of short-term mild cooling on serum ANG-




























































figure 2. Short-term mild cooling increases serum ANGPTL4 levels in white Caucasians, but only 
tended to increase in South Asians. Blood was collected from healthy, young lean white Caucasian (n=12) 
and matched South Asian (n=12) individuals before (Thermoneutral) and after short-term cooling (Cold). 
Serum ANGPTL4 levels were measured using ELISA. Individual changes in ANGPTL4 levels upon cooling in 
white Caucasian (A) and South Asian (B) individuals, respectively. Percentage increase in ANGPTL4 levels 
upon cooling in white Caucasians (white bar) and South Asians (black bar) (C). Values are mean ± SEM. 
*P<0.05 , ***P<0.001. P-values are based on paired t-tests (effect of cold) or unpaired t-tests (effect of eth-
nicity).
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that cooling increased ANGPTL4 levels and that ANGPTL4 levels positively correlated 
with FFA levels and total body fat percentage and negatively correlated with REE. The 
relative increase in ANGPTL4 levels was higher in white Caucasians compared to South 
Asians.
The finding that cooling increased ANGPTL4 levels in healthy lean men is in line with 
previous work that showed increased plasma ANGPTL4 levels after administration of 
the β3-receptor agonist Salbutamol (10). β3-receptor agonism causes FFA liberation 
from WAT and TG-derived FA uptake by BAT, thus mimicking the effect of cold expo-
sure (4). In addition, we previously showed that cooling increases FFA levels in white 
Caucasians (12), and now show that FFA levels at thermoneutrality correlate positively 
with ANGPTL4 levels. This is in concordance with other studies showing increased FFA 
levels after cooling (14,15) and β3-receptor activation (16), and a positive correlation 
between FFA levels and ANGPTL4 (10,17,18). Similarly, the increase in FFA levels that is 
induced by fasting is also accompanied by an increase in ANGPTL4 levels (10). Together, 
these data indicate that circulating FFA levels are either an important driver or predictor 
of ANGPTL4 levels. A likely explanation is that liberation of FFA from white adipocytes 
by intracellular lipolysis, as induced by cold exposure, β3-receptor activation and fast-
ing (3), activates PPARγ leading to increased ANGPTL4 expression (9) (see hypothetical 
model figure 3).
The fact that we found a positive correlation between thermoneutral ANGPTL4 levels 
and body fat percentage may support the notion that WAT is a main organ that con-
tributes to circulating ANGPTL4 levels (10). In mice, cold exposure increases ANGPTL4 




























































figure 3. hypothetical mechanism explaining that cold increases ANGPTL4 and ffA. Compared to 
thermoneutrality (panel A), cold exposure (panel B) activates the sympathetic nervous system (SNS) to 
stimulate intracellular lipolysis in white adipose tissue (WAT) and release of fatty acids (FA). The liberated FA 
is secreted as free FA (FFA) in serum, and activates PPARγ to increase expression of ANGTL4 that is subse-
quently released into the circulation where it can inhibit LPL to prevent cellular FA entry.
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in WAT and decreases ANGPTL4 protein levels specifically in BAT in order to shuttle 
TG-derived FA to BAT for combustion (11). It can be speculated that this mechanism 
also occurs in humans during cooling to guarantee lipid availability for BAT during cold 
exposure. We could only measure systemic ANGPTL4 levels, which is the net effect of 
whole-body ANGPTL4 regulation. Given that the total volume of WAT exceeds that of 
BAT by far, an overall increase in serum ANGPTL4 levels is indeed expected. We showed 
that thermoneutral ANGPTL4 levels correlated negatively with REE, which suggests that 
ANGPTL4 is a negative regulator of energy expenditure. This is line with the function 
of ANGPTL4 to inhibit LPL and thus the uptake of TG-derived FA uptake by metabolic 
tissues, especially under conditions where BAT activity is considered negligible (8,9).
When exploring the ANGPTL4 response within the different ethnicities we found that 
cooling significantly increased serum ANGPTL4 in white Caucasians but not in South 
Asians. Previously, we showed that in South Asians also the FFA response is blunted 
and that they have lower REE and BAT volume upon short-term cooling (12). Collec-
tively, these data may suggest that South Asian individuals have lower cooling-induced 
sympathetic outflow towards peripheral organs. Interesting, we recently showed that 
South Asians, compared to white Caucasians, have higher levels of circulating endocan-
nabinoid levels (19), which are thought to inhibit sympathetic signalling (20,21). Future 
studies are necessary to further elucidate the possibility that South Asians have lower 
sympathetic signalling, for example by measuring the effect of cooling on heart rate 
variability and 123I-metaiodobenzylguanidine uptake using single-photon emission 
computed tomography.
Our study has several limitations. First, we cannot exclude that the higher body fat 
percentage in the South Asians compared to the white Caucasians might also have 
contributed to the difference in ANGPTL4 response that we observed between the two 
ethnicities. Future studies in cohorts with similar body fat percentages at baseline should 
be performed to elucidate this possibility. Furthermore, we had a relatively small sample 
size of twelve South Asian and twelve white Caucasian men. Based on an unpaired 
student t-test we did not observe a significant difference in baseline ANGPTL4 levels 
between both ethnicities. In addition, when in both ethnical groups the individual with 
the highest baseline ANGPTL4 level was removed from the analysis, short-term cooling 
significantly increased ANGPTL4 levels in the South Asians as well, although the relative 
increase in ANGPTL4 levels was still larger in the white Caucasians. Whether ANGPTL4 
responses are truly different between the two ethnicities should be further investigated 
in studies with larger sample sizes. Furthermore, we only investigated a group of healthy 
lean men. Future studies in larger cohorts should investigate if baseline levels of ANG-
PTL4 are indeed not different between the two ethnicities and if these results also apply 
to the general population.
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In conclusion, our data demonstrate that short-term mild cooling increases circulat-
ing ANGPTL4 levels in healthy lean men, with a significantly higher response in white 
Caucasian compared to South Asian men. As underlying mechanism we speculate that 
cold exposure causes intracellular lipolysis in white adipocytes to liberate FFA that, via 
activation of PPARγ, increase ANGPTL4 synthesis. Possibly, this sequence of events is 
blunted in South Asians because of reduced sympathetic signalling, which would an 
interesting topic for future research.
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During mild cold exposure, non-shivering thermogenesis increases to maintain core 
body temperature by increasing utilization of substrates, especially fatty acids (FA), 
ultimately affecting lipid-associated metabolites. We aimed to investigate whether 
mild cooling induces changes in other metabolites and whether this response differs 
between white Caucasians and South Asians, who have a disadvantageous metabolic 
phenotype. 12 lean male Dutch white Caucasians and 12 matched Dutch South Asians 
were exposed to mild cold. Before and after 100 minutes exposure, serum samples were 
collected for analysis of 163 metabolites and 27 derived parameters using high through-
put metabolomics. The overall response to mild cooling between both ethnicities was 
not different, therefore the data were pooled. After Bonferroni correction, mild cool-
ing significantly changed 44 of 190 (23%) metabolic parameters. Specifically, cooling 
increased 19 phosphatidylcholine (PC) species, only those containing very long chain 
FAs, and increased the total class of PC containing mono-unsaturated FAs (+12.5%). 
Furthermore, cooling increased 10 sphingomyelin species as well as the amino acids 
glutamine (+18.7%), glycine (+11.6%) and histidine (+10.6%), and decreased short-chain 
(C3 and C4) acylcarnitines (-17.1% and -19.4%, respectively). In conclusion, mild cooling 
elicits substantial effects on serum metabolites in healthy males, irrespective of white 
Caucasian or South Asian ethnicity.
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INTRODuCTION
Mammals are programmed to tightly maintain their core body temperature, during 
high as well as low environmental temperatures. Cold exposure results in a fast physi-
ological response that includes minimizing heat loss by peripheral vasoconstriction and 
enhancing heat production by thermogenesis (e.g. ‘cold-induced thermogenesis’). Cold-
induced thermogenesis is a tightly regulated process in which a coordinated action of 
many organs is involved (1). It can be divided in non-shivering thermogenesis (NST) 
and shivering thermogenesis. NST is quickly activated upon cold exposure and is largely 
mediated by activation of UCP1 in brown adipose tissue (BAT), which uncouples the 
electron transport chain from ATP synthesis resulting in production of heat (2). Shivering 
thermogenesis is induced when NST is insufficient to maintain core body temperature 
and occurs as a consequence of muscle contractions. Shivering thermogenesis can 
increase human basal metabolic rate (BMR) by as much as 3-5 fold, however, it is gener-
ally experienced as uncomfortable. NST can contribute to BMR up to a more modest 
+30% but can be sustained without appreciable discomfort. Therefore, enhancing NST 
is generally considered an attractive target to fight obesity (2).
Exposure to mild cold exposure, generally resulting in enhanced NST, has large meta-
bolic implications, for instance it results in high demand of extra fuel, of which fatty acids 
(FAs) are likely the most important. FAs are released from white adipose tissue (WAT) as 
a consequence of lipolysis and are subsequently redirected to several metabolic organs, 
including BAT, for oxidation and subsequent production of ATP or heat (3,4). Interest-
ingly, we recently showed that the increase in FA upon mild cold-induced thermogenesis 
shows an ethnic variation in healthy lean men. When exposed to mild cold, serum FA 
levels significantly increased in white Caucasians but not in South Asians (5).
Metabolomics is an efficient approach to study many separate metabolic pathways 
in a high-throughput fashion (6). Therefore, the objective of the current study was to 
study changes in metabolites upon mild cooling and to assess ethnic differences in this 
response in white Caucasians versus South Asians.
MATERIALS AND METhODS
Ethics
Blood samples were collected as part of a clinical study aimed at investigating the ac-
tivity and volume of BAT in Dutch white Caucasian and Dutch South Asian individuals 
(5). The study was approved by the Medical Ethical Committee of the Leiden University 
Medical Center (LUMC) and undertaken in accordance with the principles of the revised 
Declaration of Helsinki. All volunteers provided written informed consent.
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Participants and study design
Twenty four Dutch healthy, lean (BMI < 25 kg/m2) males of white Caucasian (n=12) and 
South Asian (n=12) origin between 18 and 28 years of age were included. The study was 
conducted in The Rijnland Hospital, Leiderdorp (The Netherlands).
Subjects were studied in the morning after a 10-hour overnight fast and subjects were 
not allowed to exercise 24 hours prior to the study. Subjects wore standardized cloth-
ing, consisting of a T-shirt and boxer shorts. Upon arrival, subjects ingested a telemetric 
capsule (Jonah™, BMedical, Australia) to measure core body temperature at 1-minute 
intervals. An intravenous cannula was inserted for blood collection.
To establish maximum NST, an individualized cooling protocol was used in which a 
subject was placed between two water perfused cooling mattresses (Blanketrol® III, Cin-
cinatti Sub-Zero (CSZ) Products, Inc). During the procedure subjects stayed in a clinical 
examination room (temperature approx. 24°C) in a semi-supine position. The protocol 
started with a baseline period of one hour in thermoneutral condition (water tempera-
ture cooling mattresses 32°C), after which subjects were exposed to mild cold. Since the 
onset temperature of shivering shows a high interindividual variation (e.g. due to dif-
ferences in body composition), an individualized cooling protocol was used to ensure 
maximum NST for each subject. For the cooling protocol, we gradually decreased the 
water temperature of the cooling mattresses until shivering occurred. In short, we first 
decreased the temperature with steps of 5°C every 5 minutes. After we reached a water 
temperature of 17°C, we decreased the temperature with 2°C every 10 minutes. When a 
water temperature of 11°C was reached (but not all subjects reached this temperature), 
we decreased temperature with 1°C every 10 minutes. This was continued until shivering 
occurred. Shivering was detected visually and by asking the subject if he experienced 
shivering. When the shivering temperature had been reached, the subject was warmed 
for 3 minutes with a bathrobe so that shivering stopped after which he was cooled with 
a water temperature 3°C higher than the temperature at which shivering occurred. From 
that moment, a cooling period of two hours was started (defined as t=0 min). In case 
of shivering, temperature was raised by steps of 1°C until shivering just stopped. In this 
manner NST was maximized for each individual without shivering. At the end of the 
thermoneutral period and during the stable cooling period (t= 110 min) venous blood 
was drawn. For metabolomics, we used serum samples from the 22 participants that 
were BAT positive on the basis of the 18F-FDG PET-CT scan and therefore excluded the 2 
(white Caucasian) subjects that exhibited virtually no BAT. These two excluded subjects 
were both from white Caucasian descent. We measured 190 metabolic parameters (of 
which 163 small molecule metabolites) in these samples.
| 79
The effect of cooling on serum metabolites
5
Metabolomics
Metabolomic measurements were performed at the Genome Analysis Center of the Helm-
holtz Zentrum München, Germany, using the Biocrates AbsoluteIDQTM p150 kit (BIOCRATES 
Life Science AG, Innsbruck, Austria) and ESI-FIA-MS/MS measurements (7). This assay allows 
simultaneous quantification of 163 small molecule metabolites out of 10 µL serum. The 
metabolite panel consists of free carnitine, 40 acylcarnitines, 14 amino acids (13 proteino-
genic + ornithine), hexoses (of which 90-95% glucose), 92 glycerophospholipids (of which 
15 lysophosphatidylcholines; LysoPCs) and 77 phosphatidylcholines; PCs), and 15 sphin-
golipids (sphingomyelins). This assay does not measure triglyceride (TG), cholesterol or 
free FA levels. Quantification of the metabolites was achieved by reference to appropriate 
internal standards. The assay has been previously described in detail (7,8). One metabolite, 
PCae38:1, was only detected in one participant and therefore excluded from the analyses, 
leaving 162 metabolites for analyses. Furthermore, 27 additional derived metabolic param-
eters (metabolite classes and metabolite ratios) as provided by Biocrates were examined.
Statistical analyses
First, all metabolites were Z-score transformed to make effect estimates between 
metabolites comparable. Then, we assessed the effect of mild cooling on metabolite 
concentrations or metabolic parameters using paired t-tests. The percentage change 
was calculated by dividing the mean change of a metabolite or metabolic parameter by 
the mean baseline concentration. Subsequently, we examined whether the metabolic 
response to mild cooling differed between white Caucasians and South Asians using 
linear regression analysis. No adjustments (for e.g. BMI or age) were made, since these 
subjects were already matched for these factors. After Bonferroni correction, a p-value 
of 3.1x10-4 (= 0.05/162 metabolites) was considered statistically significant. All statistical 
analyses were performed using SPSS 20 (SPSS Inc, Chicago, IL, USA).
RESuLTS
Clinical characteristics
The characteristics of the participants and the effects of mild cold exposure on cardio-
metabolic parameters have been described previously and are shown in Table 1 (5). 
Subjects were matched for age and BMI. In both ethnic groups, diastolic but not systolic 
blood pressure significantly increased in response to cold (+7 mmHg in white Cauca-
sians, P<0.01; +6 mmHg in South Asians, P<0.01), while heart rate decreased (-5 beats/
min in white Caucasians, P<0.05; -8 beats/min in South Asians, P<0.01). Mean inlet water 
temperature of the cooling mattresses at which shivering started was lower for white 
Caucasians than for South Asians (8.9°C vs 10.9°C; P<0.01). Mean core body temperature 
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was not affected by cold exposure (data not shown) (5,9). Mild cold exposure increased 
energy expenditure, and thus thermogenesis, in white Caucasians (+21%; P<0.01) and a 
tendency towards an increase was observed in South Asians (+13%; P=0.07) (5).
Mild cooling increases plasma free fatty acids
After mild cooling plasma free fatty acid concentrations increased significantly in white 
Caucasians (+44%, p<0.001) but not in South Asians, which was previously published (5).
Mild cold exposure markedly affects several serum metabolites
First, we demonstrated using linear regression that the overall response to the mild cold 
challenge with respect to changes in metabolic parameters did not differ between white 
Caucasians and South Asians (Supplementary table 2, last column). Therefore, meta-
bolic changes will be presented per ethnicity and as pooled results, and results will be 
described per metabolite class in the sections. After mild cold exposure, a marked 116 
out of 189 (61%) metabolic parameters (metabolites and classes/ratios) were changed in 
serum at a nominal significance level. After correction for multiple testing, 44 of the 189 
(23%) measured metabolic parameters remained significant (see Table 2). The complete 
listings of abbreviations are shown in Supplementary Table 1. A list of the full results is 
given in Supplemental Table 2.
Table 1. Participants’ characteristics.
White Caucasians South Asians
Age (years) 24.6 (2.8) 23.6 (2.8)
Number of participants (% males) 10 (100%) 12 (100%)
Body mass index (kg/m2) 22.0 (1.6) 21.5 (2.0)
Shivering temperature (°C) 8.9 (1.5) 10.9 (1.8)##
Systolic blood pressure (mmHg)
Prior to cooling 135 (11) 126 (18)
After cooling 143 (13) 125 (13)
Diastolic blood pressure (mmHg)
Prior to cooling 77 (6) 73 (9)
After cooling 84 (6)** 79 (8)**
Heart rate (beats/min)
Prior to cooling 64 (10) 62 (8)
After cooling 57 (10)* 54 (8)**
Resting energy expenditure (kcal/day)
Prior to cooling 1727 (183) 1297 (123)###
After cooling 2084 (456)** 1462 (127) ###
Values represent number of participants (%) or mean (standard deviation). *P<0.05, **P<0.01 and ***P<0.001 
vs prior to cooling. ##P<0.01; ###P<0.001 vs white Caucasians. All P values are based on a mixed model.
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C3 -21.3% (0.0) 4.25E-04 -14.4% (0.0) 1.46E-03 -17.1 (0.0) 1.17E-06
C4 -18.7% (0.0) 6.78E-03 -19.9% (0.0) 9.25E-03 -19.4% (0.0) 1.33E-04
Amino acids
Gln +20.0% (66.4) 2.22E-03 +17.6% (50.5) 2.60E-04 +18.7% (57.1) 1.09E-06
Gly +9.8% (29.1) 3.84E-02 +13.3% (24.6) 2.59E-03 +11.6% (26.2) 1.97E-04
His +10.5% (9.4) 3.38E-02 +10.6% (5.9) 2.02E-03 +10.6% (7.5) 2.18E-04
Phosphatidylcholines
PC aa C34:1 +14.2% (23.7) 3.21E-03 +11.0% (25.4) 1.51E-02 +12.5% (24.5) 9.57E-05
PC aa C36:1 +13.3% (3.9) 4.97E-03 +11.3% (4.3) 1.45E-02 +12.2% (4.0) 1.33E-04
PC aa C38:3 +17.7% (4.3) 1.02E-03 +12.7% (4.5) 5.17E-03 +15.0% (4.4) 1.07E-05
PC aa C38:4 +19.4% (9.7) 1.01E-03 +14.5% (13.5) 2.42E-03 +16.3% (11.6) 5.59E-06
PC aa C38:5 +19.4% (4.7) 8.73E-04 +15.4% (5.0) 1.39E-03 +17.2% (4.8) 1.92E-06
PC aa C38:6 +22.6% (6.8) 2.63E-04 +12.8% (7.1) 7.43E-04 +16.5% (6.9) 3.55E-07
PC aa C40:4 +18.4% (0.4) 3.00E-03 +19.0% (0.6) 4.17E-03 +18.8% (0.5) 2.75E-05
PC aa C40:5 +22.4% (1.1) 2.66E-04 +13.1% (1.0) 1.04E-03 +17.3% (1.1) 8.31E-07
PC aa C40:6 +21.9% (1.8) 2.07E-04 +14.8% (2.5) 9.75E-04 +17.5% (2.2) 4.33E-07
PC ae C38:4 +18.2% (1.7) 4.35E-03 +15.4% (1.8) 5.93E-03 +16.6% (1.7) 4.25E-05
PC ae C38:5 +15.5% (2.2) 3.93E-03 +11.7% (2.2) 6.57E-03 +13.4% (2.2) 4.29E-05
PC ae C38:6 +15.7% (0.6) 7.79E-04 +7.4% (0.8) 4.38E-02 +10.9% (0.8) 1.58E-04
PC ae C40:0 +15.7% (0.5) 5.61E-04 +10.3% (0.6) 1.06E-02 +12.7% (0.5) 1.77E-05
PC ae C40:2 +13.6% (0.1) 5.10E-03 +19.6% (0.2) 3.74E-03 +16.8% (0.2) 5.15E-05
PC ae C40:4 +15.9% (0.3) 5.02E-03 +19.8% (0.5) 1.09E-02 +18.0% (0.4) 1.74E-04
PC ae C40:5 +16.9% (0.6) 5.93E-03 +23.5% (0.8) 3.16E-03 +20.4% (0.7) 4.10E-05
PC ae C40:6 +19.7% (0.5) 7.62E-04 +15.9% (0.5) 6.14E-04 +17.6% (0.5) 7.02E-07
PC ae C42:5 +16.6% (0.3) 9.70E-03 +14.3% (0.2) 8.45E-04 +15.5% (0.2) 3.45E-05
PC ae C44:5 +18.9% (0.1) 2.64E-03 +13.7% (0.1) 4.06E-03 +16.4% (0.1) 3.17E-05
Sphingomyelins
SM (OH) C14:1 +14.1% (0.6) 3.15E-03 +14.2% (0.7) 3.07E-03 +14.2% (0.6) 1.65E-05
SM (OH) C16:1 +16.0% (0.3) 7.48E-03 +12.2% (0.3) 1.73E-02 +13.8% (0.3) 2.33E-04
SM (OH) C22:1 +21.7% (0.6) 2.03E-04 +17.2% (0.9) 1.07E-03 +19.0% (0.8) 5.77E-07
SM (OH) C22:2 +21.5% (0.5) 2.37E-04 +18.5% (0.7) 1.19E-03 +19.8% (0.6) 7.00E-07
SM C16:0 +13.5% (10.0) 5.26E-03 +12.1% (13.2) 7.40E-03 +12.7% (11.6) 8.01E-05
SM C16:1 +13.5% (1.4) 5.37E-03 +11.6% (1.9) 8.21E-03 +12.4% (1.6) 9.29E-05
SM C18:0 +16.1% (1.5) 1.21E-03 +13.3% (2.1) 4.33E-03 +14.5% (1.8) 1.29E-05
SM C18:1 +17.1% (0.7) 6.89E-04 +15.4% (1.0) 1.07E-03 +16.1% (1.2) 1.72E-06
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Effect of cooling on serum acylcarnitines
Of the acylcarnitines, C3 (Propionyl-L-carnitine) and C4 (Butyryl-L-carnitine) were sig-
nificantly decreased upon mild cooling (-17.1% and -19.4%, respectively). Interestingly, 
these were the only two individual metabolites that showed a decrease rather than an 
increase after cooling.
Effect of cooling on amino acids
Of the fourteen measured amino acids, only glutamine (+18.7%), glycine (+11.6%) and 
histidine (+10.6%) increased significantly after mild cooling.
Effect of cooling on glycerophospholipids
None of the lysoPCs were changed significantly after Bonferroni correction upon mild 
cooling. In contrast, of the 76 measured PCs, 19 (25%) increased significantly and these 
all contained at least 34 carbon atoms. Of the increased PCs, only one was saturated 
(PCaeC40:0), two were mono-unsaturated (PCaaC34:1 and PCaaC36:1) and as many as 
16 were poly-unsaturated.
















SM C24:0 +21.4% (1.2) 2.08E-04 +20.5% (1.9) 2.66E-04 +20.8% (1.6) 1.87E-07
SM C24:1 +20.6% (3.3) 5.45E-04 +18.9% (4.4) 8.82E-04 +19.6% (3.8) 9.49E-07
Metabolite classes/ ratios
MUFA (PC) +13.7% (31.5) 3.81E-03 +10.86% (33.7) 1.62E-02 +12.2% (32.4) 1.19E-04
MUFA (PC) / SFA (PC) +6.6% (2.1) 1.36E-03 +4.1% (2.2) 2.67E-03 +5.4% (2.2) 1.42E-05
PUFA (PC) / MUFA (PC) -3.6% (0.1) 3.18E-04 -2.8% (0.1) 3.22E-04 -3.1% (0.1) 1.50E-07
Total SM +16.1% (19.7) 1.62E-03 +14.3% (27.0) 2.96E-03 +15.0% (23.5) 1.05E-05
Total SM / Total (SM+PC) +4.0% (0.0) 1.56E-02 +6.1% (0.0) 7.93E-04 +5.2% (0.0) 2.65E-05
Total SM / Total PC +4.3% (0.0) 1.50E-02 +6.7% (0.0) 8.10E-04 +5.7% (0.0) 2.74E-05
Total SM-non OH +15.7% (17.8) 1.86E-03 +14.1% (24.4) 3.19E-03 +14.8% (21.1) 1.30E-05
Total SM-OH +18.8% (2.0) 5.38E-04 +16.3% (2.7) 1.75E-03 +17.3% (2.4) 2.06E-06
Total SM-OH / Total SM-non OH +2.6% (0.0) 1.93E-03 +2.1% (0.0) 6.08E-04 +2.3% (0.0) 2.51E-06
Tyr / Phe +12.9% (0.1) 6.30E-05 +9.9% (0.1) 1.15E-04 +11.3% (0.1) 1.42E-08
Shown metabolites are those that reached Bonferroni significance (p<0.05/162, i.e. p<3.1x104). The com-
plete listings of abbreviations are shown in Supplemental Table 1. The complete table of 190 metabolites 
and related metabolic parameters is shown in Supplemental Table 2. 1Values represent % change after 
cooling with SD. P-values were calculated using paired t-tests.
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Effect of cooling on sphingomyelins (SMs)
Of the fifteen SMs, ten SMs (63%) significantly increased after mild cooling.
Effect of cooling on metabolite classes/ ratios
We also assessed the effect of mild cooling on 27 additional derived metabolic pa-
rameters (metabolite classes and metabolite ratios), and found several changes. The 
total concentration of mono-unsaturated FAs (contained in PCs) significantly increased 
(+12.2%), while saturated and poly-unsaturated FAs in PC did not change. Subse-
quently, the mono-unsaturated-to-saturated FA ratio increased (+5.4%), while the poly-
unsaturated-to-mono-unsaturated ratio decreased after mild cooling (-3.1%). Again, as 
determined from linear regression, no differences between white Caucasians and South 
Asians were observed.
DISCuSSION
Mild cold exposure increases NST and FA utilization (10) ultimately affecting lipid-
associated metabolites. In the present study, we used metabolomics to investigate 
the effect of mild cooling on serum levels of metabolites, specifically those related to 
lipid metabolism, by using the Biocrates platform. We found that 44 of the 189 (23%) 
measured metabolites and derived metabolic parameters (metabolite classes and 
metabolite ratios) were significantly changed. Interestingly, the PCs and SMs were 
significantly increased upon mild cooling, as were the amino acids glutamine, glycine 
and histidine. In contrast, the acylcarnitines C3 and C4 were significantly decreased. The 
overall response to mild cold between white Caucasian and South Asians subjects was 
not different.
The increased thermogenesis that is induced upon mild cold exposure requires 
enhanced availability of FA which can subsequently be used for thermogenesis. In our 
study subjects, we previously showed a marked increase in serum FA and triglyceride 
(TG) levels upon mild cooling (5). The enhanced FA levels are likely the consequence 
of enhanced WAT lipolysis, possibly due to increased sympathetic outflow towards the 
tissue. In our metabolomics assay, we did not measure serum FA or TG levels, but instead 
assessed several other metabolites related to lipid metabolism, including PCs, lysoPCs 
and SMs. PCs and SMs are both abundantly present in all lipoprotein classes (i.e. VLDL, 
LDL and HDL) as a component of the surface shell (11,12). We found that, upon mild 
cooling, both serum PC and SM levels were increased. This may point to either enhanced 
lipoprotein synthesis or decreased breakdown. Considering the large capacity of BAT 
to take up FA from TG-rich lipoproteins, the latter mechanism seems unlikely. In human 
serum most of the SMs are present in LDL and VLDL (approximately 63-75% of all serum 
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SM), and a minority in HDL (13). Taken together with the elevated serum TG levels seen 
upon mild cooling, these data strongly suggest that the increases in PCs and SMs are a 
result of increased hepatic VLDL production.
Interestingly, when the PCs that increased upon mild cooling were studied in more 
detail, it was evident that almost all contained unsaturated FAs. In fact, 16 of the 19 
increased PCs belonged to the poly-unsaturated PCs. In addition, all contained very long 
chain FAs, containing at least 34 carbon atoms. A clear explanation for this phenomenon 
is not yet known but may be related to desaturation and elongation of PCs synthesized 
in the liver.
Mild cold exposure may not only affect lipid-associated but also other metabolites. 
We, therefore, also assessed serum levels of amino acids and acylcarnitines. The amino 
acids glutamine, glycine and histidine were found to be increased upon two hours of 
mild cooling. This is likely to be explained by enhanced release by organs with con-
comitant decreased clearance, although the underlying biological mechanism remains 
to be determined. Surprisingly, during mild cooling, serum levels of the short-chain 
acylcarnitines C3 en C4 decreased. Acylcarnitines are involved in FA oxidation, as they 
are part of the carnitine shunt which shuttles FA into mitochondria (14-16). In case 
of inefficient FA oxidation, e.g. when FA supply exceeds FA oxidation, acylcarnitines 
accumulate in the serum. During mild cold exposure BAT becomes activated, which 
increases the need for FAs. Possibly the carnitine shunt becomes more efficient during 
mild cooling to facilitate the increased need for FAs thereby reducing acylcarnitines in 
plasma. Apparently, despite increasing the supply of FA from WAT, mild cooling does not 
result in inefficient FA oxidation, which is likely to be explained by enhanced β oxidation, 
e.g. due to enhanced BAT activity. Interestingly, recent research suggests an association 
between elevated levels of serum acylcarnitines and insulin resistance, possibly due to 
the fact that acylcarnitines activate pro-inflammatory pathways thereby facilitating the 
development of insulin resistance (17-19). In this respect, the decreased serum levels of 
C3 and C4 upon cold exposure may thus be considered beneficial.
We found no changes between white Caucasian and South Asian subjects in their 
response of serum metabolite levels upon mild cooling. A priori, we anticipated that 
the metabolic response would differ since we previously found in this study population 
that upon mild cold exposure the increase of serum FA was lower in South Asian as 
compared to white Caucasian subjects. Moreover, we found that mild cold exposure 
did not significantly increase energy expenditure in South Asians while it did in white 
Caucasians. However, mean water inlet temperature differed 2°C upon start of shiver-
ing between South Asians and white Caucasians and this might at least in part have 
influenced our results. However, we chose to use the method of a personalized cooling 
protocol to equalize NST, since muscle shivering markedly affects serum metabolites. 
Interestingly, these differences in mild-cold induced thermogenesis were not reflected 
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in differential changes in serum metabolites as measured by the Biocrates platform. 
Therefore, it seems that changes in these metabolites are, at least in part, independent 
of the extent of the increase in energy expenditure.
In conclusion, we found that mild cooling elicits substantial effects on serum me-
tabolite levels in healthy male subjects, which might provide novel insights into the 
contribution of mild-cold induced thermogenesis on whole body substrate release 
and utilization. These finding were irrespective of white Caucasian versus South Asian 
ethnicity. Future studies should investigate if these data also apply to other populations, 
e.g. subjects with obesity or type 2 diabetes.
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Activation of brown adipose tissue (BAT), either indirectly via sympathetic nervous 
system activation through cold exposure or directly by β3-adrenergic receptor agonism, 
is considered a promising treatment strategy to combat metabolic disease. Metabolic 
disease is more prevalent in South Asians compared to white Caucasians, possibly linked 
to lower sympathetic outflow. Our aim was to compare the effects of cold exposure and 
mirabegron on BAT activation and energy expenditure in South Asians versus white Cau-
casians. Ten healthy lean Dutch South Asian (aged 18–30 years; BMI 18–25 kg/m2) and 
ten age- and BMI-matched white Caucasian men participated in a randomized, double-
blinded, cross-over study consisting of three interventions; cold exposure, mirabegron 
(200 mg one dose p.o.) and placebo. Before and after each intervention, fasting serum 
lipids, glucose and insulin levels were measured. Additionally resting energy expen-
diture (REE), substrate utilisation, skin temperature and supraclavicular adipose tissue 
volume and fat fraction (FF) were assessed. Cold exposure and mirabegron increased 
free fatty acids, REE, lipid oxidation and supraclavicular skin temperature and tended to 
decrease FF of BAT. Aside from a larger cold-induced increase in free fatty acids in white 
Caucasians, all other effects were similar for South Asians and white Caucasians. Cold 
exposure and mirabegron both induce beneficial metabolic effects that are associated 
with increased BAT activity. There are no clear differences in response between South 
Asians and White Caucasians.
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INTRODuCTION
Obesity and related diseases, including type 2 diabetes (T2D) and cardiovascular disease, 
are a major public health problem worldwide (1). Certain ethnic subgroups, such as the 
South Asian population, (2-4), are particularly vulnerable to develop cardiometabolic 
disease. This is likely, at least in part, due to their disadvantageous metabolic profile, 
consisting of susceptibility to develop abdominal obesity, dyslipidaemia and insulin 
resistance (2,3). The underlying mechanisms that explain this susceptibility are not fully 
understood. As a result, treatment options to improve the metabolic profile of the South 
Asian population are limited and unfocussed, and specific strategies are needed.
Activation of brown adipose tissue (BAT) could be an interesting therapeutic target 
to improve metabolism. BAT takes up triglyceride (TG)-derived fatty acids (FA) (5) and 
glucose from the systemic blood supply for combustion into heat, thereby increasing 
energy expenditure and improving lipid and glucose metabolism (6,7). BAT is strongly 
innervated by the sympathetic nervous system. Cold exposure, resulting in sympathetic 
nervous system activation, is the most potent physiological activator of BAT, resulting in 
release of noradrenalin from sympathetic nerve endings (8) that subsequently acts on 
β3-adrenergic receptors (β3-AR) on brown adipocytes thereby enhancing thermogene-
sis (9-11). Simultaneously, BAT releases endocannabinoids, which are believed to inhibit 
noradrenalin signalling, thereby preventing excessive activation of BAT by cold (12,13). 
Circulating endocannabinoid levels are elevated in obesity (14-16) and, interestingly, 
South Asians have higher basal circulating endocannabinoid levels compared to white 
Caucasians (17). This might, at least partly, explain the reduced 18F-fluorodeoxyglucose 
(18F-FDG) uptake by BAT that was shown in one PET study and lower resting energy 
expenditure (REE) during cold exposure (18). In addition, South Asians have a lower 
cold-induced increase in free fatty acid (FFA) levels, which results from lipolysis induced 
by sympathetic stimulation of white adipose tissue (18). Taken together, these data sug-
gest that South Asians have a lower sympathetic outflow upon cold exposure compared 
to white Caucasians.
Repetitive cold exposure is an effective strategy to enhance BAT metabolism, as cold 
acclimation increases BAT volume and reduces fat mass in both lean and obese men 
(19). However, since a treatment involving prolonged cold exposure may be hard to ad-
here to, current research is focussed on pharmacological compounds that can activate 
BAT. As BAT activation by cold is considered to occur via sympathetic stimulation of the 
β3-AR, agonists of this receptor might be of interest. Indeed, pre-clinical studies have 
shown that treatment with the selective β3-AR agonist CL316,243 strongly stimulates 
BAT activity, prevents fat accumulation, improves dyslipidemia and insulin sensitivity, 
and attenuates the development of atherosclerosis (20). Likewise, in humans, the β3-AR 
agonist mirabegron increased 18F-FDG uptake by BAT as well as increased REE (21) in 
Chapter 6
96 |
healthy young men to a similar extent as cold exposure (22). In addition, a single dose 
of 200 mg mirabegron increased plasma FFA levels, which is suggestive for stimulation 
of lipolysis in white adipose tissue (21). Therefore, β3-AR agonism could be a promising 
treatment option to activate BAT and enhance REE, especially in South Asians, because 
it directly activates the β3-AR, thereby circumventing sympathetic outflow.
The aim of the current study was to study the effect of the β3-AR agonist mirabegron 
and cold exposure on REE and BAT activity in healthy lean South Asian versus white 
Caucasian men. We hypothesized that South Asians would respond better to direct acti-
vation of BAT by targeting the β3-AR using mirabegron, compared to indirect activation 
through the sympathetic nervous system by cold exposure.
MATERIALS AND METhODS
Participants
Ten healthy, young (aged 18–30 years), lean (BMI 18–25 kg/m2) Dutch South Asian men 
and ten age- and BMI-matched white Caucasian men were included in the study. South 
Asian descent was defined as born in the Netherlands with both grandparents originating 
from the Indian subcontinent. Exclusion criteria were smoking, recent weight change (> 
3 kg within the last 3 months), rigorous exercise, use of any medication known to influ-
ence glucose and/or lipid metabolism, BAT activity, cardiac function or QT interval time 
(e.g. beta blockers, thyroid medication, calcium channel blockers, monoamine oxidase 
inhibitors, or systemic corticosteroids), the presence of a chronic disease (including, but 
not limited to T2D, thyroid disease, renal disease, or liver dysfunction), and/or contrain-
dications for magnetic resonance imaging (MRI). Contraindications for undergoing an 
MRI scan were the presence of non-MR safe metal implants or objects in the body (i.e. 
a pacemaker, neurostimulator, hydrocephalus or drug pump, non-removable hearing 
aid, or large recent tattoos), a history of claustrophobia, tinnitus, or hyperacusis. The 
study was approved by the Medical Ethical Committee of the Leiden University Medical 
Center (LUMC) and performed in accordance with the principles of the revised Declara-
tion of Helsinki (23). Written informed consent was obtained from all volunteers prior to 
participation. Trial register clinicaltrail.gov number NCT03012113.
Study design
Participants were enrolled in a randomized, double-blinded, placebo-controlled cross-
over study consisting of three different interventions that were each performed on a 
different study day. During the first occasion, participants were exposed to an individual-
ized water-cooling protocol to activate BAT as previously described (18). Supraclavicular 
fat volume and fat fraction (FF) were assessed with MRI. As BAT combusts intracellular 
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lipids (20), intracellular FF of BAT is expected to decrease upon activation. Therefore, 
quantification of the FF of BAT is considered to be a read-out for its activity. Only if BAT 
could be detected on MRI after cold exposure, participants continued with drug and 
placebo treatment. Thereafter, participants were randomised to receive first either 200 
mg mirabegron (Betmiga®, Astellas BV, the Netherlands) in one oral dose or placebo. 
Mirabegron tablets were repacked into capsules by the LUMC pharmacy to resemble 
the placebo. Randomisation was performed by the LUMC pharmacy. After the cold 
exposure, there was a wash-out period of at least one week, and the wash-out period 
between the mirabegron and placebo occasion was at least two weeks. An overview of 
the study design is depicted in Supplementary figure 1. Before all study days, subjects 
were fasted for 10 hours overnight and remained fasted until the end of the experiment. 
A standardized dinner was consumed the evening before and participants wore stan-
dardized clothing consisting of a boxer short and a thin pair of MRI-compatible trousers 
and hospital gown.
Occasion 1: Cold exposure
During the first visit, a medical screening consisting of a medical questionnaire, measure-
ment of length, weight and blood pressure, and a blood draw was performed to assess if 
participants met the inclusion criteria. In case of eligibility, the study day continued with 
insertion of an intravenous cannula and a measurement of body composition by bio-
electrical impedance analysis (Bodystat 1500, Bodystat, UK). Pre-cooling (thermoneutral 
conditions), a fasted blood sample was collected, REE, lipid and glucose oxidation were 
measured via indirect calorimetry (Oxycon Pro, CareFusion, Germany), and cardiovas-
cular parameters (including heart rate, blood pressure, and heart rate variability (HRV)) 
were assessed with Finapres Nova (Finapres Medical Systems BV, the Netherlands). 
Thereafter, a pre-cooling MRI scan (3T MRI, Philips Ingenia, Philips Healthcare, Best, the 
Netherlands) was performed to assess supraclavicular adipose tissue volume and FF. 
Participants were placed in supine position head-first in the scanner, with a 16-channel 
anterior array on the pelvis and their head in the 16-channel head and neck coil. After 
being placed on the scanner table, participants were asked to reach as far as possible 
with their fingers towards their feet and to relax their shoulders afterwards to ensure 
reproducibility of subject positioning. The left supraclavicular BAT depot was assessed 
using a three-dimensional six-point chemical-shift encoded gradient-echo acquisition 
with the following parameters: repetition time TR=15 ms, first echo time TE=1.98 ms, 
echo time separation ΔTE=1.75 ms, flip angle=8°, field-of-view of 480 mm × 300 mm 
× 90 mm (Right-Left, Foot-Head, Anterior-Posterior), 1.1 mm isotropic resolution, four 
retrospectively averaged signal averages. Next, 18 wireless iButtons were placed to 
monitor skin temperature (iButton®, Maxim Integrated Products, USA), and an individu-
alized water cooling protocol was applied to activate BAT (as described previously (18)). 
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Participants were placed in a bed in semi-supine position between two water-perfused 
mattresses (BlanketRol® III, Cincinnati Sub-Zero Products, USA). The water temperature 
was set at 32°C and gradually decreased with 5°C every 10 minutes, until the participants 
started to shiver or until they reached the minimum water temperature of 9°C. Shivering 
was reported by the participants and confirmed visually by researchers. At that point, 
the water temperature was increased with 3°C to ensure maximal non-shivering thermo-
genesis. This cold exposure continued for 60 more minutes. Thereafter, a blood sample 
was obtained and cold-induced REE, lipid and glucose oxidation, and cardiovascular 
parameters were measured again. Lastly, a second MRI scan was performed to assess 
changes in supraclavicular adipose tissue after cold exposure.
Occasion 2 and 3: Mirabegron and placebo treatment
During these study days, all measurements were performed under thermoneutral condi-
tions. After insertion of an intravenous cannula and measurement of body composition, 
a fasted blood sample was collected and REE, lipid and glucose oxidation, and cardiovas-
cular parameters were assessed. Next, mirabegron or placebo was ingested. One hour 
(t=60), two hours (t=120), and three hours (t=180) after administration, REE, lipid and 
glucose oxidation, and cardiovascular parameters were again assessed. At three hours 
and a half (t=210), when reaching the maximum plasma concentration of mirabegron 
(i.e. Tmax ~3–4 h), another blood sample was drawn and an MRI scan was performed to 
assess changes in supraclavicular adipose tissue.
Serum measurements
Commercially available enzymatic kits were used to measure serum concentrations 
of TG and total cholesterol (TC) (Roche Diagnostics, the Netherlands), high density 
lipoprotein-cholesterol (HDL-C) (Roche Diagnostics), FFA (Wako Chemicals, Germany), 
and glucose (Instruchemie, the Netherlands). Insulin concentrations were measured 
using ELISA (Crystal Chem Inc., IL, USA). Low density lipoprotein-cholesterol (LDL-C) was 
calculated using the Friedewald equation (24). Data were analysed using SoftMaxPro 
5.4.1 software.
Skin temperature
18 wireless iButton temperature sensors were placed at 14 prescribed ISO-defined 
positions (25) and 4 additional positions (right hand, left lower leg, left elbow, and right 
armpit) (26). Data were analysed using Temperatus software (http://profith.ugr.es/tem-
peratus). Armpit temperature was estimated was used as a proxy of core body tempera-
ture (27). Supraclavicular skin temperature was estimated from an iButton placed above 
the left clavicula. Distal skin temperature was calculated as the average temperature of 
the left hand and right feet (28). Proximal skin temperature was defined as the average 
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of the iButtons on the chest, abdomen, scapula, and lower back (29). The difference in 
skin temperature between the right forearm and the right fingertip was calculated as an 
estimate for vasoconstriction (30).
Indirect calorimetry
Indirect calorimetry was performed in time-frames of 30 minutes. Participants were 
instructed to lie still and were not allowed to talk. Oxygen consumption and carbon 
dioxide production were determined every minute. REE and the respiratory quotient 
(RQ) were calculated and substrate utilization was assessed by calculation of lipid and 
glucose oxidation after correction for protein oxidation, as described previously (31).
MRI analysis
An in-house water-fat separation algorithm based on the known frequencies of the 
multi-peak fat spectrum and assuming monoexponential effective transverse relaxation 
time (T2*) was used to reconstruct FF maps, combined with a region-growing scheme 
to mitigate main field inhomogeneity effects (32-35). Registration was performed using 
Elastix registration software (36,37). For calculating the deformation field, the first echoes 
of the pre- and post-cooling image stacks were co-registered using a three-dimensional 
B-spline transform with a 10×10×10 mm3 grid, adaptive stochastic gradient descent 
with two resolutions for optimization and Mattes mutual information as the similarity 
measure (the registration parameter file can be downloaded from http://elastix.bigr.nl/
wiki/index.php/Par0048). Subsequently, FF and T2* maps were first transformed using 
the calculated deformation field and then smoothed using the 3×3 mean filter. Regions 
of interest (ROIs) encompassing the known location of the left supraclavicular BAT depot 
(38) were drawn manually by one observer (Supplementary figure 2). Semi-automated 
segmentation rejecting voxels below the 3% FF was performed, and a FF threshold of 
50–100% was used for data analysis. In this work, we set the lower threshold to 50% as 
it was shown to segment more non-fat areas compared with a lower threshold of 40% 
(39), which is commonly used in other studies. The change in volume and FF after cold 
exposure was estimated as the difference between before and after cooling. The change 
in volume and FF induced by mirabegron was estimated as the difference between 
post-placebo and post-mirabegron. One participant was excluded from the MRI analysis 
because of failure to reconstruct the scan due to excessive movement.
heart rate variability, blood pressure and heart rate
Heart rate, blood pressure, and HRV were continuously non-invasively assessed with 
Finapres Nova (Finapres Medical Systems BV, the Netherlands) in time-frames of 30 
minutes. A small cuff was connected to the intermediate phalanges of the middle-finger 
of the non-dominant hand to measure blood pressure. In addition, a 5-lead electrocar-
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diogram was connected to assess heart rate and parameters of HRV. Participants were 
instructed to lie still and were not allowed to talk. Data was analysed with MATLAB 
release 2017b (The Mathworks, USA).
Statistical analysis
Data were analysed using IBM SPSS Statistics for Windows version 23.0 (SPSS Inc, Chi-
cago, IL, USA). Data are shown as mean± standard error of the mean (S.E.M.) Two-tailed 
unpaired Student’s t-test was used to compare baseline characteristics between the 
two ethnicities. Two-tailed paired Student’s t-test was used to assess the effects of the 
interventions within a participant and to compare effect sizes (e.g. delta before and after 
cooling, delta before and after mirabegron, and delta before and after placebo) between 
the three interventions within one ethnicity. Two-tailed unpaired Student’s t-test was 
used to compare effect sizes between South Asians and white Caucasians. When data 




Ten healthy lean men of white Caucasian and ten of South Asian descent participated in 
the study. Participant characteristics are summarized in Table 1. South Asian and white 
Caucasian participants were comparable with respect to age (24.4±1.0 vs. 22.9±0.7 
years) and BMI (22.7±0.6 vs. 22.3±0.3 kg/m2). However, South Asians were shorter 
(1.77±0.01 vs. 1.86±0.02 m, p<0.01) and tended to have a lower body weight (71.5±2.4 
vs. 77.7±1.9 kg, p=0.06) compared to white Caucasians. In addition, body fat percentage 
was higher in South Asians (16.7±1.2 vs. 12.9±0.8 %, p<0.05) and percentage of lean 
body mass was lower (83.3±1.2 vs. 87.1±0.8 %, p<0.01). Fasting glucose, insulin, and lipid 
levels were comparable between the groups, except for LDL-C levels that were higher in 
South Asians compared to white Caucasians (4.3±0.4 vs. 3.1±0.4 mmol/L, p=0.05). MRI 
studies identified deposits of BAT in all participants and therefore, all participants could 
continue with mirabegron and placebo administration.
Mirabegron increases serum ffA and insulin levels in both ethnicities
Since active BAT takes up lipids and glucose from plasma, we first compared the effect of 
cold exposure and mirabegron on serum parameters in both ethnicities.
Cold exposure increased TC (+15%, p<0.05) in white Caucasians only (Figure 1A). This 
was mainly due to an increase in HDL-C in both ethnicities (+11%, p<0.01 for South 
Asians and +9%, p<0.05 for white Caucasians). Upon cooling, TG tended to increase in 
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South Asians (+8%, p=0.08) and white Caucasians (+13%, p=0.06) (figure 1B). In addi-
tion, serum FFA increased in white Caucasians (+52%, p<0.001) and tended to increase 
in South Asians (+18%, p=0.06) (Figure 1C). Serum glucose (not shown) and insulin 
(Figure 1D) levels were not affected by cold exposure in both ethnicities. Interestingly, 
the increase in FFA upon cold exposure was lower in South Asians compared to white 
Caucasians (p<0.05; Figure 1C).
Mirabegron did not affect TC (Figure 1A) or TG (Figure 1B) nor HDL-C, LDL-C, and glu-
cose (not shown). Serum FFA increased after mirabegron in both South Asians (+131%, 
p<0.001) and white Caucasians (+199%, p<0.001) to a similar extent. In both ethnicities 
the effect of mirabegron on FFA levels was larger than the effect of cold exposure (both 
p<0.01) (figure 1C). Serum insulin levels were similarly increased upon mirabegron treat-
ment in South Asians (+31%, p<0.01) and white Caucasians (+23%, p<0.05) (figure 1D).
Placebo did not affect TC levels (Supplementary figure 3A). Placebo decreased TG 
levels in white Caucasians only (-7%, p<0.05; Supplementary figure 3B) and increased 
FFA levels in both South Asians (+55%, p<0.01) and white Caucasians (+48%, p<0.05) 
(Supplementary figure 3C). In both ethnicities the effect of mirabegron on FFA levels 
was larger than the effect of placebo (both p<0.001; not shown). In addition, placebo 
decreased insulin in white Caucasians (-24%, p<0.05) and tended to decrease insulin in 
South Asians (-29%, p=0.07) (Supplementary figure 3D). The responses to placebo did 
not differ between the two ethnicities.
Table 1. Participant characteristics
White Caucasians (n=10) South Asians (n=10)
Age (years) 22.9 (0.7) 24.4 (1.0)
Height (m) 1.86 (0.02) 1.77 (0.01) **
Weight (kg) 77.7 (1.9) 71.5 (2.4) b
Body mass index (kg/m2) 22.3 (0.3) 22.7 (0.6)
Waist circumference (cm) 82.1 (1.8) 78.2 (1.6)
Hip circumference (cm) 86.7 (1.5) 86.1 (1.7)
Fat mass (%) 12.9 (0.8) 16.7 (1.2) *
Lean mass (%) 87.1 (0.8) 83.3 (1.2) *
Glucose (mmol/L) 4.5 (0.1) 4.6 (0.1)
Insulin (pg/mL) 126 (19) 203 (58)
Free fatty acids (mmol/L) 0.43 (0.05) 0.48 (0.04)
Triglycerides (mmol/L) 0.79 (0.17) 0.87 (0.23)
Total cholesterol (mmol/L) 4.8 (0.5) 6.0 (0.4) c
High density lipoprotein-cholesterol (mmol/L) 1.4 (0.1) 1.2 (0.9)
Low density lipoprotein-cholesterol (mmol/L) 3.1 (0.4) 4.3 (0.4) a
Values are presented as mean (standard error of the mean (S.E.M.)). Two-tailed unpaired student’s t-test was 
used for comparison. ** p<0.01, * p<0.05, a p=0.05, b p=0.06, c p=0.10 South Asians vs. White Caucasians.
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Mirabegron increases REE and lipid oxidation in both ethnicities
As BAT can influence energy expenditure and substrate use, we next compared the 
effect of cold exposure and mirabegron on REE, lipid and glucose oxidation in South 
Asians and white Caucasians.
Pre-cooling REE was lower in South Asians compared to white Caucasians (1347±46 
vs. 1563±66 kcal/day, p<0.05), while lipid oxidation, glucose oxidation, and respiratory 
quotient (RQ) were comparable (not shown). Of note, the ethnic differences in REE were 
no longer present after correction for lean body mass (not shown).
Cold exposure increased REE in both South Asians (+29%; p<0.05) and white Cauca-
sians (+20%; p<0.001) (figure 2A,B). In addition, lipid oxidation was increased in South 
Asians (+106%; p<0.05) and white Caucasians (+80%, p<0.01) (figure 2C,D), in line 
with decreased RQ in both ethnicities (-3%, p<0.01 and -4%, p<0.05, respectively) (not 
shown). Glucose oxidation was not affected by cooling (not shown). The increases in REE 




























































































































































































White Caucasians   South Asians
figure 1. Effect of cold exposure and mirabegron on serum lipids and insulin in white Caucasians 
and South Asians Serum was collected before (white bars) and after (black bars) intervention with cold 
exposure or mirabegron in white Caucasians (n=10) and South Asians (n=10), and assayed for total choles-
terol (TC) (A), triglycerides (TG) (B), free fatty acids (FFA) (C), and insulin (D). Data are presented as mean ± 
S.E.M. Two-tailed paired (within ethnicities) or unpaired (between ethnicities) Student’s t-test was used for 
comparison. * p<0.05, ** p<0.01, *** p<0.001 before vs. after intervention. ## p<0.01 effect of cooling vs. 
mirabegron. $ p<0.05 difference between the two ethnicities. Mira, mirabegron.
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When comparing the baseline measurement with the measurement three hours after 
administration of mirabegron, mirabegron increased REE in South Asians (+9%, p<0.05; 
figure 2B) and tended to increase in white Caucasians (+11%, p=0.06; figure 2A). 
Mirabegron increased lipid oxidation in South Asians (+199%, p<0.01) as well as white 
Caucasians (+66%, p<0.01) (figure 2A,B). Consequently, RQ decreased in South Asians 
(-7%, p<0.05) and white Caucasians (-4%, p<0.01) (not shown).
Placebo did not change REE (figure 2A,B) or glucose oxidation in either ethnicity, but 
tended to increase lipid oxidation in white Caucasians only (+51%, p=0.08; figure 2C).
The increase in REE and lipid oxidation upon mirabegron becomes even more clear 
when looking at the gradual change in REE and lipid oxidation after 1, 2, and 3 hours 
after administration of mirabegron or placebo. A clear increase was observed in both 




























































































































figure 2. Effect of cold exposure, placebo, and mirabegron on energy expenditure and lipid oxidation 
in white Caucasians and South Asians Before (pre-Cold; white bars) and after (post-Cold; black bars) cold 
exposure and before (white bars), after one hour (light grey bars), after two hours (dark grey bars), and after 3 
hours (black bars) of placebo or mirabegron treatment, indirect calorimetry was used to measure resting en-
ergy expenditure (REE) (A,B) and lipid oxidation (C,D) in white Caucasians (A,C) (n=10) and South Asians (B,D) 
(n=10). Data are presented as mean ± S.E.M. Two-tailed paired (within ethnicities) or unpaired (between eth-
nicities) Student’s t-test was used for comparison. * p<0.05, ** p<0.01, *** p<0.001 before vs. after intervention.
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When comparing effect sizes, cold exposure increased REE to a higher extent com-
pared to mirabegron in white Caucasians (p<0.05) and tended to increase REE to a higher 
extent compared to mirabegron in South Asians (p=0.10). The effects of cold exposure, 
mirabegron or placebo on lipid or glucose oxidation were not significantly different.
Mirabegron increases supraclavicular skin and core temperature in both 
ethnicities
The main function of BAT is heat production, and supraclavicular skin temperature 
positively associates with 18F-FDG uptake by BAT in young healthy lean men (40). There-
fore, we next compared the effects of cold exposure and mirabegron on skin and core 
temperature in South Asians and white Caucasians.
Pre-cooling skin temperature in the armpit (a proxy of core temperature) tended to be 
higher in South Asians compared to white Caucasians (35.3±0.2 vs. 34.6±0.3 °C, p=0.09; 
figure 3A), while supraclavicular skin temperature (figure 3B), distal skin temperature, 
and proximal skin temperature were comparable (not shown). In addition, the difference 
in skin temperature between the right forearm and the right fingertip (i.e. estimate for 
vasoconstriction) tended to be lower in South Asians compared to white Caucasians 
(3.8±0.8 vs. 5.7±0.9 °C, p=0.08; not shown).
Cold exposure increased core temperature in South Asians (+1.2°C, p<0.001) and white 
Caucasians (+1.1°C, p<0.01) (figure 3A). Likewise, supraclavicular skin temperature was 
increased in South Asians (+1.7°C, p<0.001) and white Caucasians (+1.6°C, p<0.001) (figure 
3B). Furthermore, cooling decreased distal skin temperature in South Asians (-3.1°C, p<0.01) 
and white Caucasians (-2.4°C, p<0.01) and proximal skin temperature (-4.9°C, p<0.001 and 
-3.2°C, p<0.001, respectively) (not shown). The estimate for vasoconstriction was increased 
in both South Asians (+67%, p<0.05) and white Caucasians (+51%, p<0.05) (not shown).
Mirabegron also increased core temperature in South Asians (+0.3°C, p<0.01) and 
white Caucasians (+0.6°C, p<0.05) (figure 3A). Furthermore, mirabegron increased 
supraclavicular skin temperature in both white Caucasians (+0.4°C, p<0.05) and South 
Asians (+0.7°C, p<0.01) (figure 3B). In contrast to cold exposure, mirabegron increased 
rather than decreased proximal skin temperature in South Asians (+1.4°C, p<0.01) and 
white Caucasians (+1.2°C, p<0.001) (not shown). Mirabegron did not affect distal skin 
temperature and vasoconstriction (not shown).
The placebo did not change core temperature (Supplementary figure 4A) or 
supraclavicular temperature (Supplementary figure 4B), but increased proximal skin 
temperature in South Asians (+1.1°C, p<0.01) and white Caucasians (+0.9 °C, p<0.01) (not 
shown).
When comparing effect sizes, the increase in supraclavicular skin temperature was 
larger upon cold exposure compared to mirabegron in both ethnicities (p<0.01; figure 
3B). In South Asians, the effect of cold exposure on core temperature was larger than 
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the effect of mirabegron (p<0.01; figure 3A). The effects on supraclavicular skin and 
core temperature upon cold exposure or mirabegron were not different between South 
Asians compared to white Caucasians.
Mirabegron tends to decrease BAT fat fraction in white Caucasians
As BAT combusts intracellular lipids (20), quantification of the FF of the supraclavicular 
fat depot by MRI after an intervention is considered to be a read-out for its activity. 
Therefore, we next compared the effect of cold exposure, mirabegron and placebo on 
BAT volume and FF using MRI in both ethnicities.
Pre-cooling BAT volume (23.9±3.7 vs. 27.9±2.4 mL; figure 4A) and FF (70.7±1.7 vs. 
69.8±1.3%; figure 4B) were comparable between South Asians and white Caucasians.
Cold exposure decreased BAT volume in both South Asians (-11%, p<0.001) and white 
Caucasians (-17%, p<0.01) (figure 4A). However, it has to be noted that after placebo 
BAT volume in South Asians was comparable to after cold exposure. In addition, cold 
exposure decreased FF in white Caucasians (-2.2%, p<0.05) and tended to decrease FF in 
South Asians (-1.0%, p=0.08) (figure 4B).
Mirabegron tended to decrease BAT FF (-1.0%, p=0.08) compared to placebo treatment 
in white Caucasians only (figure 4B), while BAT volume was unchanged (figure 4A).
When comparing effect sizes, the effect of cold exposure on BAT volume tended to be 
larger in white Caucasians compared to South Asians (p=0.09) (figure 4A). Furthermore, 
the decrease in BAT volume upon cold exposure was larger compared to the decrease 
between mirabegron and placebo (p<0.01; figure 4A) in white Caucasians only. There 
was no difference in effect size of BAT FF upon cold exposure, mirabegron, or placebo 





































































































White Caucasians   South Asians
p=0.09
figure 3. Effect of cold exposure and mirabegron on supraclavicular skin and core temperature in 
white Caucasians and South Asians Before (white bars) and after (black bars) intervention with cold expo-
sure or mirabegron, core temperature (A) and supraclavicular skin temperature (B) were assessed in white 
Caucasians (n=10) and South Asians (n=10). Data are presented as mean ± S.E.M. Two-tailed paired (within 
ethnicities) or unpaired (between ethnicities) Student’s t-test was used for comparison. * p<0.05, ** p<0.01, 
*** p<0.001 before vs. after intervention. ## p<0.01 effect of cooling vs. mirabegron. Mira, mirabegron.
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Mirabegron increases heart rate and decreases vagal components of heart rate 
variability
Since β3-ARs are also present on cardiomyocytes (41) and endothelial cells of arteries 
(42), we also investigated the effects of mirabegron on heart rate, blood pressure, and 
measures of HRV as measures of sympathetic and parasympathetic output.
Pre-cooling measurements for cardiovascular parameters were comparable between 
the two ethnicities (not shown).
Cold exposure decreased heart rate in white Caucasians (-2 beats/min, p<0.01) and 
tended to decrease heart rate in South Asians (-1 beat/min, p=0.10) (Supplementary Ta-
ble 1). In addition, cooling increased systolic (+9%, p<0.05) and diastolic (+22%, p<0.05) 
blood pressure in South Asians only (Supplementary Table 1). Cooling increased RR in-
terval in white Caucasians (RRI; +5%, p<0.01) and tended to increase RR interval in South 
Asians (+3%, p=0.08) (Supplementary Table 1). In South Asians, the Root Mean Square 
of Successive heartbeat interval Differences (rMSSD; e.g. estimate of vagal activity) was 
increased (+44%, p<0.05; Supplementary Table 1). In addition, in South Asians cooling 
tended to increase both low frequency component (LF; e.g. estimate of sympathetic 
activity) (+49%, p=0.06) and the high frequency component (HF; e.g. estimate of vagal 
activity) (+89%, p=0.08) (Supplementary Table 1). LF/HF ratio was not affected.
Mirabegron increased heart rate in South Asians (+10 beats/min, p<0.01) and white 
Caucasians (+7 beats/min, p<0.001), while systolic or diastolic blood pressure were not 
changed (Supplementary Table 1). Mirabegron decreased RR interval in South Asians 













































figure 4. Effect of cold exposure and mirabegron on BAT volume and ff in white Caucasians and 
South Asians
Magnetic resonance imaging was used to determine brown adipose tissue (BAT) volume (A) and fat frac-
tion (FF) (B), pre-cooling (white bars), after cold exposure (black bars), after placebo treatment (light grey 
bars), and after mirabegron treatment (dark grey bars) in white Caucasians (n=9) and South Asians (n=10). 
MRI data of one white Caucasian could not be reconstructed due to excessive movement in the scanner. 
A lower threshold of 50% was applied to determine fat fraction. Data are presented as mean ± S.E.M. Two-
tailed paired (within ethnicities) or unpaired (between ethnicities) Student’s t-test was used for compari-
son. * p<0.05, ** p<0.01, *** p<0.001 before vs. after intervention. ## p<0.01 effect of cooling vs. mirabe-
gron. $ p<0.05 difference between the two ethnicities. Mira, mirabegron.
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rMSSD (e.g. estimate of vagal activity) in South Asians (-36%, p<0.05) and white Cau-
casians (-29%, p<0.05). HF (e.g. estimate of vagal activity) was also decreased in South 
Asians (-49%, p<0.05) and tended to decrease in white Caucasians (-48%, p=0.07) 
(Supplementary Table 1). LF/HF ratio was not affected.
Placebo only tended to increase heart rate (+2 beats/min, p=0.06) and increased 
LF component (e.g. estimate of sympathetic activity) (+53%, p<0.05; Supplementary 
Table 1) in South Asians but not in white Caucasians.
DISCuSSION
Activation of BAT, either indirectly via the sympathetic nervous system by cold exposure 
or directly by β3-adrenergic receptor agonism, is considered a treatment strategy to 
combat metabolic disease. Metabolic disease is more prevalent in South Asians com-
pared to white Caucasians, which is possibly linked to lower sympathetic outflow. In 
the current study, we investigated the effect of BAT activation by cold exposure and the 
β3-adrenergic receptor agonist mirabegron on serum lipids, REE, glucose and lipid oxi-
dation, supraclavicular skin temperature, and BAT volume and FF in healthy lean South 
Asians versus white Caucasians. Here we report that both mirabegron and cold exposure 
increase serum FFA levels, REE, lipid oxidation and supraclavicular skin temperature 
and tended to decrease BAT FF in both ethnicities. This indicates that pharmacologi-
cal activation of BAT may be a potential strategy to combat obesity not only in white 
Caucasians, but also in South Asians, a population that is especially prone to develop 
cardiometabolic disease.
We hypothesized that the response to cold exposure and mirabegron would be differ-
ent between South Asians and white Caucasians. Since South Asians have a lower FFA 
response upon cold exposure (18) and higher circulating endocannabinoid levels (43), 
we reasoned that they have lower cold-induced sympathetic outflow compared to white 
Caucasians. This may be the reason why cold-induced 18F-Fluorodeoxyglucose uptake 
(18F-FDG) by BAT in terms of volume is lower in South Asians (18). Since mirabegron is 
thought to activate BAT directly through stimulation of β3-AR, we thus expected a more 
pronounced effect of mirabegron on REE and BAT in South Asians by circumventing 
sympathetic activation. Indeed, although the FFA response to cold was lower in South 
Asians, similar responses were observed after administration of mirabegron to South 
Asians compared to white Caucasians. Nor was there a difference in any of the HRV pa-
rameters that indicate a difference in sympathetic output between the two ethnicities. 
Clearly, additional future studies are needed to clarify whether there is a true difference 
in sympathetic output upon cooling between South Asians and white Caucasians.
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In the current study, we compared the effects of mirabegron with cold exposure in 
South Asians and white Caucasians. We showed that mirabegron increased FFA levels 
to a greater extent than cold exposure in both ethnicities. Although placebo treatment 
also increased FFA levels, suggesting an effect of prolonged fasting on serum FFA, the 
increase in FFA levels after cold and mirabegron was larger than placebo. A possible 
explanation for the higher effect of mirabegron on FFA levels is that mirabegron more 
effectively liberates FFA from white adipose tissue instead of stimulating FFA uptake or 
combustion (e.g. by BAT) compared to cold exposure. This would be in line with a smaller 
effect of mirabegron on the decrease in BAT volume compared to cold exposure, at least 
in white Caucasians, and a lower increase in REE upon mirabegron compared to cold 
exposure in both ethnicities. High FFA levels can inhibit glucose uptake and combus-
tion, thereby elevating blood glucose and insulin levels, which eventually can result in 
insulin resistance and T2D (44-46). For this reason, it is desirable that FFA liberation and 
combustion are induced to the same extent, thereby preventing accumulation of FFA in 
the blood. It would be interesting to study the effect of mirabegron in combination with 
a treatment that further stimulates FFA combustion (e.g. induces a stronger activation of 
BAT), to reveal potentially beneficial effects on blood lipids in the short time frame that 
was used in our study. However, it might be expected that after prolonged therapy FFA 
liberation and combustion will be ultimately balanced.
In addition, we observed that mirabegron, in contrast to cold exposure, increased se-
rum insulin levels. This is in line with data of Cypess et al. (22), who also found increased 
insulin levels upon administration of the same dose of mirabegron in healthy lean 
volunteers. Based on preclinical studies (47), we speculate that this rise in insulin might 
be a consequence of the action of mirabegron on β3-AR on the pancreas. Stimulation 
of β3-AR on blood vessels in the pancreas might induce local vasodilatation resulting 
in increased blood flow (47), and thus increased supply of glucose and FA to β-cells, 
thereby stimulating insulin release. Insulin stimulates the activity of lipoprotein lipase 
in adipose tissues (48). In addition, insulin increases glucose uptake by tissues due to 
increased translocation of glucose transporter type 4 (GLUT4) to the cell membrane (49). 
In this way, increased insulin levels could contribute to increased uptake of TG-derived 
FA and glucose from the circulation by BAT to facilitate intracellular combustion. Alter-
natively, the increased 18F-FDG uptake by BAT might also result from vasodilation within 
BAT due to binding of mirabegron on β3-AR on the endothelium of arteries or due to 
cross-reactivity with other β-AR subtypes (42,50).
We also observed an increase in supraclavicular skin temperature upon mirabegron 
treatment, which probably reflects local heat production and thus BAT activity (40). 
Consistent with this observation, we found that mirabegron progressively increased REE 
and lipid oxidation, which was not observed after placebo treatment. In addition, when 
assessing BAT volume and FF with MRI, we observed a trend towards decreased BAT 
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FF upon mirabegron treatment compared to placebo. However, the decrease in FF was 
only half of the effect of cold exposure on BAT FF and only clear in white Caucasians. 
To further investigate to what extent mirabegron activates BAT, future studies should 
investigate BAT activity with other imaging modalities, such as 11C-acetate to investigate 
the oxidative capacity of the tissue, among others.
We observed that mirabegron modestly increased the heart rate, which can possibly 
be explained by direct effect of the drug on β3-AR on the myocardium (41) and/or cross-
reactivity of the drug on β1-AR (50). Despite the effect being modest, over the long-
term, an increase of a few beats per minute already increases the risk of cardiovascular 
morbidity and mortality (51). Heart rate is controlled by the autonomic nervous system 
and reflects the balance between parasympathic and sympathetic outflow of the central 
nervous system (52). When assessing HRV parameters, we observed a decrease in rMSSD 
and HF upon mirabegron treatment, which may point towards reduced vagal activity 
(53). This might suggest that stimulation of the β-adrenergic receptors by mirabegron 
shifts the autonomic balance towards more sympathetic and less parasympathetic ac-
tivity. In line with this, it has been shown that β-blockers increase, rather than decrease, 
rMSSD and HF (54). However, HRV can be affected by many internal and external factors 
and the relationship between sympathetic and parasympatic branches is complex and 
dynamic (53), therefore caution must be applied when interpreting HRV parameters.
A positive feature of our study is that we were able to analyse the effect of cold ex-
posure and mirabegron on multiple parameters associated with BAT in two different 
ethnicities. In addition, a placebo was used to discriminate between the effects of 
mirabegron treatment and effects induced by prolonged fasting. One limitation of the 
current study is that we measured BAT FF at only one time point after cold exposure and 
mirabegron treatment. Since activated BAT also takes up lipids from the blood to restore 
intracellular lipid stores, we cannot exclude that this affected our FF measurement. This 
may result in an underestimation of the effect size of cold exposure and mirabegron on 
BAT FF. In addition, our relatively small sample size limited the statistical power. Because 
of the exploratory nature of the study we did not correct for multiple testing. Further-
more, we only investigated healthy lean men. Future studies should investigate if these 
results also apply to the general population including women.
In conclusion, we have shown that South Asians and white Caucasians have a compa-
rable beneficial metabolic response to mirabegron and cold exposure. Moreover, both 
mirabegron and cold exposure increased FFA, REE, lipid oxidation, and supraclavicular 
skin temperature and tended to decrease BAT FF, which are suggestive for activated 
BAT. Future studies should be aimed at unravelling the relative effect of both treatments 
on true BAT activity, for instance, by using alternative read-outs for BAT activity such as 
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Supplementary Table 1. Cardiovascular parameters
White Caucasians (n=10) South Asians (n=10)
Cooling Placebo Mirabegron Cooling Placebo Mirabegron
Heart rate (bpm) -2 ** 0 +7 *** -1 e +2 a +10 **
Diastolic BP (mmHg) +13 +4 +6 +13 * +4 +1
Systolic BP (mmHg) +16 +7 * +4 +13 * +6 +9
Mean RRI (ms) +49 ** +2 -108 *** +25 c -38 -152 ***
SDNN (ms) +18 +13 d -7 +26 * +11 -17 **
rMSSD (ms) +7 0 -20 * +16 * -3 -21 *
LF (ms) +161 +172 -71 +207 a +316 * -213
HF (ms) -46 -56 -242 b +150 c -11 -110 *
LF/HF ratio +0.04 +0.27 +0.15 -0.21 +0.81 +0.56
Values are presented as delta (post- minus pre-intervention). Two-tailed paired (within ethnicities) or un-
paired (between ethnicities) Student’s t-test was used for comparison before and after intervention. *** 
p<0.001, ** p<0.01, * p<0.05, a p=0.06, b p=0.07, c p=0.08, d p=0.09, e p=0.10 difference compared to base-
line measurement. BP, blood pressure; RRI, RR interval; SDNN, Standard Deviation of Normal to Normal RR 






Occassion 2 and 3 
Supplemental figure 1. Overview of the study design
Supplemental figure 2. Region of Interest drawn on the MRI scan Example of supraclavicular ROI deter-
mination on MRI scan before and after cold exposure.
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White Caucasians     South Asians
Supplemental figure 3. Effect of placebo on serum lipids and insulin in white Caucasians and South 
Asians Serum w  collected before (white bars) and after (black bars) intervention with placebo in white 
Caucasians (n=10) and South Asians (n=10) and assayed for total cholesterol (TC) (A), triglycerides (TG) 
(B), free fatty acids (FFA) (C), and insulin (D). Data are presented as mean ± S.E.M. Two-tailed paired (within 
ethnicities) or unpaired (between ethnicities) Student’s t-test was used for comparison. * p<0.05, ** p<0.01 


































































































































































White Caucasians     South Asians
Supplemental figure 4. Effect of placebo on core and supraclavicular skin temperature in white Cau-
casians and South Asians Before (white bars) and after (black bars) intervention with placebo, iButtons 
were used to measure supraclavicular skin temperature (A) and an estimation of core temperature (B) in 
white Caucasians (n=10) and South Asians (n=10). Data are presented as mean ± S.E.M. Two-tailed paired 
(within ethnicities) or unpaired (between ethnicities) Student’s t-test was used for comparison.
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The aim of this study was to evaluate the effect of sitagliptin on glucose tolerance, plasma 
lipids, energy expenditure and metabolism of brown adipose tissue (BAT), white adipose 
tissue (WAT) and skeletal muscle in overweight individuals with prediabetes (impaired 
glucose tolerance and/or impaired fasting glucose). We performed a randomised, dou-
ble-blinded, placebo-controlled trial in 30 overweight, Europid men (age 45.9 ± 6.2 years; 
BMI 28.8 ± 2.3 kg/m2) with prediabetes in the Leiden University Medical Center and the 
Alrijne Hospital between March 2015 and September 2016. 30 Participants were initially 
randomly allocated to receive sitagliptin (100 mg/day) (n = 15) or placebo (n = 15) for 12 
weeks, using a randomisation list that was set up by an unblinded pharmacist. All people 
involved in the study as well as participants were blinded to group assignment. Two 
participants withdrew from the study prior to completion (both in the sitagliptin group) 
and were subsequently replaced with two new participants that were allocated to the 
same treatment. Before and after treatment, fasting venous blood samples and skeletal 
muscle biopsies were obtained, OGTT was performed and body composition, resting 
energy expenditure and [18F]fluorodeoxyglucose ([18F]FDG) uptake by metabolic tissues 
were assessed. The primary study endpoint was the effect of sitagliptin on BAT volume 
and activity. One participant from the sitagliptin group was excluded from analysis, due 
to a distribution error, leaving 29 participants for further analysis. Sitagliptin, but not 
placebo, lowered glucose excursion (−40%; p < 0.003) during OGTT, accompanied by 
an improved insulinogenic index (+38%; p < 0.003) and oral disposition index (+44%; p 
< 0.003). In addition, sitagliptin lowered serum concentrations of triacylglycerol (−29%) 
and very large (−46%), large (−35%) and medium-sized (−24%) VLDL particles (all p < 
0.05). Body weight, body composition and energy expenditure did not change. In skel-
etal muscle, sitagliptin increased mRNA expression of PGC1β (also known as PPARGC1B) 
(+117%; p < 0.05), a main controller of mitochondrial oxidative energy metabolism. 
Although the primary endpoint of change in BAT volume and activity was not met, sita-
gliptin increased [18F]FDG uptake in subcutaneous WAT (sWAT; +53%; p < 0.05). Reported 
side effects were mild and transient and not necessarily related to the treatment. Twelve 
weeks of sitagliptin in overweight, Europid men with prediabetes improves glucose 
tolerance and lipid metabolism, as related to increased [18F]FDG uptake by sWAT, rather 
than BAT, and upregulation of the mitochondrial gene PGC1β in skeletal muscle. Studies 
on the effect of sitagliptin on preventing or delaying the progression of prediabetes into 
type 2 diabetes are warranted.
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INTRODuCTION
The worldwide prevalence of obesity is rapidly increasing (1). In obese individuals 
glucose homeostasis is frequently dysregulated, leading to a condition known as predia-
betes (impaired glucose tolerance and/or impaired fasting glucose). It is estimated that 
up to 70% of individuals with prediabetes eventually develop type 2 diabetes mellitus 
(2). Therefore, delaying or preventing the development of type 2 diabetes is a potentially 
fruitful therapeutic strategy. In individuals with type 2 diabetes, glucose dysregulation 
is often accompanied by atherogenic dyslipidaemia, characterised by high triacylglyc-
erol and LDL-cholesterol levels and low HDL-cholesterol levels (3,4). Current treatment 
strategies are aimed at targeting both hyperglycaemia and dyslipidaemia by combining 
glucose-lowering drugs with statins. However, a drug that improves both glucose and 
lipid profile might be of specific interest.
The dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin, which enhances the bioavail-
ability of incretin hormones, improves both glucose tolerance and lipid metabolism 
in individuals with type 2 diabetes (5-7), thereby targeting both microvascular and 
macrovascular complications. The precise mechanism by which sitagliptin exerts these 
positive metabolic effects remains largely unknown. Interestingly, preclinical data with 
sitagliptin point towards a mechanism that involves the enhancement of energy expen-
diture through an increase in the activity of energy-combusting brown adipose tissue 
(BAT) and/or enhanced skeletal muscle respiratory capacity (8).
BAT combusts glucose and fatty acids towards heat, thereby increasing energy 
expenditure (9). High amounts of BAT, at least judged from the ability of BAT to take 
up [18F]fluorodeoxyglucose ([18F]FDG), are associated with lower plasma glucose levels 
and higher insulin sensitivity in humans (10-12) and BAT prevalence is inversely cor-
related with diabetic status (13). In addition, recruitment of BAT by short-term exposure 
to cold alleviates peripheral insulin resistance in individuals with type 2 diabetes (14). 
Of note, mouse studies have shown that BAT activation can also improve lipid profile 
and attenuate atherosclerosis development (15). Notably, in white adipose tissue (WAT) 
depots (16) inducible ‘beige’ adipocytes are present that have thermogenic capacity and 
can contribute to energy expenditure (reviewed in (17)).
Human skeletal muscle is an important contributor to energy expenditure and whole-
body glucose metabolism. Insulin resistance of skeletal muscle is one of the earliest 
abnormalities that precede type 2 diabetes, and mitochondrial dysfunction has been 
implicated in the underlying pathogenesis (18). Improving human skeletal muscle me-
tabolism, including mitochondrial function, is therefore another important therapeutic 
goal to ameliorate insulin resistance.
Although many studies have focussed on improving the metabolic profile of indi-
viduals with type 2 diabetes, less attention has been paid to identifying therapies that 
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improve glucose and lipid levels in prediabetic individuals. This may be of particular 
benefit since most of these individuals eventually proceed to overt diabetes (2,19). 
Therefore, the aim of this study was to evaluate the effect of sitagliptin on glucose toler-
ance, plasma lipids, energy expenditure, skeletal muscle metabolism and uptake of [18F]
FDG by BAT and WAT in overweight individuals with prediabetes.
MATERIALS AND METhODS
An extensive description of the Materials and Methods is available in the Supplementary 
Material and Methods.
Participants
Thirty-two overweight (BMI 25–35 kg/m2) Dutch Europid men with prediabetes, aged 35–55 
years, were included. Prediabetes was defined as having a fasted serum glucose between 5.6 
mmol/L and 6.9 mmol/L, according to the ADA criteria (20), and/or a plasma glucose level 
between 7.8 mmol/L and 11.1 mmol/L following an OGTT, according to WHO criteria for 
impaired glucose tolerance. Exclusion criteria were type 2 diabetes (e.g. fasted glucose >6.9 
mmol/L and/or plasma glucose following OGTT >11.1 mmol/L), smoking, recent weight 
change, rigorous exercise, uncontrolled chronic disease or a positron emission tomography/
computed tomography (PET/CT) scan within the last year. The study was approved by the 
Medical Ethical Committee of the Leiden University Medical Center (LUMC) and performed 
in accordance with the principles of the revised Declaration of Helsinki. Written informed 
consent was obtained from all volunteers prior to participation. Thirty participants were 
initially randomised. Two participants withdrew from the study prior to completion (both in 
the sitagliptin group–one participant because of heartburn and one participant because of 
joint pain) and were subsequently replaced with two new participants that were allocated 
to the same treatment (see Supplementary figure 1). Thus, thirty participants completed 
the study. After completion of the study, one participant from the sitagliptin group was 
excluded from analyses due to a distribution error where the participant received both 
sitagliptin and placebo as treatment. Trial register number: NCT02294084.
Study design
Participants were enrolled in a randomised, double-blinded, placebo-controlled study 
and received oral administration of either sitagliptin (100 mg/day sitagliptin phosphate; 
Januvia; Merck Sharp and Dome, Haarlem, the Netherlands) or placebo for 12 weeks. The 
primary study endpoint was the effect of sitagliptin on BAT volume and activity. Second-
ary endpoints were the effects of sitagliptin on body weight and composition, resting 
energy expenditure (REE), glucose tolerance, fasting markers in blood for glucose and lipid 
| 123
Sitagliptin in overweight prediabetic men
7
metabolism, [18F]FDG uptake by WAT and skeletal muscle and gene expression in skeletal 
muscle biopsies. As a post hoc analysis, we quantified lipid and lipoprotein composition us-
ing high-throughput proton NMR metabolomics. Participants were studied at baseline and 
after 12 weeks of treatment. Before and after the treatment period, two measurement days 
took place. During the first day, body composition was measured (DEXA; iDXA; GE Health-
care, Little Chalfont, UK), followed by an individualised water-cooling protocol as described 
previously (21) (see Supplementary Methods). Thermoneutral and cold-exposed fasting 
blood samples were obtained and REE was measured by indirect calorimetry (Oxycon Pro; 
CareFusion, Heidelberg, Germany) (see Supplementary Methods) and skin temperature 
was measured (iButton; Maxim Integrated Products, San Jose, CA, USA). In addition, cold-
induced [18F]FDG uptake by BAT, WAT and skeletal muscle was determined by PET/CT scan 
(Gemini TF-64; Philips Healthcare, Best, the Netherlands) 1 h after administration of 110 
MBq of [18F]FDG (see Supplementary Methods). In the sitagliptin group, one participant be-
came claustrophobic inside the PET/CT scan and could not finish this measurement. On the 
second day, a fasted skeletal muscle biopsy was taken from the vastus lateralis muscle (22) 
and then an OGTT was performed (see Supplementary Methods). All measurements took 
place after participants had fasted for 10 h overnight and had consumed a standardised 
dinner the night before. Each week during the treatment period, participants measured 
their blood glucose and were contacted to monitor compliance and adverse events.
Serum measurements
Commercially available enzymatic kits were used to measure serum concentrations of 
triacylglycerol and total cholesterol (Roche Diagnostics, Woerden, the Netherlands), 
NEFA (Wako Chemicals, Neuss, Germany) and glucose (Instruchemie, Delfzijl, the 
Netherlands). Insulin concentrations were measured using ELISA (Crystal Chem, Elk 
Grove Village, IL, USA). Plasma catecholamines were measured in the laboratory of 
Vascular Medicine (Erasmus MC, Rotterdam, the Netherlands) using standard proce-
dure. Aspartate aminotransferase, alanine aminotransferase, γ-glutamyltransferase, 
HbA1c and HDL-cholesterol were determined by the general hospital Laboratory of 
the LUMC and LDL-cholesterol was calculated using the Friedewald equation (23). 
Lipid and lipoprotein composition was quantified using high-throughput proton NMR 
metabolomics (Nightingale Health, Helsinki, Finland), as described previously (24). The 
following components were quantified: phospholipids, triacylglycerol, total cholesterol, 
non-esterified cholesterol and cholesteryl esters. The mean size for VLDL, LDL and HDL 
particles was calculated by weighting the corresponding subclass diameters with their 
particle concentrations (25). For the analysis of the OGTT, the AUC was calculated using 
the trapezoidal rule (26). Incremental AUC was calculated by deducting the area below 
the baseline value from total AUCs. Insulin sensitivity was estimated using the Matsuda 
index (27). The insulinogenic index (IGI; ΔI0–30/ΔG0–30, where I is insulin and G is glucose) 
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was used as a measure of early insulin secretion (28). The oral disposition index (DIo; 
[ΔI0–30/ΔG0–30]/fasting insulin) was used to estimate beta cell function relative to the 
prevailing level of insulin resistance (29).
PET/CT scan analysis
[18F]FDG uptake by BAT, WAT and skeletal muscle was determined from the [18F]FDG 
PET/CT scan using Fiji ImageJ 1.51d (Beth, Israel) (30) and analysed by two researchers 
blinded to allocation. For BAT, a personalised standardised uptake value (SUV) threshold 
with a tissue radiodensity between −190 and −10 Hounsfield units was used (31). For 
WAT, skeletal muscle and reference tissues, an SUV threshold of 0 was used and no 
Hounsfield units threshold was applied.
qRT-PCR analysis in skeletal muscle biopsies
Skeletal muscle biopsies were analysed for expression of genes involved in insulin signal-
ling (INSR, IRS1), glucose metabolism (GLUT4), lipid metabolism (ACACA, ACACB, ACSL1, 
CD36, FASN) and mitochondrial function (CTP1α, CTP1β, CTP2, CYCS, DNM1L, MFN2, OPA1, 
PPARGC1α [also known as PPARGC1A], PPARGC1β [also known as PPARGC1B], UCP3), as 
well as DPP4 (DPP4) and fibroblast growth factor (FGF21), using quantitative (q)PCR 
(Bio-Rad CFX96; Veenendaal, the Netherlands) (see Supplementary Table 1 for primer 
sequences). Bio-Rad software version 3.1 (Bio-Rad Laboratories, Hercules, CA, USA) was 
used for analysis and quantification. Biopsy material from five participants (two from 
placebo and three from sitagliptin group) was insufficient for reliable mRNA analysis. 
Expression levels were normalised using the housekeeping gene β-actin (ACTB) and 
expressed as fold change using the 2-∆∆ct method.
Statistical analysis
Power calculations were made for the primary outcome measurement of BAT activity 
(SUVmean), see Supplementary Materials and Methods. On the basis of previous studies 
(32), we anticipated a 20% increase in BAT activity after sitagliptin treatment. Assuming 
a bilateral alternative, we were able to detect differences of at least 20% in SUVmean, 
with a power of more than 80% and an α of 0.05 in a group of 30 participants. Data were 
analysed using SPSS Statistics (version 23.0; IBM Corporation, Armonk, NY, USA). Data are 
shown as mean ± SEM, unless stated otherwise. Two-tailed unpaired Student’s t test was 
used to compare baseline characteristic between sitagliptin and placebo group. Mixed 
model analyses with treatment and occasion as fixed effects and subject-specific devi-
ances from the mean as random effects were used to assess the effect of the treatment. 
If the mixed model failed to converge, a non-parametric paired test (Wilcoxon signed-
rank test) was used. Statistical results are shown with adjustment for multiple testing. 
Bonferroni-corrected levels of significance are shown in the table and figure legends.
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RESuLTS
Participant characteristics and compliance
Thirty overweight, Europid men with prediabetes completed the study, although one 
participant from the sitagliptin group was excluded from analyses due to a distribution 
error (the participant received both sitagliptin and placebo as treatment). Character-
istics of the remaining participants are summarised in Table 1. All measured baseline 
characteristics were comparable between the two groups (Table 1), except for alanine 
aminotransferase, which was higher in the placebo group (0.73 ± 0.08 vs 0.47 ± 0.05 
µkat/L; p=0.009 [not significant with a Bonferroni-corrected level of significance of 
0.003]). A total of 83% of the participants had isolated impaired fasting glucose and 
17% of the participants had combined impaired fasting glucose and impaired glucose 
tolerance. The daily oral administration of 100 mg sitagliptin was well tolerated and 
reported side effects (e.g. nasopharyngitis, heartburn and joint pains) were mild and 
transient and not necessarily related to the treatment. No episodes of hypoglycaemia 
were observed. Compliance was confirmed by counting returned tablets. In the placebo 
group only transient nasopharyngitis was reported.
Table 1. Participant characteristics at screening
Placebo (n=15) Sitagliptin (n=14)
Age (years) 47.1 (1.5) 45.3 (1.7)
Height (m) 1.83 (0.02) 1.79 (0.02)
Weight (kg) 93.7 (1.6) 95.4 (3.1)
BMI (kg/m2) 27.8 (0.4) 29.6 (0.9)
Waist circumference (cm) 101 (2) 100 (2)
Hip circumference (cm) 101 (2) 103 (2)
Waist-to-hip ratio 1.00 (0.01) 0.98 (0.01)
Fasting glucose (mmol/L) 5.9 (0.1) 5.8 (0.1)
Fasting insulin (pmol/L) 81.3 (24.3) 54.2 (9.7)
HbA1c (mmol/L) 36.5 (0.8)  36.2 (0.9)
HbA1c (%) 5.5% 5.5%
Fasting triacylglycerol (mmol/L) 1.70 (0.31) 1.47 (0.19)
Fasting total cholesterol (mmol/L) 5.32 (0.32) 5.84 (0.24)
Aspartate aminotransferase (µkat/L) 0.52 (0.03) 0.42 (0.03)
Alanine aminotransferase (µkat/L) 0.73 (0.08) 0.47 (0.05) *
γ-Glutamyltransferase (µkat/L) 0.62 (0.08) 0.53 (0.07)
Values are presented as mean (standard error of the mean). BMI: body mass index, HbA1c: haemoglobin 
A1c. Two-tailed unpaired Student’s t test was used for statistical comparison *p=0.009 for sitagliptin vs 
placebo (not significant with Bonferroni-corrected level of significance of 0.003 (α=0.05/16). Data are from 




Sitagliptin improves glucose tolerance without changing body weight or 
composition
We first assessed the effects of sitagliptin on glucose metabolism. Sitagliptin did not 
change fasting serum glucose or insulin levels (Table 2). However, compared with base-
line, twelve weeks of sitagliptin treatment improved glucose tolerance as demonstrated 
by reduced glucose excursions (AUCgluc0–120 −15%, p < 0.003; Table 2), lower incre-
mental glucose excursions (AUCincrgluc0–120 −40%, p < 0.003; Table 2; figure 1B,C) and 
lower peak glucose levels (−12%, p < 0.003; Table 2) during OGTT. Incremental insulin 
excursions (AUCincrins0–120) were not significantly reduced upon sitagliptin treatment 
(Table 2; figure 1E,f). Furthermore, sitagliptin improved IGI (+38%, p < 0.003; Table 
2) and increased DIo (+44%, p < 0.003; Table 2). Placebo did not affect either glucose or 
insulin excursions (Table 2 and figure 1A,C,D,f). Using a mixed model, we confirmed 
that the sitagliptin-induced changes in peak glucose levels (p < 0.05), AUCgluc0–120 (p < 
0.05), AUCincrgluc0–120 ( p< 0.003), IGI (p < 0.05) and DIo (p < 0.003) were significantly dif-
ferent from placebo. Sitagliptin did not affect body composition (Supplementary Table 
2), nor did it affect proximal, distal or supraclavicular skin temperature upon cooling 
Table 2. Effect of sitagliptin on measures of glucose tolerance in overweight men with prediabetes
Placebo (n=15) Sitagliptin (n=14)
Week 0 Week 12 Week 0 Week 12
Fasting glucose (mmol/L) 6.3 (0.2) 6.1 (0.2) 5.9 (0.2) 5.9 (0.2)
Peak glucose (mmol/L) 12.2 (0.4) 12.1 (0.5) 11.0 (0.4) 9.7 (0.3) ** †
Peak glucose time (min) 52.7 (4.8) 40.7 (2.7) 44.3 (5.1) 31.4 (3.3)
AUC0-120 glucose (mmol/L x min) 1137 (52) 1088 (51) 969 (41) 819 (21) ** †
AUC0-120 incremental glucose (mmol/L x min) 387 (40) 371 (38) 276 (35) 166 (33) ** ††
Fasting insulin (pmol/L) 46.5 (6.3) 51.4 (7.0) 37.5 (6.3) 44.5 (12.5)
Peak insulin (pmol/L) 639 (111) 590 (83) 549 (76) 507 (83)
Peak insulin time (min) 61.3 (6.4) 65.3 (8.5) 46.4 (6.2) 40.7 (4.0)
AUC0-120 insulin (pmol/Lx min) 45565 (7881) 42960 (6048) 37437 (5652) 31858 (4879)
AUC0-120 incremental insulin (pmol/Lx min) 39941 (7296) 36805 (5366) 32957 (5036) 26533 (3571)
AUC0-120 glucose/ AUC0-120 insulin 0.25 (0.04) 0.25 (0.04) 0.22 (0.02) 0.21 (0.02)
Matsuda index 4.93 (0.72) 5.56 (1.16) 5.96 (0.65) 6.63 (0.73)
HOMA-IR 1.93 (0.26) 2.02 (0.28) 1.40 (0.24) 1.71 (0.51)
IGI (pmol/mmol) 77 (12) 75 (14) 100 (19) 138 (23) ** †
DIo 1.69 (0.21) 1.68 (0.34) 2.67 (0.30) 3.84 (0.54) ** ††
Values are presented as mean (standard error of the mean). AUC: area under the curve, DIo: oral dispo-
sition index, HOMA-IR: homeostatic model assessment insulin resistance, IGI: insulinogenic index. Mixed 
model analysis was used for statistical comparison *0.003<p<0.05 and **p<0.003 for week 0 vs week 12; 
†0.003<p<0.05 and ††p<0.003 for placebo vs sitagliptin. Bonferroni-corrected level of significance is 0.003 
(α=0.05/15). Data are from all participants that completed the study, apart from n=1 in the sitagliptin 
group, who was excluded due to pharmacy error.
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(Supplementary Table 3). In addition, the liver enzymes aspartate aminotransferase, 
alanine aminotransferase and γ-glutamyltransferase were not affected by sitagliptin 
treatment (Supplementary Table 4). Of note, placebo increased alanine aminotransfer-
ase (+82%, p < 0.01; Supplementary Table 4).
Sitagliptin lowers serum triacylglycerol reflected by decreased concentrations 
of large and medium-sized vLDL particles
Previous studies in individuals with type 2 diabetes showed that sitagliptin improves 
plasma lipid levels (5,6). Therefore, we assessed whether sitagliptin also affects serum 
lipids and lipoprotein levels in overweight individuals with prediabetes. Sitagliptin 
induced a substantial reduction in serum triacylglycerol levels (−29%; p < 0.05 [not sig-
nificant with a Bonferroni-corrected level of significance of 0.003]; figure 2A) without 
affecting serum total cholesterol (figure 2B), total HDL-cholesterol (figure 2C), total 
LDL-cholesterol (figure 2D), NEFA levels (data not shown) or plasma catecholamines 
(data not shown). Placebo did not significantly affect serum triacylglycerol, total cho-
lesterol, HDL-cholesterol or LDL-cholesterol (figure 2A–D). The sitagliptin-induced 
reduction in triacylglycerol was not significantly different from placebo.




































































































































figure 1. The effect of sitagliptin on glucose tolerance in overweight men with prediabetes. An OGTT 
was performed to assess glucose tolerance, before (white circles and bars) and after (black circles and bars) 
12 weeks of placebo (n=15) or sitagliptin (n=14) treatment. Serum was collected before and at several time 
points up to 120 min after ingestion of 75 g of glucose. Glucose and insulin excursions were determined at 
the indicated time points after treatment with placebo (A, D) or sitagliptin (B, E). Incremental AUC (AUCincr) 
was calculated for glucose (gluc; c) and insulin (ins; f). Data are presented as means ± SEM. Mixed model 
analysis was used for statistical comparison. In (A, B, D, E) *0.006<p<0.05 for week 0 vs week 12, not sig-
nificant with Bonferroni-corrected level of significance 0.006 (α=0.05/9). In (C, f) **p<0.01 for week 0 vs 
week 12, significant with Bonferroni-corrected level of significance 0.01 (α=0.05/4); ††p<0.01 for placebo vs 























































































































































































































































































  Placebo          Sitagliptin
figure 2. The effect of sitagliptin on serum lipid and vLDL and hDL particle concentration in over-
weight men with prediabetes. Serum was collected before (week 0, white bars) and after (week 12, black 
bars) treatment with placebo (n=15) or sitagliptin (n=14). Enzymatic assays were used to measure serum tri-
acylglycerol (TG) (A) and total cholesterol (TC) (B). HDL-cholesterol was determined by the general hospital 
laboratory of the LUMC (C) and LDL-cholesterol was calculated using the Friedewald equation (D). NMR was 
used to measure serum concentrations of extremely large (E), very large (f), large (G), medium-sized (h), 
small (I) and very small (J) VLDL particle and very large (k), large (L), medium-sized (M) and small (N) HDL 
particles. In addition, mean VLDL (O) and mean HDL (P) particle size was determined. Data are presented as 
means ± SEM and as individual measurements. Mixed model analysis was used for statistical comparison. 
*0.003<p<0.05 for week 0 vs week 12, not significant with Bonferroni-corrected level of significance 0.003 
(α=0.05/16).
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Since serum triacylglycerol is carried by lipoproteins, we next assessed whether the 
reduction in triacylglycerol induced by sitagliptin was specific for certain lipoprotein 
subfractions. Sitagliptin lowered serum concentrations of very large (−46%; p < 0.05; 
figure 2f), large (−35%; p < 0.05; figure 2G) and medium-sized VLDL particles (−24%; p 
< 0.05; figure 2h), although these were all non-significant with a Bonferroni-corrected 
level of significance of 0.003. Concentrations of small (figure 2I) and very small VLDL 
particles (figure 2J) were unchanged. Overall, this resulted in a decrease in mean 
VLDL particle size (−1.7%; p < 0.05 [not significant with a Bonferroni-corrected level of 
significance of 0.003]; figure 2O). In addition, sitagliptin did not significantly change 
the concentrations of very large, large, medium-sized or small HDL particle subfractions 
(figure 2k–N) or mean HDL particle size (figure 2P). Intermediate-dense lipoprotein 
(IDL), large, medium-sized and small LDL particle concentrations and mean LDL particle 
size were not affected by sitagliptin treatment (figure 2). Placebo did not alter the 
measured lipoprotein particle concentrations or particle sizes (figure. 2E–P; Supple-
mentary figure 2). The sitagliptin-induced reduction in concentration of very large, 
large or medium-sized VLDL particles was not significantly different from placebo, nor 
was the sitagliptin-induced decrease in VLDL and increase in HDL mean particle size.
In line with these findings, most components of the lipoprotein subclasses in extremely 
large, very large, large and medium-sized VLDL particles were decreased upon sitagliptin 
treatment (Supplementary Table 5). In IDL, only non-esterified cholesterol significantly 
increased and in HDL particles only phospholipids in very large HDL significantly increased 
(Supplementary Table 5), although these were not significant with a Bonferroni-correct-
ed level of significance of 0.0006. Components of the lipoprotein subclasses in LDL frac-
tions (Supplementary Table 5) and fatty acid composition did not change significantly.
Sitagliptin does not affect overall resting energy expenditure or substrate 
preference
To assess whether sitagliptin improves glucose and lipid metabolism by altering substrate 
utilisation or REE, indirect calorimetry was performed. REE was similar before and after 
treatment with either sitagliptin or placebo, also when correcting for lean body mass (Sup-
plementary Table 6). In addition, non-shivering thermogenesis, the respiratory quotient, 
glucose and lipid oxidation did not change upon treatment (Supplementary Table 6).
Sitagliptin increases [ 18f]fDG uptake in subcutaneous WAT, but not in BAT
Next, we assessed whether sitagliptin improves glucose tolerance and lipid profile 
through beneficial effects on BAT, WAT or skeletal muscle. To this end, we assessed 
cold-induced [18F]FDG uptake in these organs following PET/CT scan. Concerning the 
primary endpoint, we found that 12 weeks of sitagliptin treatment did not affect [18F]
FDG uptake in all measured BAT depots, though mean [18F]FDG uptake in BAT was very 
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low in most participants (Supplementary Table 7). Furthermore, sitagliptin did not 
alter [18F]FDG uptake in skeletal muscle or paracolic WAT. Interestingly, [18F]FDG uptake 
in subcutaneous WAT (sWAT) was increased by sitagliptin (+53%; p < 0.05 [not significant 
with Bonferroni-corrected level of significance of 0.002]) but not placebo treatment 
(Supplementary Table 7). The sitagliptin-induced effect on [18F]FDG uptake in sWAT 
did not significantly differ from placebo. In the placebo group, [18F]FDG uptake by the 
trapezius muscles was increased (+15%; p < 0.05), as was uptake by the descending 
aorta (+13%; p < 0.05), as reference tissues (neither significant with Bonferroni-corrected 
level of significance of 0.002; Supplementary Table 7).
Sitagliptin increases PGC1β gene expression in skeletal muscle
Next, we analysed skeletal muscle biopsies for pathways involved in mitochondrial func-
tion, glucose and lipid metabolism. Sitagliptin increased the expression of PGC1β (also 
known as PPARGC1B) (+117%; p < 0.05 [not significant with Bonferroni-corrected level of 
significance of 0.002]; figure 3B) in skeletal muscle. Sitagliptin also increased DPP4 gene 
expression (+51%; p < 0.05 [not significant with Bonferroni-corrected level of significance 
of 0.002]; figure 3D). Expression of genes involved in glucose or lipid metabolism were not 
significantly changed by sitagliptin (figure 3D). In the placebo group, expression levels of 
























































































































































































figure 3. The effect of sitagliptin on skeletal muscle gene expression in overweight men with pre-
diabetes. A fasted skeletal muscle biopsy was taken before (white bars) and after (black bars) 12 weeks 
of treatment with placebo (n=13) or sitagliptin (n=11). qPCR was used to determine expression of genes 
involved in mitochondrial function, glucose metabolism and lipid metabolism, as well as DPP4 and FGF21, 
upon placebo (a, c) and sitagliptin (b, d) treatment. Data are presented as means ± SEM. Expression levels 
were normalised using the mRNA content of the housekeeping gene β-actin (ACTB) and expressed as fold 
change using the 2-∆∆ct method. Mixed model analysis was used for statistical comparison. *0.002<p<0.05 
for week 0 vs week 12, not significant with Bonferroni-corrected level of significance 0.002 (α=0.05/21).
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DISCuSSION
The aim of the current study was to evaluate the effect of sitagliptin on glucose tolerance, 
plasma lipids, energy expenditure, skeletal muscle metabolism and [18F]FDG uptake by 
BAT and WAT in overweight men with prediabetes. Here, we report that 12 weeks of 
sitagliptin treatment improved glucose tolerance and lipid profile in these men. These 
beneficial effects were accompanied by an increase in mRNA expression of PGC1β, a 
gene encoding an inducer of mitochondrial biogenesis, in skeletal muscle. Sitagliptin 
did not affect [18F]FDG uptake by BAT but increased [18F]FDG uptake by sWAT. To our 
knowledge, this study is the first to provide extensive insight in the beneficial effects 
of sitagliptin on both glucose and lipid metabolism in overweight individuals with 
prediabetes, as previous studies mostly focussed on individuals with type 2 diabetes (6).
We showed that the improvement in glucose tolerance following treatment of these 
men with sitagliptin was not explained by changes in body composition. The improved 
glucose tolerance is in line with previous reports (33,34). Since we observed an improve-
ment in IGI (i.e. measure of early insulin secretion) and DIo (i.e. estimation of beta cell 
function relative to measure of insulin resistance) during OGTT, we speculate that the 
improved glucose tolerance can be explained by increased early insulin secretion, in 
turn possibly due to improved beta cell function. In accordance with this, the DPP4 
inhibitor vildagliptin (100 mg/day) improved insulin sensitivity and beta cell function 
in prediabetic individuals upon 6 weeks of treatment (35). Interestingly, animal stud-
ies have shown that sitagliptin can delay the progression of prediabetes into diabetes 
(36,37). Whether this is also the case in humans remains to be elucidated (38).
We also showed that sitagliptin lowered serum triacylglycerol levels in overweight 
men with prediabetes. This is in line with previous studies showing that sitagliptin re-
duces triacylglycerol levels in individuals with type 2 diabetes (5,39), although in those 
individuals total cholesterol levels were also reduced. We used NMR metabolomics to 
evaluate which triacylglycerol-containing lipoprotein classes were lowered. Thereby, we 
specifically observed a decrease in the concentration of very large, large and medium-
sized VLDL particles, which may point to reduced hepatic VLDL-triacylglycerol synthesis 
and/or enhanced VLDL-triacylglycerol clearance. Individuals with type 2 diabetes display 
increased hepatic synthesis of VLDL particles, resulting in elevated VLDL-triacylglycerol 
(4,40), presumably due to the impaired ability of insulin to suppress VLDL synthesis. 
Tremblay et al (6) showed that 6 weeks of sitagliptin treatment reduces triacylglycerol 
levels due to reduced hepatic VLDL synthesis (6). Therefore, it is likely that sitagliptin also 
attenuates hepatic VLDL-triacylglycerol production in our study in prediabetic men who 
also have impaired insulin sensitivity. A contribution made by the increased lipolysis 
of VLDL-triacylglycerol by LPL-containing peripheral tissues, including skeletal muscle 
and BAT, cannot be ruled out, especially since enhanced glucagon-like peptide-1 (GLP-1) 
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receptor signalling has been shown to largely increase the uptake of triacylglycerol-
derived fatty acids by BAT in mice (41). Evaluation of the potential contribution made by 
accelerated triacylglycerol clearance to the triacylglycerol-lowering effect of sitagliptin 
should be subject of future studies.
So far, the contribution of the various metabolic tissues responsible for the beneficial 
metabolic effects of sitagliptin has not been clarified. We investigated BAT, WAT and skel-
etal muscle, as those tissues are known to play an important role in energy metabolism. 
Despite us defining the primary endpoint of this study as the effect of sitagliptin on 
BAT volume and activity, we did not observe an effect of sitagliptin on [18F]FDG uptake 
by BAT. However, sitagliptin is suggested to activate BAT in rodents, as judged from 
increased expression of uncoupling protein 1 gene (8). It should be realised that the 
read-outs of BAT activity were different in rodents compared with humans. In addition, 
compared with lean individuals, it is known that [18F]FDG uptake in BAT is lower in obese 
individuals (42), in individuals with type 2 diabetes (43) and in increasing age (44), likely 
due to increased insulin resistance. Importantly, insulin resistance does not reduce the 
uptake by BAT of 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid ([18F]FTHA; a fatty acid 
tracer) or [11C]acetate (a measure of oxidative metabolism) (43). It is feasible that our 
overweight men with prediabetes are insulin resistant at the level of BAT and, as a 
consequence, display low [18F]FDG uptake in BAT. Therefore, it cannot be ruled out that 
in our study population [18F]FDG uptake by BAT reflects insulin resistance rather than 
BAT metabolism. Since fatty acids rather than glucose form the main substrate for BAT 
thermogenesis (45,46), future studies should preferably use lipid-based PET/CT tracers 
such as [18F]FTHA or PET/CT tracers imaging oxidative capacity, such as [11C]acetate, to 
better reflect BAT activity, especially in insulin-resistant individuals. Interestingly, sita-
gliptin increased [18F]FDG uptake in sWAT, possibly pointing to browning of this tissue. 
Indeed, enhanced GLP-1 receptor signalling induces massive browning of WAT in mice 
(41). Unfortunately, sWAT biopsies were not collected, so it remains unknown whether 
expression levels of thermogenic genes in WAT are increased upon sitagliptin treat-
ment. Assessment of browning would be important in future human studies using DPP4 
inhibitors or GLP1 agonists and would be of particular clinical relevance to overweight 
participants, who display large subcutaneous WAT depots.
Besides BAT, skeletal muscle is an important contributor to energy metabolism in 
humans. Sitagliptin increased DPP4 expression in skeletal muscle, which seems coun-
terintuitive since high local DPP4 levels are thought to impair insulin signalling and 
thereby induce/deteriorate the development of type 2 diabetes (47). The increased DPP4 
expression may be a consequence of a compensatory mechanism of increased plasma 
GLP-1 as a result of DPP4 inhibition, although unfortunately we were not able to mea-
sure circulating GLP-1 levels. We did show that sitagliptin increased mRNA expression of 
PGC1β, which is in line with a previous rodent study showing that sitagliptin treatment 
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increases mitochondrial gene expression in skeletal muscle (8). Since PGC1β modulates 
mitochondrial function through induction of mitochondrial biogenesis (48,49), sita-
gliptin may enhance skeletal muscle metabolism via this mechanism. Although we did 
not detect a significant effect of sitagliptin on energy expenditure, a potential contribu-
tion to whole-energy metabolism may not have been picked up by indirect calorimetry. 
Since skeletal muscles contribute largely to the composition of the human body, a small 
change in muscle respiration could have a large effect on total body metabolism.
A strength of our study is that we analysed the effect of sitagliptin on the main meta-
bolically active organs. Moreover, we analysed multiple BAT and WAT depots by [18F]FDG 
PET/CT. We also performed an extensive analysis of the serum lipoprotein profile using 
NMR metabolomics. A limitation of the current study is that we made use of the radio-
tracer [18F]FDG, so may have underestimated the metabolic activity of insulin-resistant 
tissues in individuals with prediabetes. We performed all measurements after an over-
night fast. Since DPP4 inhibitors are most effective after a meal, it might be interesting 
to investigate the effects of sitagliptin on postprandial glucose and lipid metabolism, 
which might be even more pronounced. Furthermore, the relatively small sample size 
might have limited the statistical power. A strength and limitation is that we assessed 
many variables, which necessitated Bonferroni correction. The Bonferroni threshold 
for significance was reached only for reduction in glucose excursions by sitagliptin, 
the lower peak glucose levels during the OGTT and the improvement in the IGI and 
DIo. In addition, we only investigated Europid men. We chose this specific group since 
South Asians, another large ethnic group within the Netherlands, generally display more 
insulin resistance and dyslipidaemia (reviewed in (50)) as well as higher GLP-1 levels 
(51) compared with Europids. Combination of several ethnic groups may have increased 
variation within our study groups. However, future studies should investigate whether 
these results also apply to the general population, including women.
In conclusion, we show that 12 weeks of sitagliptin treatment improves glucose 
tolerance and lipid profile in overweight men with prediabetes. Those effects might be 
mediated by browning of sWAT and/or increased energy metabolism in skeletal muscle 
possibly by upregulation of PGC1β. However, the precise mechanism linking DPP4 inhi-
bition to metabolic health still remains to be elucidated. Since up to 70% of prediabetic 
individuals eventually develop type 2 diabetes and current lifestyle and exercise pro-
grammes are often difficult to maintain in the long term, further studies on the effect of 
sitagliptin in preventing or delaying the progression of prediabetes and dyslipidaemia 
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SuPPLEMENTAL APPENDIx
Supplementary material and methods
Participants
Thirty-two overweight (BMI 25-35 kg/m2) Dutch Europid men with prediabetes, aged 
35-55 years, were included in the study. Participants were recruited via local advertise-
ments and underwent medical screening prior to participation, including an interview 
regarding medical history, physical examination, a blood chemistry test and an oral 
glucose tolerance test (OGTT) to exclude individuals with undiagnosed type 2 diabetes. 
Prediabetes was defined as having a fasted serum glucose between 5.6 mmol/L and 
6.9 mmol/L, according to the American Diabetes Association (ADA) criteria (1), and/
or a plasma glucose level between 7.8 mmol/L and 11.1 mmol/L following an OGTT, 
according to World Health Organization (WHO) criteria for impaired glucose tolerance. 
Exclusion criteria were type 2 diabetes (e.g. fasted glucose > 6.9 mmol/L and/or plasma 
glucose following OGTT > 11.1 mmol/L), smoking, recent weight change (> 3 kg within 
the last 3 months), rigorous exercise, use of beta-blockers, uncontrolled hypertension, 
hyper- or hypothyroidism, renal failure or liver dysfunction, or a positron emission 
tomography/computed tomography (PET/CT) scan within the last year. The study was 
approved by the Medical Ethical Committee of the Leiden University Medical Center 
and performed in accordance with the principles of the revised Declaration of Helsinki. 
Written informed consent was obtained from all volunteers prior to participation. Thirty 
participants were initially randomised. Two participants withdrew from the study prior 
to completion (both in the sitagliptin group; one participant because of heartburn and 
one participant because of joint pain) and were subsequently replaced, with two new 
participants, that were allocated to the same treatment. All symptoms resolved without 
sequelae. Thus, thirty participants completed the study. Also, one participant from the 
sitagliptin group was excluded from analysis, due to a distribution error where the 
participant received both sitagliptin and placebo as treatment. Trial register number: 
NCT02294084.
Study design
Participants were enrolled in a randomised, double-blinded, placebo-controlled study 
that was conducted in the Leiden University Medical Center (Leiden, The Netherlands) 
and Alrijne Hospital (Leiderdorp, The Netherlands). The primary study endpoint was 
the effect of sitagliptin treatment on brown adipose tissue volume and activity in 
overweight men with prediabetes. Secondary endpoints were the effect of sitagliptin 
on body weight and body composition, resting energy expenditure, fasting markers in 
blood for glucose and lipid metabolism, [18F]FDG uptake by white adipose tissue and 
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skeletal muscle and expression of genes involved in insulin signalling, glucose and lipid 
metabolism in skeletal muscle biopsies. As a post-hoc analysis we quantified lipid and li-
poprotein composition using high-throughput proton NMR metabolomics. Participants 
were randomly assigned in a 1:1 ratio by the unblinded hospital pharmacist to receive 
oral administration of either sitagliptin (Sitagliptin phosphate, Januvia, Merck Sharp 
and Dome, Haarlem, The Netherlands) at a dose of 100 mg oral daily, or placebo for 12 
weeks. Following initial screening, participants were studied at baseline and after 12 
weeks of treatment. Before and after the treatment period there were two measurement 
days. During the first day, which took place at the Alrijne hospital in Leiderdorp, body 
composition (DEXA, iDXA, GE Healthcare, Little Chalfont, UK), skin temperature (iButton, 
Maxim Integrated Products, San Jose, CA, USA), thermoneutral and cold-exposed rest-
ing energy expenditure (REE; indirect calorimetry, Oxycon Pro, CareFusion, Heidelberg, 
Germany), and cold-induced [18F]fluorodeoxyglucose ([18F]FDG) uptake by BAT and 
other metabolic organs such as white adipose tissue (WAT) and skeletal muscle were 
determined by PET/CT scan (Gemini TF-64, Philips Healthcare, Best, The Netherlands). 
In addition, thermoneutral and cold-exposed venous blood samples were collected. On 
the second day at the Leiden University Medical Center, a fasting skeletal muscle biopsy 
was taken from the vastus lateralis muscle followed by an OGTT. All measurements took 
place after participants had fasted for 10h overnight and had consumed a standardised 
dinner the night before. In addition, participants were asked to refrain from caffeine and 
alcohol intake or strenuous physical activity 24 h prior to the study days. Each week dur-
ing the treatment period, participants measured their blood glucose and were contacted 
by the investigator to monitor compliance, adverse events or signs of hypoglycemia. In 
addition, participants were instructed not to alter their lifestyle during the study period. 
The study was conducted between March 2015 and September 2016.
Indirect calorimetry, individualized cooling protocol and [18f]fDG PET-CT scan
On the first measurement day an intravenous cannula was placed in antecubital vein for 
blood sampling during thermoneutral and mild cold conditions and injection of the [18F]
FDG tracer. First detailed body composition was obtained by dual-energy X-ray absorp-
tiometry, followed by placement of 14 wireless temperature sensors at 14 prescribed 
ISO-defined places (2). Mean skin temperature was calculated as the average of all iBut-
tons. Distal skin temperature was calculated as the average temperature of the hand and 
feet. Proximal skin temperature was defined as the average of the iButtons on the chest, 
abdomen, scapula and lower back. Next participants were placed in a bed in semi-supine 
position between two water-perfused mattresses (BlanketRol® III Sub-Zero (CSZ) Prod-
ucts, Cincinnati, OH, USA). As described previously (3), the protocol started with 1 h of 
thermoneutrality (water temperature 32°C) at which thermoneutral REE was measured 
for 30 minutes using indirect calorimetry and a venous blood sample was drawn. After1 
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h at thermoneutrality, participants were progressively cooled until their shivering point 
or until they reached the minimum water temperature of 9°C. At this mild cold condition 
REE was measured for another 30 minutes and a second blood sample was collected. 
Oxygen consumption and carbon dioxide production were determined every minute. 
REE and respiratory quotient (RQ) were calculated and substrate utilization was assessed 
by calculation of lipid and glucose oxidation after correction for protein oxidation as 
described earlier (4). Non-shivering thermogenesis (NST) was assessed by the difference 
in REE during mild cooling compared to thermoneutral conditions. Subsequently, 110 
MBq of [18F]FDG was injected intravenously and after 1 h of incubation, the PET/CT im-
aging protocol started with a low-dose CT scan (120 kV, 30 mAs), immediately followed 
by a PET scan (10 bed positions, 4 minutes per bed position) acquired according to EARL 
standards (5) to assess [18F]FDG uptake by BAT, WAT and skeletal muscle from skull to 
pelvis. In the sitagliptin group one participant became claustrophobic inside the PET/CT 
scan and could therefore not finish this measurement.
Skeletal muscle biopsy and oral glucose tolerance test
On the second measurement day, a fasted skeletal muscle biopsy was taken from the 
vastus lateralis muscle according to the technique of Bergström (6). Subsequently, the 
samples were frozen in liquid nitrogen and stored at -80° C until further analysis. After 
1 h of rest, a glucose tolerance was assessed using a 75-g OGTT. A cannula was inserted 
in the antecubital vein for blood sampling and samples were drawn at respectively t = 
-10, 0, 10, 20, 30, 40, 50, 60, 90, 120 minutes after ingestion of the glucose drink. Serum 
was obtained, snap-frozen in liquid nitrogen and stored at -80°C until further analysis.
Serum measurements
Commercially available enzymatic kits were used to measure serum concentrations 
of triacylglycerol, total cholesterol (Roche Diagnostics, Woerden, The Netherlands), 
NEFA (Wako Chemicals, Neuss, Germany) and glucose (Instruchemie, Delfzijl, The 
Netherlands). Insulin concentrations were measured using ELISA (Crystal Chem Inc., Elk 
Grove Village, IL, USA). The intra-assay coefficients of variability (CV) were 3.8%, 4.2%, 
3.6%, 2.5% and 5.9% for triacylglycerol, total cholesterol, free fatty acids, glucose and 
insulin respectively. The inter-assay CVs were 5.3%, 4.0%, 7.9%, 4.7% and 7.1% for tria-
cylglycerol, total cholesterol, free fatty acids, glucose and insulin respectively. Plasma 
catecholamines were measured in the laboratory of Vascular Medicine (Erasmus MC, 
Rotterdam, The Netherlands) using standard procedure. Aspartate aminotransferase, 
alanine aminotransferase, γ-glutamyltransferase, HbA1c and HDL-cholesterol were 
determined by the general hospital Laboratory of the Leiden University Medical 
Center and LDL-cholesterol was calculated using the Friedewald formula (LDL; Total 
Cholesterol-HDL-(Triacylglycerol/2.17)) (7). In addition, lipid and lipoprotein composition 
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was quantified using high-throughput proton NMR metabolomics (Nightingale Health, 
Helsinki, Finland). This method provides simultaneous quantification of routine lipids, 
lipoprotein subclass profiling with lipid concentrations within 14 subclasses, fatty acid 
composition, and various low-molecular metabolites including amino acids, ketone 
bodies and gluconeogenesis-related metabolites in molar concentration units. The fol-
lowing components of the lipoprotein subclasses were quantified: phospholipids, triac-
ylglycerol, total cholesterol, non-estrified cholesterol, and cholesteryl esters. The mean 
size for VLDL, LDL and HDL particles was calculated by weighting the corresponding 
subclass diameters with their particle concentrations (8). Details of the experimentation 
and applications of the NMR metabolomics platform have been described previously 
(9). Data were analysed using SoftMaxPro 5.4.1 software. For the analysis of the OGTT, 
the AUC was calculated using the trapezoidal rule (10). Incremental AUC was calculated 
by deducting the area below the baseline value from total AUCs. Insulin sensitivity was 
estimated using the Matsuda index (11). The insulinogenic index (IGI; ΔI0-30/ΔG0-30, where 
I is insulin and G is glucose) was used as a measure of early insulin secretion (12). The 
oral disposition index (DI0; [ΔI0-30/ΔG0-30]/fasting insulin) was used to estimate beta cell 
function relative to the prevailing level of insulin resistance (13).
PET/CT scan analysis
[18F]FDG uptake by BAT, WAT and skeletal muscle was determined from the [18F]FDG 
PET/CT scan using Fiji ImageJ 1.51d (Beth Israel Deaconess Medical Center, Beth, Israel) 
(14) and analysed by two researchers (KJN, BMT) blinded to allocation. In the region of 
interest (ROI), the bilateral cervical and clavicular regions, mediastinal and paravertebral 
BAT areas were autocontoured using an set personalised standardised uptake value (SU-
Vindiv) threshold with a tissue radiodensity between -190 and -10 Hounsfield units (15). 
SUVindiv threshold was calculated with the following formula: 1.2/lean body mass (in 
kg)/body mass (in kg), according to the latest expert panel recommendations (16). BAT 
metabolic volume (BMV) was measured in millilitres, BAT activity was reported in terms 
of SUV (the ratio of activity in kBq/mL within the ROI and the injected activity [kBq] 
per bodyweight [g]). Both SUV for the hottest single voxel (SUVmax) and mean SUV for 
all voxels within a BAT region (SUVmean) are reported. For WAT areas (subcutaneous 
and paracolic), skeletal muscles (sternocleidomastoid, longus colli, trapezius, deltoid, 
pectoralis major, psoas major, and gluteus maximus muscle) and reference tissues (liver, 
cerebellum and descending aorta), an SUV threshold was set at 0 and no Hounsfield 
units threshold was applied.
qRT-PCR analysis in skeletal muscle biopsies
Skeletal muscle biopsies were analysed for expression of genes involved in insulin signal-
ling (INSR, IRS1), glucose metabolism (GLUT4), lipid metabolism (ACACA, ACACB, ACSL1, 
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CD36, FASN), and mitochondrial function (CTP1α, CTP1β, CTP2, CYCS, DNM1L, MFN2, OPA1, 
PPARGC1α [also known as PPARGC1A], PPARGC1β [also known as PPARGC1B], UCP3), as 
well as DPP4 (DPP4) and Fibroblast Growth Factor (FGF21) using qPCR (Bio-Rad CFX96; 
Veenendaal, The Netherlands) (see Supplementary Table 1 for primer sequences). 
Bio-Rad CFX Manager software version 3.1 (Bio-Rad Laboratories Inc, Hercules, CA, USA) 
was used for analysis and quantification. Biopsy material of five participants (two from 
placebo and three from sitagliptin group) was insufficient for reliable mRNA analysis. 
Expression levels were normalised using the mRNA content of the housekeeping gene β 
-Actin (ACTB) and expressed as fold change using the 2-∆∆ct method.
Statistical analysis
Power calculations were made for the primary outcome measurement of BAT activity 
(SUVmean). On the basis of previous studies (17), we anticipated a 20% increase in BAT 
activity after Sitagliptin treatment. An SUVmean of 2.20 was expected in the control 
group and a SUVmean of 2.64 in the sitagliptin group after intervention, with a SD of 
0.42. Assuming a bilateral alternative, we were able to detect differences of at least 20% 
in SUVmean with a power of more than 80% and an alpha of 0.05 in a group of 30 partici-
pants. Data was analysed using SPSS Statistics (version 23.0; IBM Corporation, Armonk, 
NY, USA). Data are shown as mean ± S.E.M, unless stated otherwise. Two-tailed unpaired 
Student’s t-test was used to compare baseline characteristic between sitagliptin and 
placebo group. Mixed model analyses with treatment and occasion as fixed effects and 
subject specific deviances from the mean as random effects were used to assess the 
effect of the treatment. Ifthe mixed model failed to converge a non-parametric paired 
test (Wilcoxon Signed-Rank Test) was used. Statistical results are shown with adjustment 
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Supplementary Table 1. Primer sequences of forward and reverse primers for qRT-PCR
Gene Forward primer Reverse primer
ACACA Ordered by Qiagen Ordered by Qiagen
ACACB Ordered by Qiagen Ordered by Qiagen
ACSL1 Ordered by Qiagen Ordered by Qiagen
ACTB Ordered by Qiagen Ordered by Qiagen


















Supplementary Table 2. Effect of sitagliptin treatment on body composition in overweight men with pre-
diabetes
Placebo (n=15) Sitagliptin (n=14)
Week 0 Week 12 Week 0 Week 12
Total body mass (kg) 93.7 (1.6) 92.7 (1.4) 95.4 (3.1) 94.6 (2.9)
Fat mass (%) 30.1 (1.4) 29.6 (1.6) 29.7 (1.4) 29.4 (1.4)
Lean mass (%) 67.4 (1.3) 67.9 (1.5) 67.7 (1.4) 68.0 (1.4)
Bone mineral density (g/cm3) 1.32 (0.03) 1.33 (0.03) 1.42 (0.04) 1.42 (0.04)
DEXA scanning was used to measure body composition at baseline (Week 0) and after twelve weeks (Week 
12) of placebo (left, n=15) or sitagliptin (right, n=14) treatment. Data are presented as mean (standard er-
ror of the mean). Mixed model analysis was used for statistical comparison. Bonferroni corrected level of 
significance is 0.01 (alpha = 0.05 / 4).
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Supplementary Table 3. Effect of sitagliptin treatment on skin temperature in overweight men with pre-
diabetes
Placebo (n=15) Sitagliptin (n=14)
Week 0 Week 12 Week 0 Week 12
Delta mean skin temperature TN vs COLD (°C) -5.5 (0.3) -5.2 (0.3) -5.6 (0.4) -5.4 (0.3)
Delta proximal skin temperature TN vs COLD (°C) -7.8 (0.6) -7.6 (0.7) -8.0 (0.8) -7.5 (0.5)
Delta distal skin temperature TN vs COLD (°C) -7.2 (0.7) -6.3 (0.6) -6.8 (0.7) -6.0 (0.5)
Delta supraclavicular skin temperature TN vs COLD (°C) -0.1 (0.2) 0.1 (0.1) -0.1 (0.2) -0.3 (0.4)
Data are presented as mean (standard error of the mean). TN; thermoneutral, before cooling. COLD; dur-
ing mild cooling. Mixed model analysis was used for statistical comparison. Bonferroni corrected level of 
significance is 0.01 (alpha = 0.05 / 4).
Supplementary Table 4. Effect of sitagliptin treatment on liver enzymes
Placebo (n=15) Sitagliptin (n=14)
Week 0 Week 12 Week 0 Week 12
Aspartate aminotransferase (µkat/l) 0.52 (0.03) 0.53 (0.03) 0.59 (0.11) 0.47 (0.04)
Alanine aminotransferase (µkat/l) 0.33 (0.03) 0.60 (0.08) ** 0.38 (0.08) 0.48 (0.10)
γ-glutamyltransferase (µkat/l) 0.52 (0.06) 0.57 (0.08) 0.51 (0.08) 0.55 (0.09)
Data are presented as mean (standard error of the mean). Mixed model analysis was used for statistical 
comparison. **p < 0.01 week 0 vs week 12, significant with Bonferroni corrected level of significance 0.01 
(alpha = 0.05 / 3).
Supplementary Table 5. Effect of sitagliptin on lipoprotein composition
Placebo (n=15) Sitagliptin (n=14)
Percentage p-value Percentage p-value
Extremely large VLDL particles
Composition
Total Lipids +12% ns -42% <0.05
Phospholipids +14% ns -47% <0.05
Total cholesterol +15% ns -48% <0.05
Cholesterol esters +17% ns -43% 0.05
Free cholesterol +13% ns -54% <0.05
Triacylglycerol +11% ns -34% <0.05
Very large VLDL particles
Composition
Total Lipids +4% ns -46% <0.05
Phospholipids +6% ns -49% <0.05
Total cholesterol +6% ns -49% <0.05
Cholesterol esters +5% ns -46% <0.05
Free cholesterol +7% ns -53% <0.05
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Supplementary Table 5. Effect of sitagliptin on lipoprotein composition (continued)
Placebo (n=15) Sitagliptin (n=14)
Percentage p-value Percentage p-value
Triacylglycerol +3% ns -45% <0.05
Large VLDL particles
Composition
Total Lipids +14% ns -35% <0.05
Phospholipids +15% ns -35% <0.05
Total cholesterol +16% ns -35% 0.05
Cholesterol esters +15% ns -30% 0.07
Free cholesterol +17% ns -41% <0.05
Triacylglycerol +12% ns -34% <0.05
Medium VLDL particles
Composition
Total Lipids +4% ns -23% <0.05
Phospholipids +5% ns -22% <0.05
Total cholesterol +7% ns -20% 0.08
Cholesterol esters +8% ns -16% ns
Free cholesterol +6% ns -26% <0.05
Triacylglycerol +4% ns -25% <0.05
Small VLDL particles
Composition
Total Lipids +6% ns -9% ns
Phospholipids +6% ns -7% ns
Total cholesterol +7% ns -2% ns
Cholesterol esters +8% ns +1% ns
Free cholesterol +6% ns -7% ns
Triacylglycerol +4% ns -15% ns
Extra small VLDL particles
Composition
Total Lipids +6% ns +4% ns
Phospholipids +6% ns +5% ns
Total cholesterol +7% ns +7% ns
Cholesterol esters +7% ns +6% ns
Free cholesterol +6% ns +7% ns
Triacylglycerol +5% ns -5% ns
IDL particles
Composition
Total Lipids +5% ns +4% ns
Phospholipids +4% ns +5% 0.08
Total cholesterol +5% ns +6% ns
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Supplementary Table 5. Effect of sitagliptin on lipoprotein composition (continued)
Placebo (n=15) Sitagliptin (n=14)
Percentage p-value Percentage p-value
Cholesterol esters +5% ns +3% ns
Free cholesterol +4% ns +9% <0.05
Triacylglycerol +6% ns +2% ns
Large LDL particles
Composition
Total Lipids +4% ns +5% ns
Phospholipids +4% ns +4% 0.08
Total cholesterol +4% ns +5% ns
Cholesterol esters +5% ns +4% ns
Free cholesterol +4% ns +7% 0.06
Triacylglycerol +7% ns +4% ns
Medium LDL particles
Composition
Total Lipids +4% ns +4% ns
Phospholipids +4% ns +2% ns
Total cholesterol +4% ns +5% ns
Cholesterol esters +4% ns +6% ns
Free cholesterol +3% ns +4% ns
Triacylglycerol +6% ns +4% ns
Small LDL particles
Composition
Total Lipids +4% ns +4% ns
Phospholipids +3% ns +1% ns
Total cholesterol +4% ns +6% ns
Cholesterol esters +4% ns +7% ns
Free cholesterol +3% ns +5% 0.09
Triacylglycerol +6% ns -5% ns
Very large HDL particles
Composition
Total Lipids +3% ns +9% ns
Phospholipids +1% ns +14% <0.05
Total cholesterol +4% ns +7% ns
Cholesterol esters +5% ns +6% ns
Free cholesterol +4% ns +9% ns
Triacylglycerol +12% ns -22% 0.09
Large HDL particles
Composition
Total Lipids -10% ns +9% ns
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Supplementary Table 5. Effect of sitagliptin on lipoprotein composition (continued)
Placebo (n=15) Sitagliptin (n=14)
Percentage p-value Percentage p-value
Phospholipids -9% ns +8% ns
Total cholesterol -11% ns +10% ns
Cholesterol esters -10% ns +9% ns
Free cholesterol -10% ns +10% ns
Triacylglycerol -7% ns +15% ns
Medium HDL particles
Composition
Total Lipids -1% ns +2% ns
Phospholipids +1% ns +2% ns
Total cholesterol -1% ns +2% ns
Cholesterol esters -2% ns +1% ns
Free cholesterol -2% ns +7% ns
Triacylglycerol +5% ns +7% ns
Small HDL particles
Composition
Total Lipids -1% ns +1% ns
Phospholipids -1% ns -1% ns
Total cholesterol -1% ns +5% 0.09
Cholesterol esters -1% ns +6% 0.06
Free cholesterol -1% ns -1% ns
Triacylglycerol +3% ns -8% ns
NMR was used to determine lipoprotein composition. Values are presented as percent increase (+) or de-
crease (-) from baseline (week 0). ns: not significant. Mixed model analysis was used for statistical compari-
son. Bonferroni corrected level of significance is 0.0006 (alpha = 0.05 / 84).
Supplementary Table 6. Effect of sitagliptin on energy expenditure and substrate utilisation
Placebo (n=15) Sitagliptin (n=14)
Week 0 Week 12 Week 0 Week 12
REE (kJ/day) 4736 (138) 4858 (146) 4807 (163) 4845 (188)
REE corrected for LBM (kJ/day/kg LBM) 75.3 (1.7) 77.4 (1.3) 77.8 (1.3) 75.7 (2.1)
RQ 0.84 (0.01) 0.84 (0.01) 0.84 (0.01) 0.81 (0.02)
Lipid oxidation (g/min) 0.065 (0.005) 0.067 (0.006) 0.069 (0.018) 0.075 (0.005)
Glucose oxidation (g/min) 0.116 (0.004) 0.119 (0.004) 0.122 (0.004) 0.118 (0.006)
Non-shivering thermogenesis (%) 13 (5) 15 (5) 8 (2) 10 (4)
Data are presented as mean (standard error of the mean). Respiratory quotient (RQ) was calculated as vCO2/
vO2. LBM: lean body mass, NST; non-shivering thermogenesis, REE: resting energy expenditure. Mixed mod-
el analysis was used for statistical comparison. Bonferroni corrected level of significance is 0.008 (alpha = 
0.05 / 6).
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Supplementary Table 7. Effect of sitagliptin on [18F]FDG uptake in brown and white adipose tissue and 
skeletal muscle
Placebo (n=15) Sitagliptin (n=13)
Week 0 Week 12 Week 0 Week 12
Brown adipose tissue depots
Classical BAT depots (cervical + supraclavicular)
Classical BMV (mL) 22.16 (8.75) 13.88 (4.67) 36.82 (13.17) 31.95 (13.09)
Classical BAT activity (SUVmean) 2.25 (0.11) 2.15 (0.08) 2.33 (0.14) 2.27 (0.12)
Classical BAT activity (SUVmax) 3.94 (0.68) 2.60 (0.40) 4.78 (0.72) 4.43 (0.70)
Total body BAT (cervical + supraclavicular + mediastinal + paravertebral)
Total BMV (mL) 32.85 (11.35) 25.11 (5.84) 54.25 (16.13) 47.47 (15.85)
Total BAT activity (SUVmean) 2.25 (0.09) 2.23 (0.08) 2.31 (0.13) 2.31 (0.12)
Total BAT activity (SUVmax) 4.41 (0.66) 3.93 (0.38) 5.05 (0.67) 4.82 (0.62)
White adipose tissue depots (WAT)
Subcutaneous (SUVmean) 0.22 (0.03) 0.26 (0.03) 0.19 (0.03) 0.29 (0.03) *
Paracolic (SUVmean) 0.53 (0.09) 0.59 (0.08) 0.59 (0.08) 0.58 (0.08)
Skeletal muscles
m. Sternocleidomastoideus (SUVmean) 1.60 (0.20) 1.64 (0.15) 1.69 (0.33) 1.46 (0.15)
m. Longius colli (SUVmean) 2.20 (0.23) 2.63 (0.30) 2.33 (0.12) 2.42 (0.26)
m. Trapezius (SUVmean) 0.61 (0.05) 0.70 (0.03) * 0.67 (0.03) 0.67 (0.04)
m. Deltoideus (SUVmean) 0.55 (0.02) 0.61 (0.02) 0.63 (0.03) 0.61 (0.02)
m. Pectoralis major (SUVmean) 0.84 (0.05) 1.00 (0.08) 0.97 (0.18) 0.93 (0.08)
m. Psoas major (SUVmean) 0.96 (0.14) 1.04 (0.17) 0.76 (0.09) 0.91 (0.05)
m. Gluteus maximus (SUVmean) 0.56 (0.04) 0.56 (0.02) 0.56 (0.03) 0.60 (0.03)
Reference tissues
Liver (SUVmean) 2.56 (0.12) 2.74 (0.08) 2.65 (0.10) 2.73 (0.09)
Cerebellum (SUVmean) 7.68 (0.50) 7.97 (0.36) 7.83 (0.39) 7.92 (0.31)
Descending aorta (SUVmean) 1.63 (0.09) 1.84 (0.07) * 1.75 (0.05) 1.78 (0.07)
Values are presented as mean (standard error of the mean). BAT: brown adipose tissue, BMV: BAT metabolic 
volume, SUV: standardised uptake value, WAT: white adipose tissue. Mixed model analysis was used for 
statistical comparison. * 0.002 < p < 0.05 week 0 vs week 12, not significant with Bonferroni corrected level 
of significance0.002 (alpha = 0.05 / 18). In the Sitagliptin group one subject was claustrophobic and did not 

























ESM Figure 1. CONSORT flow diagram of the study 
Assessed for eligibility (n=58) 
Excluded (n=28) 
   Not meeting inclusion criteria (n=28) 
   Declined to participate (n=0) 
   Other reasons (n=0) 
Analysed (n=15) 
 Excluded from analysis (n=0) 
Discontinued intervention (n=0) 
Allocated to placebo (n=15) 
 Received allocated intervention (n=15) 
 Did not receive allocated (n=0) 
Discontinued intervention (n=2; although both 
individuals were replaced with new volunteers) 
 Heartburn (n=1) 





Allocated to sitagliptin (n=15) 
 Received allocated intervention (n=15) 
 Did not receive allocated intervention (n=0) 
Analysed (n=14) 
 Excluded from analysis (n=1) due to 
distribution error of pharmacy (given both 








Supplementary figure 1. CONSORT flow diagram of the study.
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  Placebo          Sitagliptin
Supplementary figure 2. The effect of sitagliptin on serum IDL and LDL particle concentration in 
overweight men with prediabetes. Serum was collected before (open circles / white bars/ Week 0) and 
after (closed circles / black bars/ Week 12) 12 weeks of treatment with placebo (n=15) or sitagliptin (n=14). 
NMR was used to measure serum IDL (A), large- (B), medium- (C) and small-sized (D) LDL particle concen-
tration. In addition, mean LDL particle size (E) was determined. Data are presented as mean ± S.E.M., and as 
individual measurements. Mixed model analysis was used for statistical comparison. Bonferroni corrected 
level of significance is 0.01 (alpha = 0.05 / 5).
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‘Diabesity’, as the frequently occurring combination of obesity and diabetes is often 
referred to, is becoming a major global health care problem. Although obesity has just 
been recently officially recognized as a disease (1), it accounts for a large proportion 
of total health care costs. The incidence of obesity and of its related diseases, includ-
ing type 2 diabetes (T2D) and cardiovascular diseases (CVD) keep rising every year. 
Especially in the South Asian population obesity, T2D and CVD are highly prevalent. To 
gain more insight into the mechanisms that may underlie their high metabolic risk, we 
studied different regulatory aspects of the metabolic profile in South Asians, such as 
the endocannabinoid system and the circulating protein angiopoietin-like 4 (ANGPTL4). 
In this way, we aimed to identify specific therapeutic targets that might be effective in 
this vulnerable population. In the second part of this thesis, pharmacological strategies 
using the β3-adrenergic receptor (β3-AR) agonist mirabegron and the dipeptidyl pep-
tidase-4 (DPP4) inhibitor sitagliptin to combat obesity by activation of brown adipose 
tissue (BAT) were studied in risk populations, including South Asians and overweight, 
prediabetic white Caucasians. From this thesis, novel insights into the pathophysiology 
of metabolic disease in the South Asian population and possible novel therapeutic 
interventions have arisen to combat metabolic disease in South Asian and the general 
population. These insights and their implications for clinical practice, as well as future 
perspectives will be addressed in this final chapter.
1. NOvEL INSIGhTS IN ThE METABOLIC PROfILE IN SOuTh ASIANS
The role of the endocannabinoid system
Over-activity of the endocannabinoid system has been associated with obesity (2,3) and 
T2D (4), and dysregulation of the endocannabinoid system is linked to increased risk 
for CVD (5). The exact role of circulating endocannabinoids in the regulation of energy 
metabolism has not been fully elucidated, however, actions of endocannabinoids are 
thought to contribute to a positive energy balance, e.g. by reducing oxidative pathways 
in skeletal muscle (5,6), and increasing lipogenesis and adipogenesis in white adipose 
tissue (WAT) (5,9,10). In addition, endocannabinoids are thought to decrease thermo-
genesis in BAT (7,8). As underlying mechanism, endocannabinoids inhibit presynaptic 
noradrenalin release and postsynaptic noradrenalin signalling within myocytes and 
adipocytes (see Figure 2 in the Introduction of this thesis). So far, the role of the en-
docannabinoid system in relation to BAT activity has been mainly investigated in pre-
clinical studies. In this thesis we aimed to further explore the relationship between the 
endocannabinoid system and BAT in humans, more specifically in South Asians.
As compared to white Caucasians, South Asians have lower resting energy expenditure 
(REE) and lower [18F]fluorodeoxyglucose (18[F]FDG) uptake by BAT upon cold exposure, 
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which is suggestive of less BAT activity (9). Since South Asians also have a lower rise in 
plasma free fatty acids (FFA) after cold exposure (9), indicative of lower noradrenalin 
signalling within WAT, we hypothesised that South Asians might have a higher endocan-
nabinoid tone. In Chapter 2, we indeed showed that healthy lean South Asians have 
higher circulating endocannabinoid levels compared to white Caucasians. One of the 
remaining questions was; what metabolic organ(s) is/are responsible for the elevated 
endocannabinoid tone in South Asians. In an attempt to answer this question, in Chap-
ter 3 we investigated gene expression of cannabinoid (CB) receptors and enzymes 
involved in endocannabinoid synthesis and degradation in WAT and skeletal muscle of 
middle-aged overweight, prediabetic South Asian and white Caucasian men. We found 
that South Asian men have lower expression of CB receptors and endocannabinoid 
degradation enzymes, specifically in skeletal muscle. Collectively, these data may indi-
cate that low expression of degradation enzymes in skeletal muscle of South Asian men 
might contribute to higher endocannabinoid levels, both locally within skeletal muscles 
and in the blood by spill-over from skeletal muscles. It should be noted that we did not 
measure levels of endocannabinoids within the various tissues. Since endocannabinoids 
have a short half-life and, therefore, are generally believed to act locally at the site of 
synthesis, it would be relevant to assess differences in tissue-specific endocannabinoid 
levels in South Asians and white Caucasians in future studies.
Although most mechanistic studies investigating endocannabinoid signalling and 
BAT activity have been performed in rodents, the potential importance of CB1 receptors 
for BAT activity was recently confirmed in humans. Using [18F]FMPEP-d2, a radiotracer 
that targets and quantifies CB1 receptor density, it was shown that CB1 receptor density 
within the brain and BAT is lower in overweight, compared to lean men. In addition, 
cold exposure increases CB1 receptor density in the brain and BAT in lean men, but not 
in overweight men (10), possibly reflecting the reduced BAT activity and/or suggesting 
an impaired regulation of the endocannabinoid system in overweight individuals (10). 
This underscores the link between the endocannabinoid system and the regulation of 
BAT activity in humans and opens up novel perspectives to regulate BAT activity via 
modulating endocannabinoid signalling in humans. For example, it would be interesting 
to use [18F]FMPEP-d2 in healthy lean South Asians and white Caucasians to assess CB1 
receptor density in the brain and BAT upon cold exposure to reveal potential differences 
between the ethnicities.
The response to metabolic stressors
Previous studies from our department have shown that South Asians respond differently 
to dietary stressors compared to white Caucasians. When administrating a 5-day high 
fat diet, South Asians, in contrast to white Caucasians, rapidly become insulin resistant 
(11). This suggests that South Asians are less able to handle a lipid overload, which 
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could make them more prone for ectopic fat accumulation which in turn promotes the 
development of insulin resistance. Next to a high fat diet, cold exposure also induces a 
metabolic response. For that reason, we decided to further investigate differences in the 
response to short-term cooling between South Asians and white Caucasians.
Cold exposure stimulates intracellular lipolysis of WAT resulting in release of FFA into 
the blood stream, which can be taken up by BAT or skeletal muscle, to fuel metabolic 
processes that include thermogenesis. Both of these processes are driven by the sym-
pathetic nervous system. Intriguingly, we noticed that the FFA release upon short-term 
cooling is lower in South Asians compared to white Caucasians (9). FFA activate peroxi-
some proliferator-activating receptors (PPARs), which are nuclear transcription factors 
involved in the synthesis of e.g. ANGPTL4 that negatively regulates the activity of lipo-
protein lipase (LPL) (12). Therefore, we now also investigated the effect of cold exposure 
on ANGPTL4. In line with the blunted FFA response upon cooling, we also observed a 
lowered ANGPTL4 response in South Asians upon short-term cold exposure (Chapter 
4). Unfortunately, we only measured circulating ANGPTL4 levels and were not able to 
determine tissue-specific levels. To investigate the regulation of LPL by ANGPTL4 within 
the various metabolic tissues after cold exposure, additional studies are clearly needed, 
e.g. using tissue biopsies, to investigate the tissue-specific changes of ANGPTL4 upon 
BAT activation in humans.
Aside from ANGPTL4, there are other members of the ANGPTL family that could be of 
interest in the context of metabolic disease, for example ANGPTL3 and ANGPTL8. Like 
ANGPLT4, ANGPTL3 and ANGPTL8 individually can inhibit LPL, but when they form a 
complex the ability of ANGPTL3 and ANGPTL8 to inhibit LPL is greatly increased (13,14). 
ANGPTL3 is interesting because of its link with CVD (15). ANGPTL8, on the other hand, 
might be particularly of interest in the context of obesity and T2D, since ANGPTL8 is 
highly expressed in WAT (16), controlled by insulin (17) and circulating ANGPTL8 levels 
are elevated in individuals with prediabetes and T2D (18). It would be interesting to 
study if ANGPTL3 and ANGPTL8 levels differ between South Asians and white Cauca-
sians and what the effect of cold exposure is on (local) ANGPTL3 and ANGPTL8 levels.
Inhibiting ANGPTL3, 4 or 8, e.g. with monoclonal antibodies or antisense oligonucle-
otides, can be a novel strategy to target cardiometabolic disease. Indeed, inhibition of 
ANGPTL4 or 8 (in rodents and primates) improve insulin sensitivity and the lipid profile 
(19-21). In addition, inhibition of ANGPL3 reduces plasma TG levels in individuals with 
hypertriglyceridemia (22,23). Whether ANGPTL inhibitors also improve glucose and lipid 
metabolism and lowers the risk on CVD in individuals with obesity and/or T2D still needs 
to be elucidated. The recent observation that genetic ANGPTL3 inactivation associates 
with decreased odds of atherosclerotic cardiovascular disease is at least promising (22). 
Since South Asians have an increased risk on the development of cardiometabolic dis-
ease, these individuals might possibly particularly benefit from treatment with ANGPTL 
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inhibitors. Future studies are warranted to reveal the effects of ANGPTL inhibitors in 
South Asian individuals.
The role of the sympathetic nervous system
To explain the different response to cooling between the two ethnicities, we hypoth-
esize that South Asians have a reduced sympathetic outflow to peripheral organs upon 
cold exposure. A lower sympathetic output to the periphery, at the same extent of cold 
exposure, could explain both the blunted FFA response as consequence of less sympa-
thetic activation of WAT and the blunted ANGPTL4 response as a consequence of less 
FFA release.
When we speculate about the mechanism underlying the reduced sympathetic out-
flow in South Asians, the endocannabinoid system again comes in play. Sympathetic 
signalling in adipocytes is induced by the release from nerve terminals of noradrenaline 
that acts on the β3-AR. However, during cold exposure endocannabinoids are released 
from the adipocyte to inhibit noradrenalin signalling (7,8), probably to prevent excess 
sympathetic stimulation of the tissue. Since we showed that South Asians have higher 
circulating endocannabinoid levels compared to white Caucasians (Chapter 2), and 
assuming they are derived from adipose tissue, this might explain the reduced sym-
pathetic signalling in adipose tissue and thus the blunted FFA and ANGPTL4 response 
upon cooling in South Asians.
Of note, in Chapter 6, we tried to indirectly measure differences in sympathetic 
outflow between South Asians and white Caucasians by assessing parameters of heart 
rate variability before and after short-term cooling. There, we did not find differences 
between South Asians and white Caucasians, which might suggest that there is no dif-
ference in parasympathetic or sympathetic outflow upon cooling between the two 
ethnicities. However, interpretation of heart rate variability is complex, and caution 
must be applied when interpreting these data.
The influence of body fat
In all study cohorts described in this thesis, despite matching based on age and BMI, 
South Asians had a significantly higher body fat percentage and a lower lean mass per-
centage, compared to white Caucasians (Chapter 2-6) (24,25). In addition, South Asians 
in general have more visceral adipose tissue compared to white Caucasians (26,27), 
which is considered a specifically metabolically unhealthy depot and is associated with 
higher incidence of metabolic disease and CVD (28-31). The visceral adipose tissue de-
pot, compared to other fat depots, secretes more plasminogen activator inhibitor-1 (32) 
and interleukin-6 (33), both of which are associated with insulin resistance. In addition, 
visceral adipose tissue has a higher lipolytic rate, resulting in release of more FFA into 
the circulation, which can through the portal vein enter the liver thereby inducing hepa-
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tosteatosis and promoting insulin resistance (34). Of note, because of the difference in 
body composition at similar BMI in certain ethnic sub-groups, ethnic-specific BMI cut-
off points are already implemented in current guidelines for assessing metabolic risk, 
including South Asians (35-37).
It is not unlikely that a difference in body composition in itself could already explain 
some of the metabolic differences between South Asians and white Caucasians that we 
described in this thesis. For example, since thermoneutral REE is largely determined by 
lean mass (38) and South Asians have lower lean mass percentage compared to white 
Caucasians, it is not unexpected that we found lower REE in South Asians. In addition, a 
high amount of body fat is associated with elevated endocannabinoid levels (Chapter 
2). As South Asians have a higher fat percentage than white Caucasians this might 
also, at least in part, explain the fact that we observed higher endocannabinoid levels 
in South Asians. This hypothesis is supported by the fact that differences between the 
two ethnicities were lost when we corrected for lean mass (in case or REE) or fat mass 
(in case of plasma endocannabinoid levels). A follow-up question that arises is; why do 
South Asians, with similar BMI, have a different body fat distribution? Evidence suggests 
that South Asians might have a smaller subcutaneous adipose tissue depot compared 
to white Caucasians (30). Therefore, during the course of obesity development, the 
maximum storage capacity of the subcutaneous depot may be reached earlier in South 
Asians, resulting in the necessity for storage in the visceral depots and finally more 
ectopic fat accumulation.
Taken together, it is likely that a combination of various risk factors in South Asians 
explain the increased predisposition for metabolic disease and the increased risk for 
CVD as compared to white Caucasians. Aside from the already identified risk factors as 
described in the introduction of this thesis (i.e. genetics, diet, exercise, obesity, dyslip-
idemia and endothelial dysfunction), possibly, a combination of increased endocan-
nabinoid tone and reduced sympathetic outflow to peripheral tissues (including WAT 
and BAT) could also contribute to the risk profile of South Asians. The link between body 


































figure 1. hypothetical model explaining the link between body fat, endocannabinoids and sympa-
thetic outfl ow Cold exposure enhances sympathetic outfl ow to peripheral tissues, including white adi-
pose tissue (WAT) and brown adipose tissue (BAT). In WAT, sympathetic stimulation induces intracellular 
lipolysis and the subsequent release of free fatty acids (FFA) into the blood stream. In BAT, sympathetic 
stimulation activates thermogenesis, thereby increasing resting energy expenditure (REE). South Asians 
have higher endocannabinoid tone compared to white Caucasians as possibly explained by a higher body 
fat percentage with comparable BMI. As endocannabinoids inhibit noradrenalin signalling, South Asians 
have a blunted FFA and ANGPTL4 response, less BAT activation and no signifi cant increase in REE compared 
to white Caucasians upon cold exposure. ANGPTL4, angiopoietin-like 4; BAT, brown adipose tissue; ECB, en-
docannabinoids; FFA, free fatty acids; NA, noradrenalin; SNS, sympathetic nervous system; TG, triglyceride; 
WAT, white adipose tissue.
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future perspectives in research into ethnic differences in metabolic disease
When assessing the translational value of our work it is important to note that observa-
tional clinical trials, like the ones described in this thesis, have some important limita-
tions. The use of relatively small cohorts in specific subgroups (e.g. healthy men) limits 
the translational value of the findings. Additional studies in different cohorts of subjects 
(e.g. women) and patients are warranted to investigate the clinical value for the general 
population. In addition, our results might have been confounded by other factors, for 
example differences in body composition, genetic make-up or diet. Therefore, future 
dedicated studies are required in cohorts of South Asians and white Caucasians who are 
matched on body fat percentage instead of BMI. Also, it would be interesting to look into 
genetics, aiming at identifying gene polymorphisms or mutations in risk susceptibility 
genes such as the β3-AR, the melanocortin 4 receptor (MC4R) or fat mass and obesity 
associated genes. Furthermore, it has recently been established that lipid uptake by BAT 
has a diurnal rhythm, with highest uptake of TG-derived FA at the onset of the active 
period (39). In this context, the influence of differences in diet and eating habits (e.g. 
timing of eating) on the risk of metabolic disease in South Asians compared to white 
Caucasians deserves more attention. Since current treatment options for South Asians 
with metabolic disease are limited and unfocussed, more research on the underlying 
mechanisms is needed. Identification of specific risk factors in South Asians may eventu-
ally result in the discovery and development of potential novel treatment strategies to 
combat obesity, T2D and CVD in this especially vulnerable population.
2. NOvEL BAT-TARGETED PhARMACOLOGICAL STRATEGIES TO COMBAT 
METABOLIC DISEASE SPECIfICALLy IN SOuTh ASIANS
Current treatment strategies for obesity and metabolic disease are often focussed on 
reducing food intake and/ or on increasing energy expenditure. For example, obesity 
is treated by dietary modifications, e.g. low or very low calorie diets, behaviour modi-
fications, e.g. psychotherapy, exercise programs, bariatric surgery or a combination. 
However, compliance to low-calorie diets or intensive exercise programs is difficult. As 
a consequence, except for bariatric surgery, current treatment strategies are often not 
effective on the long-term as a high number of individuals regain most of the weight 
that they initially lost (40). Therefore, novel treatment strategies are warranted. Modu-
lation of adipose tissue, specifically activation of BAT, is considered a promising novel 
therapeutic strategy to increase energy expenditure (41). In addition, the observation 
that with the correct stimuli white adipocytes have the ability to transform into a brown 
adipocyte-like phenotype (42) (a process called ‘browning’) has further broadened the 
implications of activating BAT for the treatment of metabolic disease, especially since 
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humans have a substantial amount of WAT. Beneficial metabolic effects of BAT activa-
tion by means of cold exposure have been irrefutably shown in the past years, first in 
animal models (43-46) and later also in humans (47-51). However, cold exposure does 
not seem to be a suitable treatment option in the long-term, again because of potential 
compliance issues. Therefore, more suitable alternative therapeutic modalities, such 
as pharmacological activation of BAT are currently of interest. In this thesis, we have 
investigated two potential pharmacological strategies, i.e. β3-AR agonism and DPP4 
inhibition, which will be further discussed below.
Direct activation of BAT for the treatment of metabolic disease
Targeting the β3-adrenergic receptor
In the past years, β3-AR agonists gained attention as novel therapeutic tools to combat 
metabolic disease. Although β3-AR agonism stimulates BAT activity, prevents fat ac-
cumulation, improves dyslipidemia and insulin sensitivity and attenuates the develop-
ment of atherosclerosis in rodent studies (46), the effects in human studies, so far, were 
less conclusive. Mirabegron, a selective β3-AR agonist, was developed and marketed as 
a drug for hyperactive bladder disease at a daily dose of 50 mg. Interestingly, recently it 
was shown that a single dose of mirabegron (200 mg) increased [18F]FDG uptake by BAT 
as determined by PET/CT imaging, and increased REE in healthy lean men, with similar 
effectiveness as cold exposure (52).
In Chapter 6, we were able to confirm that mirabegron increases REE in healthy lean 
men. In addition, we observed a trend towards lowering of the fat fraction in supracla-
vicular adipose tissue, which is indicative of combustion of intracellular lipids by BAT. 
Interestingly, mirabegron is thought to activate both the wild-type β3-AR as well as a 
less functional form of the β3-AR which contains a missense mutation. This mutated 
form of the β3-AR is highly prevalent in Pima Indians (53). Like South Asians, they are 
particularly vulnerable for metabolic disease, and have a lower REE and an earlier onset 
of T2D than white Caucasians (53). In addition, South Asians with this mutation are, 
compared to individuals from other ethnical backgrounds, particularly at high risk to 
develop T2D (54). Therefore, South Asians with this polymorphism might also benefit 
from treatment with this drug.
Results of trials investigating the long-term effects of mirabegron, for example on lipid 
levels of body weight, are currently lacking. Whether mirabegron is an effective treat-
ment option for the long-term has to be determined in larger randomized-controlled 
trials in populations at risk, for example overweight/obese and/or prediabetic individu-
als and/or South Asians. Recruitment of BAT and browning of WAT should be assessed, 
as well as chronic effects on glucose tolerance and the lipid profile.
In addition, the side effects of chronic mirabegron treatment should not be overlooked. 
With one dose of 200 mg we observed a slight increase in heart rate (+8 bpm). Although 
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rather small, on the long-term, a few beats per minute increase in heart rate can increase 
the risk of cardiovascular morbidity and mortality (55). This is particularly important in 
risk populations, including obese individuals, who might already have elevated risk for 
the development of CVD.
The side effects of mirabegron on the heart are considered to result from actions on 
β1- and β2-adrenergic receptors. Although mirabegron is a relatively specific β3-AR 
agonist, at high dose it activates the β1- and β2-adrenergic receptors. Interestingly, 
[18F]FDG uptake by BAT might also partly be mediated through activation of β1- and/or 
β2- adrenergic receptors (56,57). Pre-treatment with the nonselective β1/β2-adrenergic 
receptor antagonist propranolol before performing a PET/CT scan in cancer patients to 
assess metastasis, largely reduces background [18F]FDG uptake by BAT (56,57). In line, 
data from rodent studies suggest that an increase in blood flow to BAT through stimula-
tion of β2-adrenergic receptors, already is sufficient to increase metabolic activity of 
BAT (58). Possibly, the effect of mirabegron on BAT activity, may partly explained by an 
increased blood flow to BAT through stimulation of β2-adrenergic receptors. If true, this 
may implicate that modulation of (local) endothelial cells, instead of direct activation 
of brown adipocytes, might also be an interesting strategy to treat metabolic disease. 
Clearly, additional studies should be performed to critically assess the beneficial and 
potentially adverse effects of mirabegron before it can be launched onto the market 
as a novel drug for the treatment of metabolic disease. In addition, strictly selective 
β3-adrenergic receptor agonists should be developed, if only to observe whether strict 
β3-AR agonism activates BAT activity.
Targeting the endocannabinoid system
A few years ago, a systemic CB1 receptor blocker (rimonabant) was brought into the 
market for the treatment of obesity. It was very effective in humans to induce substantial 
and long-term maintained weight loss and in addition improved the lipid profile (59-61). 
However, in 2008, the use of this drug was suspended in Europe due to psychiatric side 
effects, probably due to off target effects in the brain. Nevertheless, based on the results 
of our studies described in Chapter 2 and 3, modulation of the endocannabinoid sys-
tem might still be an interesting approach to treat metabolic disease, particularly in the 
South Asian population. Since South Asians have higher circulating endocannabinoid 
levels, a drug that inhibits endocannabinoid signalling might be even more effective in 
South Asians compared to white Caucasians. Possibly, specifically blocking peripheral 
endocannabinoid receptors, which would eliminate central effects in the brain, might 
be a promising option. Peripheral blockers can prevent (circulating) endocannabinoids 
from binding to (and signalling through) their receptors thereby reducing their unwant-
ed metabolic effects on skeletal muscle, WAT and BAT. In addition, strictly peripheral 
CB receptor blockers would circumvent the off target effects of CB receptor agonism 
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in the brain, thereby preventing psychiatric side effects. Of note, since some of the 
weight-reducing effects of rimonabant are induced via the brain, e.g. inhibition of food 
intake, it should be investigated whether strictly peripheral CB1 blockage is as effective 
in reducing body weight in humans as CB1 receptor agonists that also act centrally. In 
this respect it is interesting that we previously showed that a strictly peripheral CB1 
receptor antagonist activates BAT, enhances REE, and still induces substantial weight 
loss in mice (62).
Another, more direct approach could be to target the endocannabinoid levels them-
selves, as high concentrations of local endocannabinoids rather than their receptors are 
the actual cause of the problem. Lowering of circulating endocannabinoid levels might 
be achieved by interfering with the activity of enzymes involved in the synthesis and/
or degradation of endocannabinoids, e.g. using endocannabinoid synthesis inhibitors. 
However, endocannabinoids are pleiotropic hormones, influencing many different 
processes in the human body. For example, endocannabinoids can also be beneficial 
for regulating pain or inflammation. In fact, drugs that increase endocannabinoid tone 
(e.g. inhibitors of the endocannabinoid degradation enzymes FAAH1 and MAGL) are cur-
rently studied for the treatment of anxiety disorders and neurodegenerative diseases 
(63). Therefore, modulating endocannabinoid synthesis and degradation should prob-
ably be tissue-specific and may turn out to be a difficult approach to pursue.
Targeting ANGPTL4
In Chapter 4, we showed that serum ANGPTL4 levels increase in response to short 
term mild cooling. ANGPTL4 stimulates intracellular lipolysis (12,64) and inhibits LPL-
mediated extracellular lipolysis (65) in WAT. Therefore, with respect to the treatment of 
obesity, it might be interesting to develop a WAT-specific ANGPTL4 stimulator, possibly 
based on the C-terminus of the ANGPTL4 molecule which can directly stimulate intracel-
lular lipolysis while preventing LPL-dependent influx of FA, resulting in release of FFA 
into the circulation (64). To prevent accumulation of FFA in the blood (which is toxic 
in high concentrations and can leads to steatohepatosis), this drug should preferably 
be combined with a strategy that stimulates combustion of FFA, for example exercise, 
a direct activator of BAT or a compound that stimulates browning of WAT. Because we 
showed that South Asians had a lower ANGPTL4 response upon cooling as compared 
to white Caucasians, a drug that increases ANGPTL4 levels, specifically in WAT, might 
particularly effective in this population.
Indirect activation of BAT for the treatment of metabolic disease
Targeting the glucagon-like-peptide-1 receptor
An indirect pathway that may result in BAT activation is the glucagon-like peptide-1 
(GLP-1) pathway. This can be achieved by either stimulation of the receptors with GLP-
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1 receptor agonists, or by inhibition of degradation of endogenous GLP-1 with DPP4 
inhibitors. Both GLP-1 receptor agonists and DPP4 inhibitors are already known for their 
beneficial effects on glucose metabolism and are, therefore, currently used in the clinic 
for the treatment on T2D. Interestingly, these drugs also improve lipid metabolism and 
enhance REE (66-70).
Both GLP-1 receptor agonists and DPP4 inhibitors increase GLP-1 receptor signalling 
e.g. in the pancreas, resulting in increased insulin and reduced glucagon secretion, 
thereby improving glucose metabolism. However, the mechanism by which these drugs 
affect lipid metabolism in humans has not yet been clarified. Possibly, part of the ef-
fect is mediated through activation of BAT, which has at least been confirmed in mice 
(71-77). Specifically, activation of central GLP-1 receptors in the hypothalamus results 
in increased sympathetic outflow towards BAT, mimicking the effect of cold exposure 
(71). In addition, in Chapter 7, we showed that the DDP4 inhibitor sitagliptin improves 
glucose and lipid metabolism in overweight prediabetic men, concomitant with brown-
ing of WAT and/or increased energy metabolism in skeletal muscle. However, an effect 
of sitagliptin on the activity of classical BAT, as measured with [18F]FDG PET/CT scanning, 
was not observed, possibly due to insulin resistance of the tissue and a consequently 
low uptake of the glucose tracer. Future studies should probably use alternative PET/CT 
tracers (e.g. lipid-based tracers or measures of oxidative capacity), to better estimate BAT 
activity, which would be especially relevant in insulin resistant individuals.
Aside from the beneficial effects on glucose and lipid metabolism, GLP-1 receptor 
agonists also reduce food intake resulting in weight-loss, an effect that is however 
not observed for DPP4 inhibitors (Chapter 7). In addition, DDP4 inhibitors might have 
more off target effects because the DPP4 enzyme is involved in the breakdown of many 
proline (or alanine) containing peptides, including also growth factors and chemokines. 
Therefore, in my opinion, GLP-1 receptor agonists are more promising than DPP4 inhibi-
tors as a strategy to improve cardiometabolic health.
South Asians have an increased GLP-1 response upon a glucose load (78,79), which 
is indicative for GLP-1 resistance. Interestingly, GLP-1 analogues lower HbA1c more ef-
fectively in South Asians compared to white Caucasians (80). GLP-1 receptor agonists 
are currently only prescribed and reimbursed by health care insurance companies for 
patients with T2D and a BMI≥ 35 kg/m2. This is peculiar since South Asians, already at a 
lower BMI, have an increased risk on development of T2D and (cardio)metabolic disease 
(35,81). Dedicated studies are needed to investigate if GLP-1 receptor agonism already 
improves glucose and lipid metabolism in South Asians with a BMI lower than 35 kg/
m2. If so, as for the assessment of diabetes risk (35), there should probably also be an 
ethnic-specific threshold for the administration of GLP-1 receptor agonists, in which 
South Asians should receive the drug already at a lower BMI than white Caucasians. Of 
note, based on preliminary data from a recently completed study in young healthy lean 
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South Asians and white Caucasians, 12 weeks of exenatide (Bydureon 2 mg s.c. once a 
week) indeed decreased serum triglycerides, total cholesterol, low-density lipoprotein 
and glucose levels and lowered body weight in both ethnicities (Janssen & Nahon, 
unpublished).
Targeting the melanocortin-4 receptor
A second promising target might be the melanocortin pathway. The MC4R in the hy-
pothalamus is involved in controlling energy intake and expenditure, and mutations in 
this receptor are associated with morbid obesity (82). Moreover, MC4R deficiency is the 
most common monogenetic form of childhood obesity (83). Central melanocortins are 
thought to dampen sympathetic nervous system outflow to WAT and BAT, thereby regu-
lating the function of these tissues (84); Indeed, in mice, MC4R antagonism increases 
food intake and decreases REE, which collectively contribute to increased body weight 
(85). On the contrary, treatment with an MC4R agonist decreases body weight and 
improves insulin sensitivity and cardiovascular function in a diet-induced obese nonhu-
man primate model (86). In addition, a recent study convincingly showed that chronic 
treatment with the MC4R agonist setmelanotide induced long-term induced weight loss 
in individuals with leptin receptor or pro-opiomelanocortin (POMC) deficiencies, both of 
which are upstream of the MC4R. Whether MC4R agonists also increases BAT activity in 
humans need to be elucidated.
To conclude, it is undisputable that the development of novel pharmacological 
approaches to treat obesity and related diseases is warranted, and that targeting BAT 
activity can be beneficial in this respect. However, it must be noted that promoting a 
healthy lifestyle should always be the most desirable treatment option, and should be 
the cornerstone for the prevention and treatment of metabolic disease.
3. METhODOLOGICAL ASPECTS Of CLINICAL TRIALS TARGETING BAT
Research into human BAT has some well-recognized limitations. Not only visualisation of 
BAT is difficult, also other direct or indirect read-outs of BAT activity are far from straight-
forward. Whereas in animal models BAT tissue can be easily collected and assessed 
for histology and expression of genes and proteins, taking BAT biopsies in humans is 
ethically and practically more challenging. The relatively low amounts of human BAT in 
combination with its localisation, hided deeper within the body and close to major ves-
sels and nerves, makes it difficult to safely take tissues biopsies, especially in otherwise 
healthy lean men without indication for a surgical intervention. In addition, some indi-
rect read-outs of BAT, such as increase in lipid oxidation may not be sufficiently specific 
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for BAT activity. In fact, based on the current available technologies and literature there 
is no ‘ideal’ read-out yet.
visualisation of BAT by [18f]fDG PET/CT as a ‘gold’ standard
The presence of active BAT in human adults was initially discovered with [18F]FDG PET/
CT scanning (87-89). Since no better alternatives are currently available, this technique 
is currently still considered the ‘gold’ standard for assessing BAT volume and activity 
in human research. However, this method has some important limitations. Firstly, this 
method makes use of a radioactive tracer, which limits the frequency of scans that can 
be made in one volunteer (typically twice a year). Secondly, the use of a glucose tracer 
(i.e. fluorodeoxyglucose; FDG) is an important limitation as active BAT rather uses FA 
as the main source to fuel thermogenesis (90), while glucose probably is mainly taken 
up for de novo lipogenesis (91). Moreover, some interventions that activate BAT spe-
cifically affect the FA uptake by BAT, while glucose uptake is not necessarily changed 
(92). This implicates that with a glucose tracer the effects on BAT might, in some cases, 
be underestimated or missed. In addition, insulin resistance of BAT limits the uptake 
of glucose. Therefore, it is feasible to assume that in some populations, for example in 
prediabetic, overweight or ageing individuals, [18F]FDG uptake by BAT reflects insulin 
resistance of BAT rather than oxidative metabolism of BAT. Of note, the presence of 
insulin resistance in overweight prediabetic men could also have been a reason why 
we did not observe an effect of sitagliptin on BAT activity, as described in Chapter 7. 
Thirdly, environmental factors including room temperature influence [18F]FDG uptake, 
which is the reason why cooling to shivering is required to visualize and quantify BAT 
with this technique. Finally, until recently there were no consensus guidelines about the 
standardized uptake values (SUV) and Hounsfield units (HU) thresholds (93,94), which 
limited the comparison between different studies. Recently, this last issue has recently 
been solved with publication of the first general recommendation guidelines (BARCIST 
1.0) (95). An important aspect of this guideline is the recommendation to use a personal-
ized SUV threshold, which takes into account the lean mass as well (SUVindividualized 
= 1.2/(lean body mass/body mass)] (95). We used this guideline for the analyses of BAT 
activity in Chapter 7, and, hopefully, this guideline lead to more uniform analysis of BAT 
on [18F]FDG PET/CT in future studies allowing between-institute comparisons.
Alternative methods for BAT visualisation
As outline above, probably the most important disadvantage of the use of a glucose 
tracer to trace BAT activity in metabolic research is the problem of insulin resistance that 
develops during weight gain and ageing. As the ultimate goal of BAT-targeted research 
is to develop novel treatments for obesity and T2D, these drugs eventually have to be 
tested in the target population. Since obese individuals and T2D patients are often insu-
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lin resistant, leading to decreased translocation of glucose transporter 4 (GLUT4) to the 
cell membrane, the uptake of the glucose tracer by BAT will be diminished. This does not 
necessarily mean that they have less active BAT. In fact, a hallmark study demonstrated 
that ageing and T2D status decrease the uptake of [18F]FDG by BAT, while the FA uptake 
and oxidative capacity of BAT are not reduced (96,97). Mainly for reason of insulin resis-
tance, the search for alternative tracers are techniques is warranted.
For reasons described in the previous paragraph, 14(R,S)-[18F]fluoro-6-thia-heptadec-
anoic acid ([18F]FTHA; i.e. a fatty acid tracer) or [11C]acetate (i.e. a measure of oxidative 
metabolism) can be used as alternative tracers to visualize BAT activity. However, a main 
disadvantage of [18F]FTHA is the large background signal, which is due to binding of 
the radiotracer to albumin and subsequent high uptake of the tracer by other tissues, 
mainly the liver. In addition, our previous studies in mice showed that BAT takes up 
preferably TG-derived FA instead of FFA (98), and we have no reason to assume this 
would not be the case in humans. In addition, at least in mice, under conditions of 
GPR120 agonism, TG-derived FA uptake by BAT is approx. 10-fold higher than glucose 
uptake (71). Therefore, a radiolabeled FA molecule that is built into TG which is packed 
inside lipoprotein-like particles (99) may be a more elegant approach, thereby directly 
visualizing TG-derived FA uptake by BAT while strongly reducing non-specific uptake 
by the liver. However, under highly insulin-resistant conditions TG-derived FA uptake is 
probably also diminished, which might also restrict the application of this tracer in very 
obese/insulin-resistant volunteers. Future studies should further explore the feasibility 
of such a tracer, first in rodents and later in human trials.
Alternatively, 123I-meta-iodobenzylguanidine ([123I]MIBG) might be an interesting 
tracer. [123I]MIBG is a radiolabeled analogue of guanethidine that enters the cell via the 
noradrenalin transporter and, therefore, visualizes the presynaptic reuptake and storage 
of noradrenalin within the sympathetic neuron, which occurs during sympathetic BAT 
activation. Since increased noradrenalin release from the sympathetic nerve results in 
more stimulation of brown adipocytes, a higher 123I-MIBG uptake would imply increased 
BAT activity. However, such a tracer may not be relevant in case brown adipocytes are 
post-synaptically modulated.
Aside from PET/CT, which has the disadvantageous of exposure to radiation, other im-
aging modalities are currently being investigated. One of these non-invasive techniques 
is magnetic resonance imaging (MRI), which uses water-fat separation to estimate the fat 
fraction (FF) of a tissue (100-103). As BAT combusts intracellular lipids (46), intracellular 
FF of BAT is expected to decrease upon activation. Indeed, in mice intracellular lipolysis 
of TG is directly related to BAT thermogenesis (43), and BAT activation generally strongly 
reduced the intracellular lipid content (46). Therefore, quantification of the FF of BAT is 
likely an appropriate read-out for its activity. An advantage of MRI is that it involves no 
radioactive burden as with PET-CT and can thus be repeated multiple times in the same 
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individual without harm. This can be particularly useful when monitoring changes in 
BAT activity during the day (i.e. pre-clinical data point towards differences in BAT activ-
ity during the day, with the highest activity at the start of the wakeful period (39)) or 
during a period of pharmacological intervention. In addition, assessing the intracellular 
FF of BAT probably gives a more direct estimation of its activity than [18F]FDG uptake 
since intracellular lipid stores within BAT are considered to be the main source to fuel 
thermogenesis (90,104). However, a limitation of this technique is that during BAT acti-
vation, intracellular lipid stores are concomitantly replenished by uptake of TG-derived 
FA from the blood (98) and/or the uptake of glucose which can be used for de novo 
lipogenesis. Therefore, during mild BAT activation, when intracellular FA consumption 
equals FA influx and production, the net FF will not be changed and BAT activity may be 
underestimated or even missed.
Additionally, MRI can be used to monitor blood flow. Since blood flow to BAT is thought 
to be increased upon stimulation, monitoring changes in blood flow might give addi-
tional information about the activation state of the tissue. Interestingly, next to changes 
in FF and blood flow, recent evidence suggests changes in glutathione content of BAT 
upon activation and browning of WAT (105,106). Glutathione acts as an anti-oxidant to 
protect cells against oxidative stress/damage. Upon activation of BAT, reactive oxygen 
species (ROS) are generated as a by-product of high metabolic activity in mitochondria 
(107). It has been suggested that ROS play a critical role in regulating thermogenesis 
and uncoupling protein 1 activity in BAT (108) and that BAT activation by means of cold 
exposure reduces intracellular glutathione content (105,109). Therefore, visualisation 
of glutathione content of BAT could potentially be a novel approach to monitor BAT 
activation with MRI. However, the relation between glutathione concentration and BAT 
activity as well as the potential of MRI in clinical research should be further investigated 
before this technique can replace or be added to [18F]FDG PET/CT scanning.
Another novel non-invasive method to visualize BAT might be infrared thermography 
(IRT) (110). Supraclavicular skin temperature, as monitored with IRT, increases upon cold 
exposure in healthy lean men (111) and predicts [18F]FDG uptake by PET/CT (112). In 
chapter 6, we showed that mirabegron treatment of healthy lean also increases the 
supraclavicular skin temperature, as measured with iButtons, indicative of BAT activa-
tion. Because of its non-invasive properties, IRT is also very suitable for BAT research in 
children. Since children, especially neonates, rely on BAT for their thermogenesis and 
have more BAT compared to adults, studies in children will result in novel insights on 
the physiology of BAT. However, although IRT might be feasible in lean participants 
(as described in (113) and (114)), this technique might be less reliable in overweight or 
obese individuals with large subcutaneous WAT depots covering the BAT depots due to 
insulation. As a note of caution, vasodilation related to increased blood flow to BAT upon 
activation of this tissue might interfere with interpretation of IRT.
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Finally, microdialysis has recently been proposed as a novel technique to quantify sub-
strate utilisation by BAT (115). By inserting a catheter into the tissue, interstitial fl uid can 
be collected for analysis. This is particularly interesting because in this way it is possible 
to measure changes in locally produced hormones and metabolites upon activation 
of BAT. However, for secure placing of the needle PET/CT imaging modalities are still 
needed, which has a radiation burden and limits the frequency of the measurements. In 
addition, this technique is diffi  cult to perform and is invasive, which makes large-scale 
application in healthy human questionable.
A summary of the above described approaches to analyse BAT function is given in 
figure 2.
figure 2. Direct and indirect read-outs of BAT activity. This fi gure summarises the currently available 
techniques to assess BAT activity directly and indirectly. CO2, carbon dioxide; FA, fatty acids; [18F]FDG, [18F]
fl uorodeoxyglucose; [18F]FTHA, [18F]fl uoro-6-thia-heptadecanoic acid; HRV, heart rate variability; [123I]MIBG, 
[123I]meta-iodobenzylguanidine; MRI, magnetic imaging resonance; O2, oxygen; ROS, reactive oxygen spe-
cies; TG, triglycerides.
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4. CONCLuDING REMARkS AND fuTuRE DIRECTIONS
The emergence of metabolic diseases are rapidly increasing worldwide, leading to high 
morbidity and mortality and increased health care costs. By identifying risk factors and 
underlying pathophysiological processes for these diseases novel treatment modalities 
might be discovered to combat the ‘diabesity’ epidemic. Here, we specifically focussed 
on the South Asian population as they are especially recognized for their increased 
susceptibility to develop (cardio)metabolic disease. Apart from ‘classical’ risk factors, 
‘non-classical’ risk factors including differences in energy metabolism, endocannabinoid 
tone and autonomic dysfunction are probably involved. However, additional research is 
needed to validate these risk factors and assess the translational value for the general 
population. One of the biggest challenges in this respect is to disentangle the ethnic 
aspect from the other factors (such as body composition or dietary habits), which are 
often linked to each other.
Current treatment options for metabolic disease are generalized and mainly focus on 
food intake while increasing energy expenditure might be a more effective approach 
on the long-term. During the last few years, it has been recognized that activation and/
or recruitment of BAT could be a valuable tool to combust lipids and glucose, thereby 
improving lipid and glucose metabolism and increasing energy expenditure. Moreover, 
in some patient groups, e.g. patients with T2D, BAT activation by cold exposure has 
already been shown to reduce fat mass and improve glucose tolerance and insulin sen-
sitivity. Although these results are promising, unfortunately cold exposure is probably 
not a suitable therapeutic strategy for humans, especially in warm climates. Therefore, 
identifying pharmacological targets to activate BAT is of high importance.
Based on currently available data the most promising BAT-activating drug to date 
seems to be the β3-AR agonist mirabegron, which increases serum FFA, REE, lipid oxida-
tion and supraclavicular skin temperature, and tends to decrease the FF of BAT in healthy 
lean South Asians and white Caucasians. Whether this drug improves the metabolic 
phenotype in obese or prediabetic individuals and/or prevents the progression into T2D 
or CVD needs to be shown in the coming years. Furthermore, we recently showed that 
the GLP-1 receptor agonist exenatide activates BAT in healthy lean South Asians and 
white Caucasian men (Janssen & Nahon, unpublished). Especially since GLP-1 receptor 
agonism also reduces food intake, this might be a very interesting drug to further in-
vestigate. However, next to pharmacological approaches, lifestyle modifications should 
always be the cornerstone for the treatment for obesity and related conditions.
In conclusion, with the discovery of energy-combusting BAT in human adults in 2009, 
research into the pathophysiology and treatment of metabolic disease was put in a 
novel perspective. The studies described in this thesis underscore the potential of phar-
macological BAT activation as a strategy to combat metabolic disease, which might be 
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particularly beneficial for South Asians, because of their increased risk for the develop-
ment of metabolic disease. The coming years will reveal the potential therapeutic power 
of BAT to combat the ‘diabesity’-epidemic that is threatening the world.
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‘Diabesity’, as the frequently occurring combination of obesity and diabetes is often 
referred to, is becoming a major global health care problem. The incidence of the 
obesity and of its related diseases, including type 2 diabetes (T2D) and cardiovascular 
diseases keep rising every year. South Asians are specifically at risk for the development 
of (cardio)metabolic disease, due to a combination of several known and unknown risk 
factors. Since effective long-term treatment strategies are currently lacking, the search 
for additional risk factors and development of targeted treatment strategies to combat 
these diseases is warranted. An attractive novel approach to combat metabolic disease 
seems to be activation of energy-combusting brown adipose tissue (BAT), which can re-
sult in increased energy expenditure, an improvement in glucose and lipid metabolism 
and possibly a reduction in the development of atherosclerosis, the main underlying 
cause of cardiovascular diseases. The physiological activator of BAT is cold exposure. 
However, modulation of BAT activation by means of cold exposure is far from optimal 
in humans. In this thesis, we aimed to address two key objectives: 1) unravelling the 
underlying mechanisms that could explain the increased predisposition for metabolic 
disease in the South Asian population, and 2) identifying novel treatment strategies 
that activate BAT and increase energy expenditure in risk populations, including South 
Asians and individuals with overweight and prediabetes. Chapter 1 serves as a general 
introduction into the pathophysiology of obesity and related conditions such as T2D 
and cardiovascular diseases. In addition, the metabolic phenotype and some known 
risk factors for the development of metabolic disease in the South Asian population are 
described. Finally, the physiology of BAT is explained as well as its therapeutic potential 
as a target drug to combat metabolic disease.
In the first part of this thesis, we investigated different factors that may contribute to 
the increased predisposition for metabolic disease in South Asians compared to white 
Caucasians. South Asians were previously shown to have a lower resting energy ex-
penditure (REE) as related to less energy-combusting BAT. Since over-activation of the 
endocannabinoid system is associated with obesity and low BAT activity, we hypoth-
esized that South Asians have a higher endocannabinoid tone. Therefore, in Chapter 
2, we aimed to investigate differences in circulating endocannabinoid levels between 
South Asians and white Caucasians. To this end, ten healthy lean white Caucasian and 
ten South Asian men, aged 18-28 years, were included. REE was assessed and plasma 
was collected for analysis of endocannabinoids and lipids. We found that, South Asians 
had higher plasma levels of 2-arachidonoylglycerol (2-AG), N-arachidonylethanolamine 
(AEA) and arachidonic acid (AA) compared with white Caucasians. After pooling of both 
ethnicities, plasma 2-AG, but not AEA, positively correlated with plasma triglycerides 
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and body fat percentage. Interestingly, AA negatively correlated with REE and positively 
with body fat percentage. Based on these data, we concluded that healthy lean South 
Asian men, compared to white Caucasian men, have a higher endocannabinoid tone. 
Given that endocannabinoids attenuate noradrenergic signalling, these data suggest 
that endocannabinoids may, at least in part, underlie the disadvantageous metabolic 
phenotype of South Asians later in life.
Since endocannabinoid tone is a reflection of local endocannabinoid regulation in 
metabolic organs, we next focussed on potential differences in local endocannabinoid 
signalling between ethnicities. Therefore, in Chapter 3, we aimed to investigate whether, 
next to circulating endocannabinoid levels, also gene expression of endocannabinoid 
(CB) receptors and enzymes involved in endocannabinoid synthesis and degradation 
in white adipose tissue (WAT) and skeletal muscle differed between middle-aged over-
weight, prediabetic men of South Asian and white Caucasian descent. We demonstrated 
that, compared to overweight prediabetic white Caucasians, overweight prediabetic 
South Asians had higher levels of the plasma endocannabinoids 2-linoleoyl glycerol and 
N-linoleoylethanolamine. Interestingly, in skeletal muscle of South Asians, expression 
of the cannabinoid receptors CB1 and CB2 was 10-fold lower and that of the endocan-
nabinoid degradation enzyme FAAH2 was 5-fold lower compared to white Caucasians. 
Expression of genes involved in the endocannabinoid system in WAT was not different 
between the two ethnicities. After pooling of both ethnicities, plasma 2-AG positively 
correlated with plasma triglycerides and lipid oxidation. These data support our findings 
in chapter 2 that South Asians have a higher endocannabinoid tone compared to white 
Caucasians, which might possibly due to a endocannabinoid deregulation in skeletal 
muscle. Further studies are required to show if therapeutic interventions that target the 
endocannabinoid system will improve the metabolic profile of these individuals, and 
whether South Asians respond differently than white Caucasians.
Next, we switched our focus from the endocannabinoid system to angiopoietin-like 4 
(ANGPTL4). Previously, we showed that the free fatty acid (FFA) release upon short-term 
cooling is lower in South Asians compared to white Caucasians. FFA activate peroxi-
some proliferator-activating receptors (PPARs), which are nuclear transcription factors 
involved in the synthesis of e.g. ANGPTL4 that negatively regulates the activity of 
lipoprotein lipase (LPL) and increases intracellular lipolysis. Therefore, in Chapter 4 now 
also investigated the effect of short-term cooling on serum ANGPTL4 levels in healthy 
lean men of white Caucasian and South Asian descent. We showed that short-term 
cooling increased ANGPTL4 levels. The relative increase in ANGPTL4 levels upon cooling 
was higher in white Caucasians compared to South Asians. In addition, thermoneutral 




more, ANGPTL4 negatively correlated with REE. In conclusion, our data demonstrate 
that short-term mild cooling increases circulating ANGPTL4 levels in healthy lean men, 
with a higher response in white Caucasian compared to South Asian men. As underlying 
mechanism we speculate that cold exposure causes intracellular lipolysis in white adi-
pocytes to liberate FA that, via activation of peroxisome proliferator-activated receptor 
γ (PPARγ), increase ANGPTL4 synthesis to limit uptake of triglyceride-derived FA by this 
tissue. Possibly, this sequence of events is blunted in South Asians because of reduced 
sympathetic signalling, which would an interesting topic for future research.
During mild cold exposure, non-shivering thermogenesis increases to maintain core 
body temperature by increasing utilization of substrates, especially FA, ultimately affect-
ing lipid-associated metabolites. In Chapter 5, we aimed to investigate whether mild 
cooling induces changes in other metabolites and whether the metabolite response 
differs between healthy lean white Caucasian and South Asian men. First, we showed 
that the effect of mild cooling on 190 measured metabolites was not different between 
both ethnicities. Therefore, to assess the effect of cooling on metabolites, we pooled the 
data. After Bonferroni correction, mild cooling significantly changed 44 of 190 metabolic 
parameters. Specifically, cooling increased 19 phosphatidylcholine (PC) species, only 
those containing very long chain FAs, and increased the total class of PC containing 
mono-unsaturated FAs. Furthermore, cooling increased 10 sphingomyelin species as 
well as the amino acids glutamine, glycine and histidine, and decreased short-chain (C3 
and C4) acylcarnitines. In conclusion, mild cooling elicits substantial effects on serum 
metabolites in healthy males, irrespective of white Caucasian or South Asian ethnicity. 
Future studies should focus on the physiological relevance of this change in metabo-
lome.
In the second part of this thesis, we focussed on two promising pharmacological strat-
egies to activate BAT and investigated these strategies in risk populations (e.g. South 
Asians and individuals with overweight and prediabetes). In Chapter 6, we aimed to 
study the effect of the β3-adrenergic receptor agonist mirabegron on REE and BAT in 
healthy lean South Asian and white Caucasian men. To this end, we performed a ran-
domized, double-blinded, cross-over study consisting of three different interventions; 
short-term individualized cooling protocol, placebo (once p.o.) and mirabegron (200 mg 
once p.o.) treatment. We showed that both mirabegron and cold exposure increased FFA, 
REE, lipid oxidation and supraclavicular skin temperature, and tended to decrease BAT 
FF, which might be suggestive for activated BAT. We did not observe clear differences 
in metabolic response between the two ethnicities. Based on these data we concluded 
that mirabegron increases REE and activates BAT in both ethnicities similarly. However, 
additional studies should be aimed at unravelling the relative effect of both treatments 
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on true BAT activity, for instance by using alternative read-outs for BAT activity such as 
glucose or lipid uptake, or oxidative capacity.
Next to a β3-adrenergic receptor agonist, dipeptidyl peptidase-4 (DPP4) inhibitors 
might also be a promising class of drugs to investigate in the context of BAT activation. 
In Chapter 7, we assessed the effect of the DPP4 inhibitor sitagliptin on energy me-
tabolism and BAT in overweight prediabetic men. Currently, there is only little attention 
for identification of therapies that improve glucose and lipid metabolism in these indi-
viduals. This may, however, be highly relevant since most of these individuals eventually 
proceed to overt diabetes. Therefore, the aim of this study was to evaluate the effect of 
sitagliptin on glucose tolerance, plasma lipids, energy expenditure and metabolism of 
BAT, WAT and skeletal muscle. To this end, thirty overweight, prediabetic white Cauca-
sian men received sitagliptin (100 mg/day) (n=15) or placebo (n=15) for twelve weeks. 
We demonstrated that sitagliptin, but not placebo, lowered glucose excursion during 
OGTT, accompanied by an improved insulinogenic index and oral disposition index. In 
addition, sitagliptin lowered serum triglycerides, and very large-, large- and medium-
sized very-low-density lipoproteins. In skeletal muscle, sitagliptin increased mRNA 
expression of PGC1β, a main controller of mitochondrial oxidative energy metabolism. 
Furthermore, sitagliptin increased [18F]FDG uptake in subcutaneous WAT but not in BAT 
or muscle. From this study, we concluded that twelve weeks of sitagliptin in overweight, 
prediabetic white Caucasian men improves glucose tolerance and lipid metabolism, as 
related to increased [18F]FDG uptake by subcutaneous WAT rather than BAT and upregu-
lation of the mitochondrial gene PGC1β in skeletal muscle.
Finally, in Chapter 8 we evaluated the results of the studies described in this thesis and 
discussed their implications for future research. In this final chapter, we highlighted 
some novel factors that might, at least in part, contribute to the increased risk of the 
South Asian population for developing metabolic disease, and speculated about the 
underlying mechanisms. Furthermore, we discussed novel treatment strategies that 
might activate BAT, thereby modulating REE, lipid and glucose metabolism and thus 
potentially serve as a novel treatment strategy to combat metabolic disease. In addition, 
challenges in current research into BAT will be discussed as well as novel techniques 
to assess BAT activity in human. The clinical value of BAT activation in common clini-
cal practice and its implications for the treatment for obesity, T2D and cardiovascular 





Ernstig overgewicht, ofwel obesitas, is momenteel wereldwijd één van de grootste 
gezondheidsproblemen. Obesitas ontstaat door overmatige opslag van suiker en vet 
als ‘triglyceriden’ in vetweefsel. Men spreekt van obesitas als de body mass index (BMI), 
berekend als het gewicht gedeeld door de lengte in het kwadraat, hoger is dan 30 kg/
m2. Sinds 1980 is het aantal mensen met obesitas verdubbeld tot maar liefst 12% van 
de wereldbevolking in 2015 (604 miljoen mensen). Naar verwachting zal dit aantal de 
komende jaren blijven stijgen. Obesitas gaat vaak gepaard met een situatie waarin 
organen niet meer gevoelig zijn voor het hormoon insuline (zogenaamde ‘insulinere-
sistentie’), wat leidt tot suikerziekte (‘diabetes’), een conditie waarin het bloedsuiker 
verhoogd is. Insulineresistentie leidt ook tot ophoping van triglyceriden en cholesterol 
in het bloed (zogenaamde ‘dyslipidemie’), waardoor obesitas vaak samengaat met 
slagaderverkalking (‘atherosclerose’), de belangrijkste oorzaak van hart- en vaatziekten.
De huidige behandelstrategieën voor obesitas zoals calorische beperking en bewegen 
zijn vaak niet effectief op de lange termijn met uitzondering van sommige operaties die 
tot doel hebben om gewicht te verminderen (‘bariatrische chirurgie’), zoals maagver-
kleining of een zogenaamde ‘bypass’. Daarnaast verschilt de incidentie van obesitas per 
bevolkingsgroep. Zo heeft de Hindoestaanse populatie een verhoogd risico op obesitas 
en gerelateerde ziekten waaronder diabetes en hart- en vaatziekten ten opzichte van 
West-Europeanen. Waarom Hindoestanen hier een verhoogd risico op hebben is niet 
volledig bekend. Door de ontstaansmechanismen van obesitas in de diverse etnische 
groepen beter te begrijpen kunnen er specifieke behandelstrategieën ontwikkeld wor-
den in de strijd tegen obesitas en gerelateerde ziekten.
In het lichaam zijn twee typen vetcellen te onderscheiden: witte en bruine vetcellen. 
Witte vetcellen zorgen voor de opslag van triglyceriden terwijl bruine vetcellen juist tri-
glyceriden kunnen verbranden voor de productie van warmte (‘thermogenese’). Lange 
tijd werd gedacht dat alleen pasgeborenen over bruin vet beschikken voor het in stand 
houden van de lichaamstemperatuur. Echter, in 2009 werd ontdekt dat volwassen ook 
nog bruin vet hebben (ongeveer 200-300 gram), en dat dit door blootstelling aan kou 
wordt geactiveerd wat resulteert in een toename in het energieverbruik. Daarom wordt 
bruin vet momenteel beschouwd als een interessant aangrijpingspunt om obesitas en 
gerelateerde ziekten te behandelen. Bij blootstelling aan kou wordt in de hersenen een 
signaal opgewekt dat via het stimuleren van zenuwen bruine vetcellen aanzet tot warm-
teproductie. Belangrijk hierbij is dat door zenuwuiteinden het hormoon noradrenaline 
wordt uitgescheiden dat vervolgens bindt aan zogenaamde β3-adrenerge receptoren 
op de bruine vetcellen. Alhoewel bruin vet dus geactiveerd kan worden door kou, is 
blootstelling aan kou geen prettige behandelstrategie om de hoeveelheid lichaamsvet 
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in mensen te doen verminderen. Wereldwijd zijn onderzoekers dan ook naarstig op zoek 
naar andere manieren om bruin vet te activeren, bijvoorbeeld door geneesmiddelen.
De studies waarvan de resultaten in dit proefschrift zijn beschreven, hadden tot doel 
om 1) nieuwe verklaringen te vinden waarom Hindoestanen een verhoogd risico heb-
ben op de ontwikkeling van obesitas en obesitas-gerelateerde ziekten, en 2) nieuwe 
behandelstrategieën te onderzoeken om bruin vet te activeren en het energieverbruik 
kunnen verhogen in bevolkingsgroepen met een verhoogd risico op obesitas en 
gerelateerde ziekten, waaronder Hindoestanen en mensen met overgewicht en een 
voorstadium van diabetes (‘prediabetes’). hoofdstuk 1 fungeert als een algemene 
inleiding waarin de ontstaanswijze van obesitas, diabetes en hart- en vaatziekten wordt 
uitgelegd. Daarnaast worden het metabole fenotype en de reeds bekende risicofacto-
ren voor de ontwikkeling van obesitas en gerelateerde ziekten van de Hindoestaanse 
bevolking beschreven. Tenslotte wordt de werking van bruin vet uitgelegd alsmede de 
mogelijke rol van bruin vet in de behandeling van obesitas en gerelateerde ziekten.
In het eerste deel van dit proefschrift onderzochten we verschillende factoren die 
mogelijk het verhoogde risico op het ontstaan van obesitas en obesitas-gerelateerde 
ziekten in Hindoestanen mede verklaren. Het was al bekend dat hoge bloedconcen-
traties van endocannabinoïden, lichaamseigen stofjes die de noradrenaline signalering 
kunnen remmen, geassocieerd zijn met obesitas en met een lage activiteit van bruin vet. 
Tevens is uit eerder onderzoek gebleken dat Hindoestanen een lager energieverbruik 
in rust (‘ruststofwisseling’) en minder bruin vet hebben dan West-Europanen. Op basis 
van deze gegevens vormden wij de hypothese dat Hindoestanen hogere plasmacon-
centraties van endocannabinoïden hebben dan West-Europeanen, wat we vervolgens 
onderzochten in hoofdstuk 2. Hiertoe includeerden wij tien jonge, gezonde, slanke 
Hindoestaanse mannen tussen de 18 en 28 jaar en tien West-Europese mannen van 
dezelfde leeftijd en BMI. Het energieverbruik werd gemeten en bloedplasma werd 
verzameld om endocannabinoïden en lipiden te meten. We toonden aan dat Hin-
doestanen, vergeleken met West-Europeanen, hogere plasmaniveaus hadden van de 
endocannabinoïden 2-arachidonoylglycerol (2-AG), N-arachidonylethanolamine (AEA) 
en arachidonzuur. Tevens bleek er een positief verband te bestaan tussen plasma 2-AG 
niveaus en plasma triglyceridenniveaus en tussen plasma 2-AG niveaus en het lichaams-
vetpercentage. Daarnaast was er een negatief verband tussen het plasmaniveau van 
arachidonzuur en het energieverbruik en een positief verband tussen het plasmaniveau 
van arachidonzuur en het lichaamsvetpercentage. Aangezien endocannabinoïden de 
noradrenalinesignalering remmen zouden de verhoogde plasma endocannabinoid 
levels mogelijk kunnen bijdragen aan het ontstaan van het ongunstige metabole feno-




Omdat endocannabinoïden in verschillende organen worden geproduceerd en ver-
volgens aan het bloed worden afgegeven, vroegen wij ons af in welke mate de diverse 
metabole organen bijdragen aan het plasmaniveau van endocannabinoïden. Om die 
reden hebben wij in hoofdstuk 3, naast endocannabinoïdenniveaus in het plasma, 
ook de regulering van endocannabinoïden in wit vet en spierweefsel bestudeerd. 
Tien Hindoestaanse mannen tussen de 35 en 50 jaar met overgewicht en prediabetes 
en tien West-Europese mannen van dezelfde leeftijd en BMI, werden geïncludeerd in 
deze studie. Wederom werd het energieverbruik gemeten en bloedplasma verzameld 
om endocannabinoïden en lipiden te meten. Daarnaast werden er biopten genomen 
van wit vet en spierweefsel om genexpressie van de endocannabinoïdreceptoren en 
de expressie van genen die betrokken zijn bij de productie en afbraak van endocan-
nabinoïden te meten. Wij toonden aan dat Hindoestanen hogere niveaus hadden van 
de endocannabinoïden 2-linoleoyl glycerol en N-linoleoylethanolamine in bloedplasma 
vergeleken met West-Europeanen. Daarnaast was de genexpressie van de endocan-
nabinoïdreceptoren CB1 en CB2 in spierweefsel veel lager in Hindoestanen vergeleken 
met West-Europeanen. Ook was de genexpressie van het enzym FAAH2 dat betrokken 
is bij de afbraak van endocannabinoïden veel lager in Hindoestanen. In wit vet was er 
geen verschil in de genexpressie van de endocannabinoïdreceptoren of de expressie 
van genen die betrokken zijn bij de synthese en afbraak van endocannabinoïden tussen 
de etniciteiten. Tevens bleek er een positief verband te bestaan tussen 2-AG niveaus in 
het bloedplasma en zowel triglyceridenniveaus als de vetverbranding. Deze resultaten 
ondersteunen onze bevindingen in Hoofdstuk 2, namelijk dat Hindoestanen hogere 
endocannabinoïdenconcentraties in het bloedplasma hebben dan West-Europeanen. 
Mogelijk kan dit verklaard worden door een verlaagde afbraak van endocannabinoïden 
in de spier. Aanvullende studies zijn nodig om te onderzoeken of Hindoestanen moge-
lijk baat hebben bij behandelingen die het endocannabinoïdensysteem beïnvloeden.
Vervolgens verplaatsten wij onze focus van het endocannabinoïdensysteem naar 
angiopoietine-achtige eiwitten, specifiek het angiopoietine-achtig eiwit 4 (ANGPTL4). 
Eerder onderzoek heeft laten zien dat blootstelling aan kou de vrije vetzuurniveaus in 
het bloedplasma minder doet stijgen in Hindoestanen vergeleken met West-Europea-
nen. Vrije vetzuren kunnen peroxisoomproliferatorgeactiveerde receptoren activeren 
die betrokken zijn bij de synthese van ANGPTL4. ANGPTL4 remt de lipolytische activiteit 
van lipoproteïnelipase, en daarmee de opname van vrije vetzuren door organen vanuit 
triglyceriden uit het bloed. In hoofdstuk 4 bestudeerden wij het effect van kortdu-
rende blootstelling aan milde kou op het serumniveau van ANGPTL4 in jonge, gezonde 
Hindoestaanse en West-Europese mannen. Wij toonden aan dat ANGPTL4 niveaus 
stegen na blootstelling aan milde kou. De toename in ANGPTL4 was minder groot in 
Hindoestanen vergeleken met West-Europeanen. Daarnaast was er een positief verband 
tussen thermoneutrale ANGPTL4 niveaus en vrije vetzuurniveaus in het serum en met 
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het lichaamsvetpercentage. ANGPTL4 niveaus lieten een negatief verband zien met het 
energieverbruik. Als onderliggend mechanisme speculeren wij dat blootstelling aan kou 
intracellulaire lipolyse in wit vet stimuleert, wat resulteert in vrijmaking van vetzuren en 
ten gevolge daarvan een verhoging van vrije vetzuren in het bloed. Intracellulair kun-
nen vrije vetzuren via peroxisoomproliferatorgeactiveerde receptoren de aanmaak van 
ANGPTL4 stimuleren dat vervolgens de opname van vrije vetzuren vanuit triglyceriden 
vanuit het bloed remt. De efficiëntie van dit proces is lager in Hindoestanen, mogelijk 
door verminderde sympathische signalering.
Tijdens blootstelling aan kou neemt de warmteproductie toe om de lichaamstempe-
ratuur op peil te houden. Hierbij worden vetten verbrand, wat resulteert in de vorming 
van afbraakproducten (‘metabolieten’). In hoofdstuk 5 onderzochten wij hoe kortdu-
rende milde blootstelling aan kou 190 metabolieten in het bloed beïnvloedt en of deze 
respons verschilt tussen Hindoestanen en West-Europeanen. Hoewel milde kou effecten 
had op meerdere metabolieten, was de respons niet verschillend tussen de twee etnici-
teiten. Na het samenvoegen van de data van beide etniciteiten, konden wij aantonen dat 
blootstelling aan kou 44 metabolieten beïnvloedde. Met name de phosphatidylcholines 
met lange vetzuurketens en sphingomyelines namen toe na kou. Daarnaast verhoogde 
kou glutamine, glycine en histidine en verlaagde het de korte-keten acylcarnitines (C2 
en C4). Kortdurende blootstelling aan milde kou induceert dus substantiële veranderin-
gen in de serum metabolieten maar deze effecten zijn onafhankelijk van de vergeleken 
etniciteiten. Toekomstig onderzoek zal moeten uitwijzen wat de fysiologische relevantie 
is van deze veranderingen in niveaus van metabolieten in het serum in respons op kou.
In het tweede deel van dit proefschrift bestudeerden wij twee veelbelovende farma-
cologische strategieën om bruin vet te activeren in Hindoestanen en mensen van 
West-Europese afkomst met overgewicht en prediabetes, beiden risicopopulaties voor 
het ontwikkelen van diabetes en hart- en vaatziekten. In hoofdstuk 6 onderzochten 
wij het effect van mirabegron, een specifieke agonist van de β3-adrenerge receptor 
die in de fysiologische situatie door stimulatie van het centraal zenuwstelsel wordt 
geactiveerd, op het energieverbruik en bruin vet in 20 jonge, gezonde Hindoestaanse 
en West-Europese mannen. Zij participeerden in een gerandomiseerde, dubbelblinde, 
cross-over studie die bestond uit drie verschillende interventies; kortdurende milde kou, 
een enkele dosis mirabegron (200 mg) en een placebo behandeling. Wij toonden aan 
dat zowel blootstelling aan kou als mirabegron resulteerden in een toename van vrije 
vetzuren in het bloed, het energieverbruik, de vetverbranding en de supraclaviculaire 
huidtemperatuur. Daarnaast leken beide strategieën het percentage vet in bruin vet 
te verlagen. Aangezien actief bruin vet zijn intracellulaire vetten verbrandt, suggereert 
de afname van de intracellulair vetfractie activatie van bruin vet. Er was echter geen 




uitwijzen of kou en mirabegron ook de vetopname en oxidatieve capaciteit van bruin 
vet verhogen.
Remmers van dipeptidylpeptidase-4 (DPP4), die de beschikbaarheid van het hor-
moon glucagonachtige peptide-1 (GLP-1) verhogen, activeren bruin vet in muizen. Om 
te onderzoeken of DPP4 remming ook bruin vet activeert in mensen bestudeerden wij 
in hoofdstuk 7 het effect van de DPP4 remmer sitagliptine op de bruin vet activiteit in 
West-Europese mannen met overgewicht en prediabetes. Daarnaast onderzochten wij 
ook het effect van sitagliptine op de suiker- en vetstofwisseling en de spierstofwisse-
ling in deze populatie. Dertig West-Europese mannen met overgewicht en prediabetes 
participeerden in een dubbelblinde, gerandomiseerde, placebo-gecontroleerde studie 
waarin zij gedurende 12 weken sitagliptine (100 mg/dag) ofwel placebo toegediend kre-
gen. Voor en na de 12-weekse behandeling werden er bloedmonsters afgenomen voor 
bepaling van suiker, insuline en lipiden en werden het energieverbruik en de suiker- en 
vetverbranding gemeten. Ook werd de opname van een suikerlabel door bruin vet, wit 
vet en spier gemeten door middel van een PET-CT scan, en werd een orale glucose tole-
rantie test verricht en een spierbiopt afgenomen. Wij toonden aan dat sitagliptine, ten 
opzichte van placebo, de gevoeligheid voor suiker verbeterde. Daarnaast verlaagde sita-
gliptine de triglyceridenniveaus in plasma. In de spierbiopten verhoogde sitagliptine de 
expressie van PGC1β, een gen dat betrokken is bij de verbranding in de mitochondriën. 
Daarnaast verhoogde sitagliptine de opname van het suikerlabel in wit vet, maar niet in 
bruin vet en spier. Hieruit concludeerden wij dat sitagliptine een gunstig effect heeft op 
de suiker- en vetstofwisseling in mannen met overgewicht en prediabetes en dat deze 
effecten mechanistisch mogelijk verklaard kunnen worden door ‘verbruining’ van het 
witte vet en/of een verbeterde oxidatieve capaciteit van de mitochondriën in de spier.
Tot slot werden de belangrijkste resultaten van de studies die beschreven zijn in dit 
proefschrift geëvalueerd in hoofdstuk 8. Tevens werden de implicaties voor toekomstige 
onderzoeken besproken. Enkele nieuwe factoren worden benadrukt die deels kunnen 
bijdragen aan het verhoogde risico op obesitas en obesitas-gerelateerde ziekten in de 
Hindoestaanse populatie en er wordt gespeculeerd over onderliggende mechanismes. 
Ook komen er nieuwe mogelijke behandelstrategieën aan bod die bruin vet kunnen 
activeren en daarmee ook het energieverbruik en de suiker- en vetstofwisseling kunnen 
moduleren om daarmee obesitas en obesitas-gerelateerde ziekten te behandelen. Tot 
slot worden enkele methodologische uitdagingen in het huidige onderzoek naar bruin 
vet besproken, alsmede enkele nieuwe uitleesmaten voor de activiteit van bruin vet in 
mensen. Wat de klinische waarde is van bruin vetactivatie in de kliniek voor de behande-
ling van obesitas, type 2 diabetes en hart- en vaatziekten zal waarschijnlijk duidelijk 
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